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ABSTRACT 
Ovarian cancer is the fifth most common cancer which affects women in the United 
Kingdom. The 5-year survival rate is less than 45% despite improvements in 
chemotherapeutic regimens. Platinum-based therapy in combination with other 
chemotherapy including paclitaxel is currently the best standard of care for ovarian 
cancer. However, many women relapse with drug-resistant disease and this has led to 
the development of alternative drug therapies. This research evaluated two statins, 
simvastatin and pitavastatin, in several ovarian cancer models. Statins competitively 
inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in the mevalonate 
pathway, resulting in the cellular depletion of the isoprenoid, geranylgeranyl 
diphosphate, and a reduction in the prenylation and localisation of many proteins 
including Ras, Rho and Rab involved in cell signalling. This is likely to have 
contributed to the decrease in cell proliferation, induction of apoptosis, and 
simultaneous induction and inhibition of autophagy observed when ovarian cancer 
cells were exposed to statins, although the mechanisms remain poorly defined. The 
concentration of statins required to cause cell death in ovarian cancer cells was 
significantly higher than that achieved in patients receiving a standard 40 mg dose for 
hypercholesterolaemia. Continual inhibition of HMGCR for several days was 
necessary to induce cell death. Lipids consumed in the diet may reverse the cytotoxic 
effects of the statins, suggesting that patients receiving statins for cancer therapy may 
require dietary modification. Studies evaluating statins in combination with carboplatin 
or targeted therapeutics demonstrated limited synergy, and in some cases, profound 
antagonism, and therefore, statins may be best evaluated as single agents. Statins 
retained cytotoxic activity in ovarian cancer cells resistant to chemotherapy, 
supporting the use of statins in chemoresistant disease. These observations will help 
to inform the design of future clinical trials evaluating statins in ovarian cancer.  
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CHAPTER 1 
 
INTRODUCTION 
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1.1   The Female Reproductive System 
 
The uterus (womb), ovaries and fallopian tubes make up the internal organs found in 
the female reproductive system (figure 1.1). The ovaries produce, store and release 
eggs that are required for reproduction. Up to seven million primordial follicles are 
produced in the foetus by the final trimester of gestation. However, less than 1% will 
mature and ovulate during their lifetime, as most undergo a programmed mechanism 
of cell death known as apoptosis (follicle atresia). A small number of recruited 
primordial follicles undergo cell proliferation and differentiation in order to develop into 
graafian follicles over a period of 1 year. Following this, the follicle either ovulates its 
egg into the ovarian cortex mid-way through the menstrual cycle or is removed by 
follicle atresia. An ovulated egg moves down the fallopian tube and through the 
uterus. During this time it may be fertilised by sperm, implant into the lining of the 
uterus and develop into a foetus. Conversely, an unfertilised egg will be expelled from 
the uterus during menstruation. A layer of supportive connective tissue surrounds the 
cortex along with an outer epithelial layer.  
 
 
Figure 1.1: The female reproductive system and ovulation. 
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1.2   Introduction to Ovarian Cancer 
 
1.2.1   Epidemiology 
 
1.2.1.1   Incidence 
Ovarian cancer is the fifth most common cancer in women with an overall 5-year 
survival rate of less than 45%, making it the principal cause of death from 
gynaecological cancer in the UK [1, 2]. A quarter of the women diagnosed with 
ovarian cancer between the years 2005 and 2009 died within the first year [2]. Despite 
this, survival rates have doubled over the last 30 years following the initiation of 
chemotherapy including platinum-based treatments and modifications in surgical 
practice [3]. Around 50-60% of cases comprise epithelial ovarian cancer occurring in 
women between the ages of 45 and 79 [4, 5]. Furthermore, serous carcinoma is the 
most common histological subtype, accounting for around one-third of all cases in 
2009 [6]. A report by the National Cancer Intelligence Network indicated that the 
incidence of ovarian cancer is lower in Asian and Black ethnic groups compared to the 
White ethnic group [7]. The incidence of ovarian cancer is not affected by 
socioeconomic status [7]. Several risk factors have been identified which can increase 
the probability of developing ovarian cancer. 
 
1.2.1.2   Age 
Most ovarian cancers develop after the age of 40, with around half in women over the 
age of 63. The incidence continues to rise with increasing age, and reaches a peak in 
the 80-84 year old age group (61.8 cases of ovarian cancer per 100,000 women) [8]. 
Furthermore, the 5-year survival rate varies dramatically with age, as 84.2% survived 
in the 15-39 age group compared to only 13.7% of women over 85 years old [6]. This 
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may reflect differences in the tumour, as low-grade less aggressive ovarian tumours 
tend to occur in younger women. Other factors, including the earlier diagnosis and 
referral of younger women [9], and medical comorbidities in older women which can 
limit treatment, may also impact survival rates.  
 
1.2.1.3   Family History 
Approximately 10-15% of ovarian cancers (mostly type II) are hereditary, resulting 
from an inherited mutation of the breast cancer gene, BRCA1 or BRCA2 [10]. Whilst 
this predisposes women to a high risk of ovarian and breast cancer, they generally 
have a better prognosis than patients with sporadic ovarian cancer. Furthermore, 
women with either a history of breast cancer (particularly those under the age of 40) or 
a family history of breast or ovarian cancer were at least twice as likely to develop 
ovarian cancer [11]. Other inherited genetic susceptibility to ovarian cancer includes 
mutations in the hereditary nonpolyposis colorectal gene [12].  
 
1.2.1.4   Reproductive Factors 
An extended reproductive history can also increase the risk of ovarian cancer. Ovarian 
epithelial cells have a low proliferative index and generally proliferate to repair the 
damage caused when mature follicles rupture to release oocytes during ovulation. 
Ovulation can also lead to the development of epithelial cell-lined subsurface inclusion 
cysts. Both cellular proliferation and the growth of cysts can increase the likelihood of 
spontaneous genetic mutations and development of ovarian cancer. Ovulation has 
also been demonstrated to cause DNA damage in fallopian tube epithelial cells, 
possibly due to an increase in activated macrophages and release of inflammatory 
factors during ovulation [13], and this may contribute to the development of ovarian 
cancer in the fallopian tube. Increasing parity was shown to reduce ovarian cancer 
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risk, even when taking into account pregnancies which were terminated early [14]. 
Furthermore, breastfeeding appeared to have a slight protective effect [14]. Despite 
this, other factors which increase the number of ovulatory cycles including early 
menarche (before age 12) or late menopause (after age 50) had no significant effect 
on the risk of ovarian cancer [14, 15]. Increased levels of follicle-stimulating hormone, 
luteinising hormone, oestrone and androgen following menopause can also increase 
the proliferation of ovarian epithelial cells and thus contribute to the development of 
cancer. Thus unsurprisingly, the use of contraceptives which prevent ovulation can 
significantly decrease the risk of ovarian cancer, including in women with a BRCA 
mutation [16-19].  
 
1.2.1.5   Hormone Replacement Therapy 
The use of oestrogen replacement therapy following the menopause has also been 
linked to a slightly increased risk of ovarian cancer, particularly in women who are 
treated for more than 10 years [20, 21]. This treatment has been superseded by 
combined hormone replacement therapy (oestrogen and progesterone), which is 
believed to have little impact on the likelihood of developing ovarian cancer. 
 
1.2.1.6   Chemical Agents 
Whilst chemical carcinogens have not been directly linked to ovarian cancer, several 
studies have indicated that exposure to talc may increase the risk of developing 
ovarian cancer [22, 23]. Despite this, a recent meta-analysis of epidemiological 
studies failed to endorse an association between the use of talc powders on the 
female perineum and ovarian cancer [24]. 
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1.2.1.7   Medical Conditions 
Endometriosis increases the risk of developing ovarian cancer, particularly with 
endometrioid and clear cell morphology [25-27]. The use of oral contraceptives for 
more than 10 years in women with endometriosis substantially reduced this risk [25], 
suggesting that long-term oral contraceptive use may protect this high-risk population.  
 
 
1.2.2   Origin 
 
Cancer arises from a series of genetic mutations in a cell resulting in reregulated 
proliferation and apoptosis. Genetic changes can lead to the activation of oncogenes 
which, in the absence of normal external factors, can cause cell division. The 
suppression or deletion of many tumour suppressor genes prevents both the inhibition 
of this cell division and the programmed cell death that would normally follow. Cancer 
cells secrete growth factors which promote angiogenesis, thereby increasing blood 
supply and nutrient provision to the tumour. Together with other factors which inhibit 
the immune response to the cancer cells, this results in the progression of the tumour, 
leading to invasive and metastatic disease. 
 
Ovarian carcinomas were originally thought to arise from the epithelium which covers 
the ovarian surface. Early studies reported high rates of ovarian cancer in hens forced 
to produce large numbers of eggs without interruption in ovulation [28]. From this, it 
was hypothesised that epithelial cells on the surface of the ovary were damaged 
during ovulation, leading to the formation of cortical inclusion cysts and subsequent 
development of ovarian cancer [28, 29]. However, whilst ovarian cystadenomas can 
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progress into low-grade ovarian cancer, transformation into high-grade serous ovarian 
carcinoma (HGSC) is rare [29].  
 
A breakthrough came during the start of the 21st century, when fallopian tubes and 
ovaries removed from women with a high risk of developing ovarian cancer were 
sectioned to reveal both non-invasive and invasive carcinomas primarily in the 
fallopian tube fimbria [30-33]. It was then proposed that malignant cells from these 
tubal carcinomas may metastasise to the ovary, resulting in ovarian cancer [34]. A 
number of studies have since supported the theory that the fallopian tube is the origin 
of serous ovarian carcinoma. Gene expression analysis demonstrated that there was 
a high degree of similarity between HGSC and tubal carcinoma gene expression 
profiles [35]. Tubal carcinomas have been reported in 50-60% of women with pelvic 
HGSC, however the possibility that the tubal carcinomas developed from a primary 
ovarian cancer cannot be excluded [36, 37]. Furthermore, a mouse model was used to 
demonstrate that removal of the fallopian tubes at an early age prevented the 
formation of ovarian cancer [38]. 
 
Despite the compelling evidence indicating the importance of tubal carcinomas as 
precursors to ovarian cancer, there are still a significant proportion of HGSC which 
appear to have no fallopian tube involvement. Some tubal carcinomas may be 
obscured by the growth of a secondary high-grade invasive cancer [39]. Alternatively, 
ovarian cancer may develop suddenly from a normal-appearing ovary. Data from 35 
patients with epithelial ovarian cancer were retrospectively analysed to determine 
abnormalities in the adnexal regions (the space containing the ovaries, fallopian tubes 
and uterus) [40]. In 8 patients with no apparent abnormalities 2-12 months prior to the 
diagnosis, stage III tumours were identified and following surgery, no malignancies in 
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adjacent tissue were identified [40]. Therefore, it is possible that some serous 
carcinomas may develop within the ovary and progress rapidly.  
 
 
1.2.3   Histological Subtypes and Molecular Features 
 
Epithelial ovarian cancer comprises more than 80% of all ovarian cancers and 
includes serous, endometrioid, clear cell and mucinous histotypes [41]. Serous 
epithelial ovarian carcinoma accounts for more than 70% of epithelial ovarian cancers 
and the majority (90%) are HGSC [42]. Endometrioid and clear cell types represent 
20%, and mucinous type accounts for 3% [43]. Germ cell tumours begin in the egg 
and are a rare type of ovarian cancer which generally affects younger women.  
 
There are four main histotypes that resemble differentiated cells found in the fallopian 
tube (serous), endometrium (endometrioid), endocervix (mucinous) and vagina (clear 
cell) (figure 1.2). 
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Figure 1.2: The four major types of ovarian cancer: serous, endometrioid, mucinous 
and clear cell. Tumour sections have been stained with hematoxylin and eosin and 
represent maturing ovarian follicles [44]. 
 
 
These four subtypes of ovarian cancer can be divided into two broad categories.  
Type I tumours include low-grade serous, mucinous, endometrioid and clear cell 
cancers and are believed to originate from precursor lesions in the ovary. Type II 
tumours may be derived from tubal or ovarian surface epithelium and encompass 
HGSC, undifferentiated cancers and carcinosarcomas.  
 
 
 
 
10 
 
1.2.3.1   Type I Tumours 
 
Endometrioid and clear cell ovarian cancers 
Endometrioid and clear cell ovarian cancers have both been linked to endometriosis. 
The inflammatory processes occurring during endometriosis may play a role in the 
growth and malignant transformation of ovarian surface epithelium. This is 
demonstrated by an induction of tumour necrosis factor-alpha (TNF-α) and growth 
factors such as insulin-like growth factor (IGF), which promote cellular growth and 
proliferation [45]. A corresponding increase in DNA repair can lead to more mutations 
which support the development of cancer. Mutations in the phosphatase and tensin 
homolog (PTEN) tumour suppressor and the phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PI3KCA) oncogene are common and likely to be early 
events in the development of endometrioid cancer. Furthermore, mutations in the 
beta-catenin gene (CTNNB1) are present in up to 30% of endometrioid cancers [46]. 
CTNNB1 is involved in cell proliferation and the Wnt pathway, suggesting that 
dysregulation of this pathway may be implicated in the growth of endometrioid cancer 
[46, 47]. Clear cell ovarian cancer is relatively rare in Europe (4%) and tumours are 
generally resistant to chemotherapeutic agents [48]. Like endometrioid ovarian 
cancer, clear cell ovarian cancer is characterised by mutations in PTEN and PI3KCA 
[41]. A genetic signature was recently identified for clear cell cancer using microarrays 
and most of the 437 genes identified were related to oxidative stress [49].  
 
Mucinous ovarian cancer 
Mucinous cancers have also been linked to endometriosis, however this is relatively 
uncommon. They have been associated with other cancers including ovarian 
teratomas (germ cell tumours) and Brenner tumours, or may develop from surface 
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epithelial inclusions [50, 51]. Smoking has previously been identified as a risk factor 
linked to mucinous cancer [52, 53]. Mutations in the kirsten rat sarcoma viral 
oncogene homolog (K-Ras) gene occur in the early stages of mucinous cancer 
development. Furthermore, tumor protein p53 (TP53) mutations are associated with 
the transition from borderline tumours to carcinomas [41]. 
 
Serous ovarian cancer 
Low-grade serous cancer is believed to develop gradually from serous cystadenomas 
and serous borderline tumours (figure 1.3). This subtype is characterised by a small 
number of mutations, of which activated K-Ras, v-raf murine sarcoma viral oncogene 
homolog B (BRAF) and v-erb-b2 avian erythroblastic leukemia viral oncogene 
homolog 2 (ERBB2) oncogenes are located upstream of the mitogen-activated protein 
kinase (MAPK) pathway, leading to uncontrolled cell proliferation [54].  
 
 
Figure 1.3: The origins of serous ovarian cancers in type I and type II pathways. 
APST, atypical proliferative serous tumour; MPSC, micropapillary serous carcinomas; 
SBT, serous borderline tumour [54]. 
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1.2.3.2   Type II Tumours 
 
Type II cancers include HGSC, undifferentiated cancers and carcinosarcomas [55]. 
These aggressive tumours are often detected at advanced stages following rapid 
spread to the surrounding tissues. HGSC frequently metastasise over the peritoneal 
surface forming many small nodules on the visceral and parietal peritoneum.  
 
A summary of the genetic mutations recently found in HGSC is shown in table 1.1. 
More than 90% of type II tumours have TP53 mutations and substantial genomic 
instability [41, 56]. The wild-type form of p53 functions as a tumour suppressor, which 
is critical to protect against cancer. In many tumours, TP53 missense mutations result 
in the production of the full-length p53 protein with only a single amino acid 
substitution [57]. This mutant p53 protein may accumulate in cancer cells because of 
a prolonged half-life, and more importantly, possess activities which may contribute to 
tumour progression [58]. This oncogenic activity is described as “gain-of-function” 
mutant p53 [59]. Approximately 100 of the 301 tumour samples with TP53 mutations 
in the Cancer Genome Atlas analysis of HGSC were considered to have “gain-of-
function” mutant p53 [58]. Interestingly, “gain-of-function” mutant p53 was correlated 
with ovarian tumours with greater metastatic potential and resistance to platinum-
based chemotherapy, although there was no difference in patient survival between 
tumours with or without “gain-of-function” mutant p53 [58].  
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Gene Chromosome 
Percentage of 
cancers mutated 
Function 
Tumor protein 
p53 (TP53) 
17p13.1 96% 
Tumour suppressor, cell 
cycle regulation 
Breast cancer 
1, early onset 
(BRCA1) 
17q21.31 9% 
Tumour suppressor, DNA 
damage repair, 
transcriptional regulation 
Breast cancer 
2, early onset 
(BRCA2) 
13q13.1 8% 
Tumour suppressor, DNA 
damage repair, 
transcriptional regulation 
CUB and Sushi 
multiple 
domains 3 
(CSMD3) 
8q23.3 6% Possible tumour suppressor 
FAT tumor 
suppressor 
homolog 3 
(FAT3) 
9x 6% 
Tumour suppressor, planar 
polarity, neuronal 
development 
Neurofibromin 
1 (NF1) 
17q11.2 4% 
Negative regulation of Ras 
signalling pathway 
Cyclin-
dependent 
kinase 12 
(CDK12) 
17q12 3% Transcriptional regulation 
Retinoblastoma 
1 (RB1) 
13q14.2 3% 
Tumour suppressor, cell 
cycle regulation 
Gamma-
aminobutyric 
acid (GABA) A 
receptor, alpha 
6 (GABRA6) 
5q34 2% Inhibitory neurotransmitter 
 
Table 1.1: Genes significantly mutated in high-grade serous ovarian carcinoma 
(HGSC) (Modified from [56]). 
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In addition to the three well documented tumour suppressor genes, TP53, BRCA1 and 
BRCA2, a further six mutated genes were identified in 2-6% of HGSC [56]. CDK12 
mutations have been previously reported in lung adenocarcinoma [60] and in the 
human GNAS1 gene [61]. In ovarian cancer, four missense mutations in CDK12 were 
located in the protein kinase domain and a further five were nonsense, potentially 
resulting in loss of function [56]. Whilst both FAT3 and GABRA6 were significantly 
mutated in ovarian cancer, neither were expressed in the ovarian cancer tissue or 
fallopian tube tissue, suggesting that they may not have a significant contribution to 
HGSC [56]. In contrast to type I tumours, BRAF, K-Ras, neuroblastoma Ras viral 
oncogene homolog (N-Ras) and PI3KCA are rarely mutated in type II tumours, but 
may still be significant drivers in the transformation to HGSC [56].   
 
Molecular pathways altered in HGSC 
Pathway analyses in 316 high-grade serous ovarian tumours revealed that the 
retinoblastoma (Rb) and phosphatidylinositol 3-kinase (PI3K) / Ras pathways were 
deregulated in 67% and 45% of cases respectively, and this is likely to contribute to 
cancer cell survival and cell cycle progression [56]. Furthermore, NOTCH signalling 
was altered in 22% of cases, genes in the homologous recombination (HR) pathway 
including BRCA1 and BRCA2 were mutated or hypermethylated in around 51% of 
cases, and the FOXM1 transcription factor network was activated in 84% of cases, 
most likely as a result of the high rate of TP53 mutations [56]. These pathways also 
contribute to cell cycle progression and DNA repair in cancer cells. Taken together, 
these observations may provide further opportunities for the treatment of HGSC. 
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1.2.4   Clinical Features 
 
Symptoms of ovarian cancer are vague and can be the result of other less serious 
conditions. They include abdominal swelling, unusual vaginal bleeding, pelvic 
pressure, increased urinary urgency or frequency, back or leg discomfort and 
gastrointestinal complaints such as indigestion, early satiety, stomach pain and 
bloating [3]. Women have often experienced symptoms for many months prior to 
diagnosis and consequently most present with advanced disease [62-64]. 
 
 
1.2.5   Screening 
 
The probability of undiagnosed ovarian cancer in women presenting to primary care 
with symptoms experienced within the previous year was estimated to be 
approximately 1 in 25 [65]. A screening programme for ovarian cancer could aid in 
early detection and reduce mortality as has already been demonstrated for breast, 
bowel and cervical cancers [66]. Despite this, screening for ovarian cancer is not 
currently undertaken in the general population due to the absence of a proven 
reduction in mortality using current detection methods [67].  
 
Many ovarian cancer screening trials utilise the serum biomarker CA125, a 
transmembrane glycoprotein that is expressed by epithelial cells in the fallopian tubes, 
endometrium and endocervix [68]. CA125 is released from the cell surface by 
proteolytic cleavage at an extracellular site, a process thought to be regulated by post-
translational modifications, including glycosylation [69, 70]. Serum CA125 is elevated 
in around 50% of stage I ovarian cancer cases and over 90% of advanced stage 
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cases [68, 71]. However, CA125 levels can also be increased in benign conditions 
including ovarian cysts, endometriosis and fibroids, thereby complicating its use as a 
screening tool in the general population [72]. The Japanese Shizuoka Cohort Study of 
Ovarian Cancer Screening utilised a combination of CA125 and ultrasound, and the 
results suggested that women in the screened arm were more likely to have ovarian 
cancer detected in the early stages compared to the control arm [73]. Furthermore, 
the ongoing UK Collaborative Trial of Ovarian Cancer Screening (UKCTOS) has 
incorporated several arms including no intervention (control), annual screening using 
transvaginal ultrasound or serum CA125 interpreted using the Bayesian algorithm 
‘Risk of Ovarian Cancer’ (ROCA) [74]. An early report indicated that there was 
encouraging sensitivity for detecting ovarian cancer in both screening arms [75]. The 
Kentucky Screening study used ultrasound to screen women. The five-year survival 
rate in women diagnosed with primary invasive epithelial cancer was significantly 
greater than the survival rate in women treated with the same surgical and 
chemotherapeutic interventions who were not part of the study [76, 77]. Despite these 
promising studies, screening by ultrasound or CA125 has been unsuccessful at 
detecting early stage ovarian cancer in women at an increased risk due to genetic 
factors or a family history of the disease [78, 79]. 
 
The continued search for cancer-specific biomarkers has resulted in some promising 
results. In addition to CA125, Human Epididymis protein 4 (HE4) also has a high 
sensitivity for the detection of ovarian cancer, however there was no advantage in 
detecting both HE4 and CA125 in ovarian cancer screening compared to CA125 alone 
[80]. Despite this, a panel of CA125, HE4 and mesothelin were increased in women 
three years prior to diagnosis of ovarian cancer and reached detectable levels within 
the final year before diagnosis [81]. In a UKCTOCS case-control study, an elevation of 
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putative platelet factor 4 (PF4) and connective tissue-activating peptide III (CTAPIII) 
was detected before the increase in CA125 and ovarian cancer diagnosis [82].  
 
The high frequency of type-II ovarian cancers with TP53 gene mutations has led to the 
use of tagged-amplicon deep sequencing (TAm-Seq) to detect TP53 mutations in 
patients with high levels of circulating tumour DNA [83]. However, this technique does 
not currently afford the sensitivity to allow the detection of TP53 mutations in patients 
with less advanced cancers. Furthermore, mutations in a panel of 12 genes were 
identified in cervical samples from women with ovarian cancer, advocating the use of 
alternative biospecimens to overcome the problems of biomarker dilution in traditional 
blood assays [84].  
 
Enhanced imaging techniques have also been employed to detect cancerous tissue 
and angiogenesis at an earlier stage. Screening protocols may include contrast-
enhanced transvaginal ultrasound with microbubbles that can be transported through 
capillaries and used to detect changes in tumour vascularity [85]. Furthermore, light-
induced intrinsic tissue fluorescence or autofluorescence can be used to identify 
cancerous or precancerous epithelial tissue. Use of this technique on fallopian tubes 
removed during surgery can detect precursor cancerous leisons with good levels of 
sensitivity and specificity [86], suggesting that this technique could be introduced in 
vivo. 
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1.2.6   Diagnosis 
 
The diagnosis of ovarian cancer is based upon the symptoms experienced by the 
patient. Clinical guidelines recommend that if symptoms are persistent, experienced 
more than 12 times per month or are suggestive of irritable bowel syndrome (IBS) in 
women aged 50 or over, further tests for ovarian cancer should be initiated [3]. The 
measurement of CA125 is the initial test and standard for the management of ovarian 
cancer. A meta-analysis reported that the sensitivity of CA125 for detecting borderline 
and malignant ovarian cancer was 80% [71]. However the specificity was slightly 
reduced at 75%, representing the elevation of CA125 levels in benign lesions in 
addition to ovarian cancer [71]. Therefore, the use of CA125 alone for the diagnosis of 
ovarian cancer is inadequate and other techniques including ultrasound and computed 
tomography (CT) scans are required to confirm the presence and extent of the 
disease. The diagnosis and histological subtype of ovarian cancer should also be 
confirmed by a laparotomy, where the staging (spread) of the disease can also be 
determined. During this surgical procedure to gain access to the abdominal cavity, 
peritoneal cytology should be collected and all visible tumours are removed where 
possible [87]. Staging the cancer (table 1.2) can inform subsequent treatment 
decisions and give an insight into the survival prognosis. CA125 monitoring is 
routinely used to indicate a response to chemotherapy and has been shown to detect 
recurrent ovarian cancer in 70% of patients [88]. This enables early initiation of 
combination chemotherapy, which can help to extend progression-free survival (PFS) 
and overall survival (OS). Despite this, the benefit of monitoring CA125 in patients 
with recurrent disease is uncertain and should be considered in each case. 
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Stage Description 
I Tumour confined to ovaries or fallopian tubes 
IA Tumour confined within one ovary (capsule intact) or fallopian tube 
IB Tumour confined within both ovaries (capsules intact) or fallopian tubes 
IC 
Tumour confined to one or both ovaries (capsules intact) or fallopian 
tubes with IC1/IC2/IC3: 
IC1 Surgical spill 
IC2 
Capsule ruptured prior to surgery or tumour on ovarian or fallopian tube 
surface 
IC3 Ascites or peritoneal washings contain malignant cells 
II 
Tumour involves one or both ovaries or fallopian tubes with pelvic 
extension (below pelvic brim) or primary peritoneal cancer 
IIA Extension/implants on uterus/fallopian tubes/ovaries 
IIB Extension to other pelvic intraperitoneal tissues 
III 
Tumour involves one or both ovaries or fallopian tubes, or primary 
peritoneal cancer, with metastasis to the peritoneum or retroperitoneal 
lymph nodes 
IIIA1 
Positive retroperitoneal lymph nodes only: IIIA1(i) metastasis up to 10 
mm or IIIA1(ii) metastasis greater than 10 mm 
IIIA2 
Microscopic extra-pelvic peritoneal involvement with or without positive 
retroperitoneal lymph nodes 
IIIB 
Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm with or 
without retroperitoneal lymph node metastasis (includes extension to 
the liver or spleen) 
IIIC 
Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm 
with or without retroperitoneal lymph node metastasis (includes 
extension to the liver or spleen) 
IV Distant metastasis excluding peritoneal metastases 
IVA Pleural effusion with positive cytology 
IVB 
Metastases to extra-abdominal organs, liver or spleen including 
inguinal lymph nodes and lymph nodes outside the abdominal cavity 
Table 1.2: The FIGO staging classification for cancer of the ovary, fallopian tube and 
peritoneum (Modified from [5, 87]). 
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1.2.7   Current Treatment 
 
Ovarian cancer treatment currently involves surgical removal of the tumour followed 
by chemotherapy, a regimen that has advanced over the last 50 years (figure 1.4). 
Platinum-based monotherapy was introduced in the late 1970’s and, in combination 
with other chemotherapeutic agents, is currently the best standard of care. 
Conversely, radiotherapy has shown little success in the treatment of ovarian cancer 
and can have adverse effects on surrounding abdominal organs. 
 
 
 
Figure 1.4: The evolution of ovarian cancer treatment over the last 50 years (Modified 
from [89]). 
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1.2.7.1   Surgery 
The majority of patients are offered surgery with the aim of removing the majority of 
the tumour. This often results in the removal of the ovaries, fallopian tubes, womb or 
omentum, a fatty layer that covers the organs in the abdomen. If the tumour is limited 
to one ovary, consideration should be given to conserve the uterus and contralateral 
ovary in order to maintain fertility.  
 
1.2.7.2   Chemotherapy 
 
First-line chemotherapeutic agents 
Chemotherapy can be used to reduce the size of the tumour before surgery or to 
control tumour growth in cases where surgery is not appropriate. Chemotherapy is 
predominantly administered to remove any remaining cancer following surgery. 
Current UK guidelines state that chemotherapy must be started no later than 8 weeks 
after surgery [3]. Adjuvant chemotherapy is not recommended for tumours that are 
diagnosed at an early stage (grade 1 or 2, stage Ia or Ib). Where the cancer has 
spread beyond the ovaries, chemotherapy comprising platinum-based therapy alone 
or in combination with paclitaxel is first line. Several factors including disease stage, 
the extent of surgical treatment required, disease-related performance status and side 
effect profiles should be considered when prescribing chemotherapy [90].  
 
Platinum-containing compounds 
Both cisplatin and carboplatin are platinum-based compounds which cause intrastrand 
linking in DNA. After entry into the cell, the compound loses a chloride ion whilst 
reacting with water, and subsequently, binds to DNA. Intrastrand cross-linking occurs 
between N7 and O6 of adjacent guanine molecules, resulting in a DNA damage 
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response, cell cycle arrest and apoptosis [91]. Cisplatin is highly nephrotoxic and 
intravenous treatment is coupled to strict hydration and diuresis regimens. Treatment 
also causes nausea and vomiting, tinnitus and peripheral neurotoxicity. Carboplatin is 
a derivative of cisplatin which has fewer toxic side effects and can be given on an 
outpatient basis, making it the platinum drug of choice. 
  
Taxanes 
Paclitaxel is a taxane derived from the bark of the yew tree. Taxanes function by 
stabilising microtubules in the polymerised state, which inhibits cell division and 
results in G2/M phase cell cycle arrest and apoptosis. In addition to myelosupression 
and cumulative neurotoxicity, the risk of hypersensitivity requires treatment with 
corticosteroids and antihistamines prior to chemotherapy.  
 
Most patients are defined as having responded to first-line chemotherapy when 
malignant disease is not detected for at least 4 weeks (complete response) or tumour 
size is reduced by at least 50% for more than 4 weeks (partial response) [90]. Despite 
this, 55-75% of responders relapse within two years [90]. 
 
Second-line chemotherapeutic agents 
Combination treatment of carboplatin and other chemotherapeutic agents including 
pegylated liposomal doxorubicin (PLD), gemcitabine and topotecan can improve PFS 
in patients with recurrent disease. Current NICE guidelines recommend that PLD is 
used in patients whose disease does not respond to carboplatin, or relapses within 12 
months of carboplatin treatment [90]. Topotecan is only recommended if both PLD 
and paclitaxel are unsuitable for the treatment of disease unresponsive to first-line 
therapy (platinum-refractory ovarian cancer) or disease which initially responds to 
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therapy but relapses within 6 months following treatment (platinum-resistant ovarian 
cancer) [90]. 
 
Doxorubicin 
Doxorubicin is an anthracycline antibiotic that has several cytotoxic actions. The 
topoisomerase II enzyme nicks both DNA strands during DNA replication to enable 
uncoiling and subsequently reseals the breaks. Doxorubicin intercalates in the DNA 
and stabilises the DNA-topoisomerase complex, thereby halting DNA replication. 
Anthracyclines also disrupt the function of cell membranes, and generate hydrogen 
peroxide and hydroxyl radicals which are damaging to cells [90]. Doxorubicin can 
accumulate, leading to dose-related cardiotoxicity and therefore, patients must not 
receive more than the maximum cumulative dose. The use of liposomal formulations 
of doxorubicin (e.g. PLD) may reduce the incidence of cardiotoxicity and local 
necrosis; however, hand-foot syndrome is a common side effect.  
 
Topotecan 
Topotecan is a campothecin derived from the stem of the tree Camptotheca 
acuminata. Campothecins prevent DNA replication by binding to and inhibiting the 
topoisomerase I enzyme. They have fewer side effects compared to other 
chemotherapeutic agents. 
 
1.2.7.3   Route of Chemotherapy Administration 
Most chemotherapeutic agents are administered either orally or intravenously. A 
review of eight clinical trials reported a significant reduction in the risk of death and 
disease recurrence following intraperitoneal (IP) delivery [3]. The aim is to increase 
the concentration of drug in contact with the tumour on the peritoneal surface. IP 
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therapy is most appropriate for patients who have undergone surgery to remove the 
majority of the tumour. This allows the chemotherapy to penetrate small tumour 
nodules and have an enhanced cytotoxic effect. Despite this, IP drug administration is 
inconvenient and can be poorly tolerated by patients due to the increased incidence of 
adverse effects. Current guidance does not support the routine use of IP 
chemotherapy, except as part of a clinical trial [3].   
 
1.2.7.4   Bevacizumab 
Blood vessel formation (angiogenesis) is crucial for the progression of cancer since 
tumour growth is unable to proceed beyond 2mm in the absence of angiogenesis [92]. 
Pro-angiogenic factors including vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), platelet-derived growth factors (PDGFs), TNF-α, interleukins (IL-
6, IL-8) and angiopoietins are important for cell growth and metastasis in tumour 
angiogenesis [92, 93]. Bevacizumab is a monoclonal antibody which recognises 
VEGF-A and has recently been approved for the treatment of women with recurrent 
platinum-resistant ovarian cancer. Initial phase II studies of bevacizumab as a single 
agent for the treatment of ovarian cancer demonstrated improved patient survival [94, 
95]. Following this, the phase III studies GOG 218 and ICON7 both reported that 
bevacizumab in combination with chemotherapy in patients with stage III or stage IV 
ovarian cancer improved PFS compared to chemotherapy alone (GOG 218: 14.1 
versus 10.3 months; P < 0.001; ICON7: 19.0 versus 17.3 months; P = 0.004) [96, 97]. 
Despite this, OS was only improved in high-risk women during the ICON7 trial. In the 
OCEANS trial, the combination of bevacizumab, gemcitabine and carboplatin for 6-10 
cycles followed by bevacizumab until disease progression improved PFS compared to 
chemotherapy alone in women with platinum-sensitive recurrent ovarian cancer (12.4 
versus 8.4 months; P < 0.0001) [98]. Furthermore, in platinum-resistant recurrent 
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disease, there was a significant improvement in PFS in patients randomised to 
chemotherapy (pegylated liposomal doxorubicin, paclitaxel or topotecan) with 
bevacizumab versus chemotherapy alone (6.7 versus 3.4 months; P < 0.001) [99]. 
Despite a trend in favour of the addition of bevacizumab to chemotherapy, there was 
no significant improvement in OS in the bevacizumab arm [99]. A recent study 
determining the effects of bevacizumab on patient-reported outcomes during the 
AURELIA trial found that there was a significant improvement in gastrointestinal 
symptoms in women with recurrent platinum-resistant ovarian cancer in the 
bevacizumab arm [100]. A review of the clinical efficacy and cost effectiveness of 
bevacizumab resulted in NICE not recommending bevacizumab in combination with 
paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer [101], 
or bevacizumab in combination with gemcitabine and carboplatin for the treatment of 
the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian 
tube or primary peritoneal cancer) that has not been previously treated with 
bevacizumab or other VEGF inhibitors [102]. 
 
 
1.2.8   Potential of Olaparib for the Treatment of Ovarian Cancer 
 
Pathways involved in DNA damage repair mechanisms have an important role in 
maintaining genome integrity and the response to chemotherapy. Cancer cells have 
several mechanisms which function to repair this damage by removing platinum-DNA 
adducts from the tumour DNA [103]. The nucleotide excision repair (NER) pathway is 
primarily responsible for repairing platinum-induced DNA damage in ovarian cancer 
cells, and increased expression of NER proteins correlated with cisplatin resistance 
[104]. The mismatch repair (MMR) pathway is involved in the repair of post-replicative 
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errors and is deficient in around 10% of ovarian cancers [105]. MMR inactivation may 
contribute to DNA damage tolerance in cancer cells and correspondingly, several 
studies have linked downregulated or mutated MMR genes to platinum resistance in 
ovarian cancer [106, 107].  
 
BRCA1 and BRCA2 proteins are involved in the HR pathway, which functions to repair 
DNA strand breaks (figure 1.5). BRCA1/2 loss-of-function mutations can increase the 
risk of ovarian cancer, as cells are unable to repair damaged DNA through the 
defective HR pathway [108]. Poly (ADP) ribose polymerase (PARP) facilitates the 
addition of ADP-ribose polymers to damaged DNA, which results in the repair of DNA 
single-strand breaks through the base excision repair (BER) pathway [109]. The 
inhibition of PARP leads to an increase in DNA lesions, including double-strand 
breaks or collapsed replication forks that can only be repaired by HR (figure 1.5). The 
result, known as synthetic lethality, is the combined inhibition of two DNA repair 
pathways which leads to cell death [108]. However, secondary mutations may restore 
BRCA1/2 and HR function and this, in combination with other mechanisms (section 
1.2.9), may contribute to drug resistance [110, 111]. 
 
The Cancer Genome Atlas analysis of HGSC demonstrated that approximately 25% 
of cases may have disruption to the HR pathway [56], and these patients could be 
treated with PARP inhibitors. Tumours with BRCA1/2 mutations were highly sensitive 
to PARP inhibitors, indicating that PARP inhibitors may be selective for tumour cells 
since normal cells retain wild-type BRCA1/2 [112, 113]. In contrast, ongoing phase II 
studies have recently reported some response to PARP inhibition in patients with no 
BRCA mutations [114], suggesting that these tumours may have other mutations in 
genes which function in the HR pathway [115]. This provides evidence of the potential 
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benefit of PARP inhibitors in non-BRCA mutant ovarian cancer and highlights the 
need to define the population best served by PARP inhibition. 
 
 
 
Figure 1.5: DNA repair and PARP inhibitors. Normal cells have functional HR and 
BER pathways which facilitate the repair of DNA strand breaks (A). Tumour cells with 
mutant BRCA are HR deficient and require the BER pathway to repair DNA single-
strand breaks. PARP inhibitors prevent DNA repair through BER and this leads to cell 
death (B).   
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The PARP inhibitor, olaparib, demonstrated anti-tumour activity and was well tolerated 
in women with BRCA-mutated ovarian cancers in early phase I/II clinical trials [116, 
117]. However, when olaparib was compared to liposomal doxorubicin, no significant 
benefit was observed [118]. Several recent clinical trials have demonstrated that PFS 
was significantly longer in the olaparib group compared to the placebo group (11.2 
months versus 4.3 months; P < 0.0001), although no OS benefit was observed [114, 
119]. Furthermore, the adverse effects of olaparib therapy were generally mild, 
including nausea, vomiting, fatigue and anaemia [114]. Taking into account these 
promising results, the Committee for Medicinal Products for Human Use of the 
European Medicines Agency have recommended the marketing authorisation of 
olaparib as monotherapy for the maintenance treatment of women with platinum-
sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube 
or primary peritoneal cancer who are in response (complete or partial) to platinum-
based chemotherapy.  
 
Olaparib is also being evaluated in novel drug combinations in an attempt to improve 
clinical outcomes. A recent phase I clinical trial combining olaparib and the VEGF 
receptor (VEGFR) inhibitor, cediranib in patients with recurrent epithelial ovarian 
cancer resulted in an overall response rate of 44% [120]. A multi-institutional 
randomised phase II clinical trial is currently in progress [121]. Furthermore, an early 
study evaluating olaparib in combination with carboplatin in BRCA1/2 mutated ovarian 
cancer reported that this combination is well tolerated and demonstrated some 
promising signs of clinical activity [122]. 
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1.2.9   Major Mechanisms of Chemotherapy Resistance 
 
In addition to the alteration of DNA repair processes, there are several other 
mechanisms of drug resistance in cancer cells and these include a decrease in 
intracellular drug accumulation, drug metabolism and inhibition of apoptosis.  
 
1.2.9.1   Impaired Intracellular Drug Accumulation 
A decrease in the accumulation of drug in cancer cells has been documented as one 
of the major mechanisms contributing to drug resistance [123]. For example, copper 
transporter-1 (CTR1) is involved in regulating the entry of cisplatin and carboplatin into 
the cell. Copper can competitively inhibit the transport of cisplatin into ovarian cancer 
cells, resulting in a downregulation of CTR1 expression [124]. Furthermore, copper 
exporters (ATP7A and ATP7B) are overexpressed in some ovarian cancers and can 
sequester platinum-based compounds, resulting in drug resistance [125, 126]. The 
multidrug resistance protein, P-glycoprotein (P-gp) is a membrane protein which 
functions to remove P-gp substrates from the cell. For example, P-gp has been shown 
to reduce the intracellular concentrations of platinum-based compounds, leading to 
chemoresistance [123]. Combination with P-gp inhibitors may increase the retention of 
chemotherapeutic agents in the cell, and subsequently improve clinical outcome. 
Indeed, this has been observed for combinations of doxorubicin and statins in ovarian 
cancer cell lines (discussed in chapter 7). However, the administration the P-gp 
inhibitor, valspodar with paclitaxel had limited activity in patients with paclitaxel-
resistant disease and considerable toxicity [127].  
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1.2.9.2   Drug Inactivation 
Glutathione is involved in the detoxification of platinum-based compounds, where they 
are converted into thiol conjugates by glutathione S-transferase and inactivated [123]. 
Glutathione S-transferase and enzymes involved in glutathione synthesis have been 
linked to cisplatin resistance in ovarian cancer cell lines [128]. The glutathione analog 
prodrug, canfosfamide, increased the sensitivity of ovarian cancer cells to apoptosis 
by reducing intracellular glutathione levels [123]. Despite this, clinical trials combining 
canfosfamide with chemotherapy in carboplatin-refractory or resistant ovarian cancer 
failed to demonstrate any clinical benefit compared to standard therapy alone [123].  
 
1.2.9.3   Apoptosis Deregulation 
Chemotherapeutic drugs can induce apoptosis in ovarian cancer cells, and therefore, 
inhibition of this mechanism of cell death has been associated with drug resistance. 
Expression of anti-apoptotic proteins (Bcl-2 and Bcl-XL) and the caspase inhibitor, X-
linked inhibitor of apoptosis protein (XIAP), have been correlated with drug resistance 
in ovarian cancer cells [129-131]. 
 
 
1.3   The Mevalonate Pathway and HMGCR Inhibitors 
 
1.3.1   Deregulation of the Mevalonate Pathway in Cancer 
 
Deregulation of cholesterol synthesis in mouse hepatomas was first reported around 
50 years ago [132], and this observation has since been extended to other tumour 
types. Early studies showed that the synthesis of mevalonate had an essential 
function in DNA replication, and that feedback control of cholesterol synthesis was lost 
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in premalignant and malignant states both in vitro and in xenograft studies (reviewed 
by [133]). Following these early observations, there has been an abundance of 
evidence in support of increased cholesterol synthesis in cancer cells [134-138]. The 
increase in cellular cholesterol may be due to an increase in the activity of 3-hydroxy-
3-methylglutaryl coenzyme A reductase (HMGCR) in tumours as a result of increased 
transcriptional regulation or deregulated feedback control of HMGCR [139-145]. 
HMGCR was recently described as a metabolic oncogene as ectopic expression of 
HMGCR increased anchorage independent growth and co-operated with other 
oncogenes including Ras to transform cells [137]. Furthermore, overexpression of 
HMGCR promoted cell growth and migration in esophageal squamous cell carcinoma 
cells [146] and correlated with poor prognosis and reduced survival in breast cancer 
patients [137]. Several cholesterol-related genes including HMGCR are 
transcriptionally regulated by the sterol regulatory element binding protein isoform 2 
(SREBP-2). Correspondingly, SREBP-2 correlated with cell viability in prostate tumour 
cells [147]. Furthermore, TP53 is almost ubiquitously mutated in ovarian cancer, and 
this can cause a “gain-of-function” association of mutant p53 with the promoters of 
sterol biosynthesis genes, leading to upregulation of the mevalonate pathway and 
tumorigenesis as demonstrated in breast cancer cells [148]. Alternatively, enhanced 
cholesterol synthesis may depend on the availability of other precursors in the 
mevalonate pathway including acetyl-CoA [149]. The Cancer Genome Atlas analysis 
identified gene amplification or increased mRNA expression of around 40% of the 
genes in the mevalonate pathway, including those involved in the synthesis of acetyl-
CoA and HMG-CoA [56]. Despite this, increased HMGCR expression has been 
correlated with an improved clinical prognosis in breast, ovarian and colorectal 
cancers [150-152]. The association between cholesterol and cancer is also currently 
unclear, with some evidence indicating that cancer patients with high cholesterol 
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levels may have an improved outcome [153]. However, the levels of oxidised low 
density lipoprotein cholesterol (LDL) were increased in ovarian cancer patients, and 
were later found to stimulate cancer cell proliferation and reduce sensitivity to 
chemotherapeutic agents [154, 155]. Taken together, the findings regarding 
cholesterol are confusing, and it may be that cholesterol has no direct effect on 
cancer. Rather, this could be reflection of activity of the mevalonate pathway, whose 
real “driver” role in cancer is to make isoprenoids. 
 
 
1.3.2   Introduction to HMGCR Inhibitors 
 
HMGCR catalyses the irreversible reduction of HMG-CoA to mevalonate at the 
beginning of the isoprenoid biosynthetic (mevalonate) pathway (figure 1.6). This is the 
rate-limiting step in the pathway and the primary point of regulation of cholesterol 
synthesis. HMGCR is regulated both at the transcriptional level, and by 
phosphorylation, following an increase in intracellular cholesterol, which results in a 
reduction in HMGCR catalytic activity and an increase in proteolytic degradation [156]. 
Therefore, a decrease in HMGCR activity can regulate the output of the mevalonate 
pathway without accumulating unusable intermediates. Statins are a class of drug 
which competitively inhibit HMGCR. 
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The Mevalonate Pathway 
 
 
Figure 1.6: The mevalonate pathway. Statins (blue) inhibit 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR, red), which prevents the genanylgeranylation of 
proteins involved in a number of signalling pathways. 
 
 
There are currently six clinically approved statins in the UK for the treatment of 
hypercholesterolemia (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin 
and simvastatin, figure 1.7). Lovastatin is an additional statin approved by the US 
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Food and Drug Administration (figure 1.7). Mevastatin was one of the first fungal 
statins isolated from Penicillium citrinum, although it was never marketed due to 
adverse effects in xenograft studies [157]. This was quickly followed by the type 1 
statins, lovastatin, simvastatin and pravastatin, which are all derivatives of fungal 
products [158-160]. Type 2 statins include fluvastatin, cerivastatin, atorvastatin, 
rosuvastatin and pitavastatin, and are fully synthetic with larger, more polar groups 
attached to the HMG-like moiety to improve binding to HMGCR. Cerivastatin was 
withdrawn from the market in 2001 following an unacceptable number of deaths 
resulting from kidney failure attributed to statin-induced rhabdomyolysis. 
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Figure 1.7: The chemical structures and half-lives (T1/2) of the statins [161, 162]. 
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The chemical structure of the statins can be divided into three parts: a HMG-CoA 
analogue, a hydrophobic ring structure involved in binding of the statin to HMGCR, 
and side groups which define other pharmacokinetic properties of the statins (e.g. n-
octanol/water partition coefficient, logP). Statins occupy the enzyme active site of 
HMGCR where HMG-CoA is normally bound and form mostly polar interactions with 
residues located in the HMG-binding pocket loop (figure 1.8) including Ser684, Asp690, 
Lys691 and Lys692 [163]. A hydrogen-bonding network is formed between Lys691, 
Glu559, Asp767 and the statin O5-hydroxy group [163]. Additionally, the final carboxylate 
of the statin HMG moiety forms a salt bridge with Lys735. Hydrophobic side chains in 
HMGCR also participate in a large number of van der Waals interactions with the 
statins (figure 1.8); this is likely to contribute significantly to the high affinity of statins 
to HMGCR [163]. The variable hydrophobic groups of the statins occupy a non-polar 
groove, which is accessible when the carboxy-terminal residues of HMGCR are 
disordered [163]. 
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Figure 1.8: The binding interactions between HMGCR and ligand. Hydrogen bonding 
is indicated by the black dashed lines. Hydrophobic interactions are indicated by the 
green solid lines. Graphic generated using PoseView by BioSolveIT [164].  
 
 
Statins were developed and licenced for the treatment of high cholesterol as they are 
highly efficient in lowering LDL. Rosuvastatin affords the greatest reduction in LDL 
(63%) following a standard daily dose of 40 mg [165]. The newest statin, pitavastatin 
reduced LDL by 38% after a 2 mg daily dose [166]. Statins also increase high density 
lipoprotein cholesterol (HDL) by up to 10% [167]. Furthermore, numerous clinical trials 
have shown that statins can either prevent or improve the outcome of ischemic stroke, 
myocardial infarction and peripheral arterial disease (Reviewed by [168-170]). Aside 
from these indications, statins also have cholesterol-independent or “pleiotropic” 
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effects arising from the inhibition of farnesyl diphosphate or geranylgeranyl 
diphosphate, which are substrates for the post-translational modification of proteins 
involved in various cell signalling pathways. This will be the focus of the remainder of 
this chapter. 
 
 
1.3.3   Protein Prenylation and the Role in Cancer 
 
1.3.3.1   Protein Prenylation 
The anti-cancer activity of statins is thought to arise from the inhibition of several 
intermediate lipids, farnesyl diphosphate and geranylgeranyl diphosphate, in the 
mevalonate pathway, which subsequently prevents the activity of many proteins in 
downstream signalling pathways. It is thought that several hundred proteins undergo 
prenylation [171, 172]. Many of these contain a carboxy-terminal motif that is 
recognised as the site of isoprenylation. Farnesyltransferase (FT) or 
geranylgeranyltransferase-I (GGT1) recognise a CAAX motif, where ‘C’ is a cysteine 
moiety, followed by to two aliphatic residues, and ending in ‘X’ representing any amino 
acid [173]. The CAAX prenyltransferases add either a 15-carbon farnesyl or a 20-
carbon geranylgeranyl group to the cysteine residue. The nature of this final amino 
acid ‘X’ determines if the protein is a substrate for FT or GGT1: in general, FT prefers 
‘X’ to be methionine, serine, glutamine or cysteine, whereas GGT1 prefers ‘X’ to be 
leucine or isoleucine [174]. The prenylated protein is then further processed at the 
endoplasmic reticulum, where the three terminal amino acids (‘AAX’) are removed by 
the Ras-converting enzyme 1 (RCE1) protease, leaving the prenylcysteine at the C-
terminus [175]. The protein is subsequently methylated on the carboxyl group by 
isoprenylcysteine carboxyl methyltransferase (ICMT) using S-adenosyl-L-methionine 
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as a methyl donor, and directed to the appropriate location which is often cytoplasmic 
surface of cell membranes [175]. Prenylcysteine methylation of the protein is believed 
to be important for protein-protein interactions [175], although proteolysis and 
methylation may not be essential for the function of some geranylgeranylated proteins 
[176]. Prenylated proteins which contain an additional cysteine near the C-terminus 
may also be further modified at the Golgi by a protein acyltransferase (PAT), which 
catalyses the addition of a palmitoyl group onto the cysteine [177]. Palmitoylation can 
provide further regulation of protein membrane localisation [178]. Many members of 
the Rab family lack the CAAX motif, but instead possess a CC or CXC sequence 
[179]. A Rab escort protein (REP) binds to the Rab protein through these motifs and 
presents the protein to geranylgeranyltransferase-II (Rab geranylgeranyltransferase, 
GGT2) [179]. This GGTase transfers two geranylgeranyl groups to the cysteine 
residues of the Rab protein and this dual prenylation has been shown to be essential 
for targeting to specific membranes [180]. Guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs) are involved in cycling prenylated 
proteins between active and inactive states, resulting in the transduction of a signal to 
downstream effectors. Guanine nucleotide dissociation inhibitors (GDIs) bind to 
prenylated inactive proteins, and function to regulate their transport to, or extraction 
from, membrane compartments [181]. Once at the required destination, GDI 
displacement factors (GDFs) catalyse the dissociation of the prenylated proteins from 
GDIs, and the subsequent delivery of the protein to the membrane [181]. Many 
prenylated proteins are involved in tumorigenesis, including cancer cell proliferation, 
apoptosis, angiogenesis and metastasis [173]. 
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1.3.3.2   Prenylated Proteins Involved in Cancer Development 
Several protein families, particularly small GTPases, are known to undergo 
prenylation. Statins may exert their anti-cancer activity by modifying the prenylation of 
these proteins and consequently, their subcellular targeting. 
 
Ras GTPases 
The Ras subfamily of GTPases has 21 members, and of these, harvey rat sarcoma 
viral oncogene homolog (H-Ras), K-Ras and N-Ras have been found to be mutated in 
human cancers [182]. H-Ras is farnesylated, whereas K-Ras and N-Ras can be both 
farnesylated and geranylgeranylated and this is critical for localisation to the cell 
membrane and interactions with downstream signalling molecules (e.g. Raf-1) [183]. 
Both K-Ras and N-Ras have been shown to be overexpressed in ovarian cancers as 
previously described [54, 56]. Oncogenic Ras activates downstream signalling 
pathways (e.g. Raf/Mek/Erk and PI3K pathways) resulting in the uncontrolled growth, 
proliferation and survival of cancer cells [182]. 
 
Rho GTPases 
The Rho family of GTPases belongs to the Ras superfamily and consists of around 20 
GTP-binding proteins, including RhoA, RhoB, RhoC, Rac1 and Cdc42. RhoA, RhoC, 
Rac1 and Cdc42 are exclusively geranylgeranylated [184-186], and RhoB is either 
geranylgeranylated or farnesylated [186]. Rho GTPases have been shown to promote 
cancer cell survival in some cell types [187]. Correspondingly, RhoA, Cdc42 and Rac1 
stimulate cell cycle progression and Ras-induced transformation [188, 189]. Rho 
GTPases have also been reported to regulate processes during angiogenesis [190] 
and cell migration, including the formation of membrane profusions [191], focal 
adhesions and stress fibres, cell contraction and rear detachment [192]. Furthermore, 
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increased RhoA and RhoC have been associated with the progression of ovarian 
cancer [193].  
 
Rheb GTPases 
The Rheb GTPase is also part of the Ras superfamily and its function has been 
associated with cell growth, the cell cycle, autophagy and amino acid uptake [194]. 
Rheb1 and Rheb2 are farnesylated and this is essential for localisation of Rheb to 
endomembranes [195]. Rheb is commonly overexpressed in human cancers including 
ovarian cancer, and may mediate cancer cell growth and cell cycle progression by 
binding and activating the Mammalian Target of Rapamycin (mTOR) functional 
complex, mTORC1 [56, 196, 197].  
 
Rab GTPases 
There are more than 60 Rab GTPases which have a range of different functions 
focussed on intracellular trafficking, including the regulation of protein secretion, 
endocytosis, recycling and degradation [198]. Most Rab GTPases are 
geranylgeranylated by GGT2, and this is required for Rab localisation and function 
[180]. Rab25 was found to be overexpressed in ovarian cancer where it correlated 
with poor survival [199]. Rab25 may promote cancer cell migration and invasion, 
thereby contributing to tumour aggressiveness and metastasis [200]. In contrast, a 
recent genomic analysis of almost 500 patients with HGSC reported that Rab25 was 
epigenetically silenced in a subset of HGSC [56]. This suggests that Rab25 may have 
different effects depending on the cellular context of the tumour, where it may function 
as an oncogene or a tumour suppressor. Rab GTPases have also been shown to 
contribute to tumour-stromal cell communication and cell cycle progression in other 
cancer types (reviewed by [198]).  
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Ras-like (Ral) GTPases 
Ral GTPases are also members of the Ras superfamily and consist of RalA and RalB 
isoforms [201]. Both RalA and RalB require geranylgeranylation for membrane 
association and function [201, 202]. The Ral GTPases appear to have collaborative 
functions in tumorigenesis as RalB was shown to be critical for tumour survival and 
RalA was required for the anchorage-independent growth of cancer cells [203]. RalA 
activity was found to be increased in ovarian cancer tumours [204]. Subsequent 
depletion of RalA inhibited ovarian cancer cell growth and invasion [204].  
 
Protein tyrosine phosphatases 
The 4a-family of protein tyrosine phosphatases (PTPases) comprise of PR-1, PR-2 
and PR-3, which are farnesylated or geranylgeranylated in vivo [205]. Little is known 
about the function of the 4a-family of PTPases, although PR-3 has recently been 
linked to tumour invasiveness and poor prognosis [206]. Furthermore, ovarian cancer 
effusions were found to express high levels of PR-1, PR-2, PR-3, although these were 
not associated with tumorigenesis, suggesting that these PTPases may have different 
cellular functions in ovarian cancer [207].  
 
Lamins 
Lamins are nuclear membrane proteins which are divided into A and B types based 
upon structural and protein features [208]. A-type and B-type lamins are farnesylated 
and localised to the nuclear envelope, however farnesylation may not be required for 
function, as the farnesyl group along with 18 amino acids is proteolytically removed 
from lamin A in the nuclear envelope [209]. Lamins have been associated with a 
range of nuclear functions including chromatin regulation, transcription, DNA 
replication and DNA repair, although their role in cancer is less clear [208]. Altered 
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lamin expression has been reported in a number of cancers with conflicting results 
(reviewed by [208]). In ovarian cancer, expression of A-type lamins was upregulated 
whereas expression of lamin C was reduced [210, 211]. These changes in lamin 
expression could control cancer cell growth, epithelial-to-mesenchymal transition and 
migration, although further research is required to confirm this [211, 212].  
 
CENP-E and CENP-F 
CENP-E and CENP-F are centromere proteins involved in chromosomal capture and 
alignment during mitosis [213]. Farnesylation of CENP-E and CENP-F is critical for 
their functionality in maintaining chromosomal alignment during metaphase and for 
G2/M progression, thereby enabling cell cycle progression in cancer cells [214]. 
Inhibition of the farnesylation of CENP-E and CENP-F using the FT inhibitor, 
lonafarnib, resulted in mitotic chromosomal alignment defects in cell lines and human 
tumours [213]. 
 
 
1.3.4   Molecular Mechanisms of Tumorigenesis and the Cytotoxic Activity of 
Statins 
 
1.3.4.1   The Cell Cycle and Cancer Progression 
The cell cycle consists of four processes: cell growth, replication of DNA, transfer of 
duplicated chromosomes to daughter cells and cell division. Each cell cycle phase is 
regulated by various proto-oncogenes and tumour suppressors to allow the repair of 
genetic damage and to prevent tumorigenesis (figure 1.9). Cyclin dependent kinases 
(CDK) and cyclins form complexes which are involved in the cell cycle machinery 
during various stages of the cell cycle. During the first gap phase (G1), the cell 
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contains two copies of each chromosome. CyclinC/CDK3, CyclinD/CDK4/6, and 
CyclinE/CDK2 complexes control progression through G1 phase of the cell cycle [215]. 
Hypophosphorylated Rb proteins negatively regulate G1 phase progression by binding 
to transcription factors including E2F and inhibiting the expression of genes which 
encode proteins required for cell cycle progression [215]. Furthermore, CDK inhibitors 
(CDKI) including p15, p16, p17, p19, p21 and p27 inhibit the phosphorylation and 
activation of cyclin/CDK complexes [215]. Rb is phosphorylated by CyclinD/CDK4/6 to 
allow the release of the transcription factors and subsequent G1 transition [215]. The 
cell then enters synthesis or S-phase, where CyclinA/CDK2 controls DNA replication 
and maintains Rb phosphorylation. The cell then enters a second gap phase (G2) 
which functions to prevent the cell from undergoing mitosis with DNA damage. Here, 
cyclin B interacts with CDK1, and the phosphatase Cdc25 is maintained in an inactive 
state, thereby allowing G2 phase transition to mitosis (M). However, in response to 
DNA damage or stalled replication, Cdc25 is hyperphosphorylated which results in the 
ubiquitylation of Cdc25 and cell cycle arrest [216]. Aberrations in oncogenes (e.g. 
cyclins or CDKs) or tumour suppressor genes (e.g. Rb1 or CDKIs) have been 
associated with tumorigenesis. In HGSC, the genes encoding p16 and Rb were 
inactivated in 32% and 10% of cases respectively [56]. Furthermore, genes encoding 
cyclin D1, cyclin D2 and cyclin E1 were all amplified in 4-20% of HGSC cases, likely 
contributing to the development of some ovarian cancers [56]. 
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Figure 1.9: The cell cycle involving the first gap phase (G1), DNA synthesis phase (S), 
second gap phase (G2) and mitosis phase (M). Statins primarily inhibit cell cycle 
mediators involved in G1 progression. 
 
 
1.3.4.2   The Cell Cycle and Statins 
Statins inhibit the proliferation of many cancer cell lines by causing G0/G1 cell cycle 
arrest [217-233]. Furthermore, statins have also been shown to inhibit Rb 
phosphorylation [220, 232], and this, in combination with a reduction in the expression 
of the E2F transcription factor [234], may contribute to the inhibition of G1 progression. 
Others have also reported S-phase cell cycle arrest in multiple myeloma cells [235], 
and G2/M cell cycle arrest in Namalwa Burkitt lymphoma cells and MCF-7 breast 
cancer cells [219, 236]. These effects on cell division may be mediated through the 
inhibition of RhoA-dependent cell signalling [226, 237, 238], resulting in the 
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downregulation of the cell cycle mediators cyclin D1, cyclin E, CDK1, CDK2 and 
CDK4, and augmentation of the CDK inhibitors, p19, p21 and p27 (figure 1.9) [220, 
223, 224, 226, 229-232, 235, 236, 238-241]. 
 
1.3.4.3   Angiogenesis and Statins 
During VEGF-induced angiogenesis, activation of VEGFR leads to the release of 
endothelial nitric oxide synthase (eNOS) from caveolae in the plasma membrane 
[242]. The subsequent liberation of nitric oxide (NO) promotes endothelial 
proliferation, migration and vascular permeability [242]. High micromolar 
concentrations of statins have been reported to inhibit angiogenesis in cancer cells 
and endothelial cells through the attenuation of pro-angiogenic factors including 
VEGF, urokinase plasminogen activator, IL-8, angiopoietin 2 and binding 
immunoglobulin protein [240, 243-249]. Statins have also contributed to the inhibition 
of endothelial cell proliferation [250], prevention of endothelial cell adhesion to the 
extracellular matrix (ECM) [243], and induction of endothelial apoptosis [250, 251]. 
Furthermore, these effects were mediated through inhibition of the mevalonate 
pathway [245]. Conversely, low nanomolar concentrations of statins have been shown 
to stimulate angiogenesis, possibly through the activation of Akt [252], eNOS 
activation [253], and the release of NO [254].   
 
1.3.4.4   Metastasis and Statins 
Cancer cell migration into the ECM is a multistep process involving Rac and Rho 
GTPases. Cell adhesion molecules (CAMs) including cadherins, integrins and 
selectins regulate cell-cell or cell-matrix adhesion [255]. Protrusion of the leading edge 
involves actin polymerisation which is stimulated by Rac GTPases [256]. Integrins in 
the extending lamellipodia then make contact with ECM ligands and collect in the cell 
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membrane [256]. Following attachment to the ECM, Rac GTPases regulate the 
formation of a focal complex assembly containing focal adhesion kinase, the actin 
binding compounds, vinculin, paxillin and α-actinin, and other regulatory molecules 
[256]. Furthermore, Rho GTPases regulate the secretion and activation of proteases 
(e.g. matrix metalloproteinases (MMP)) which degrade the ECM in order to enable 
cells to move through the matrix [256]. Contraction of the cell body requires the 
generation of an actomyosin contraction, which is controlled by Rho and the Rho-
associated serine/threonine kinase (ROCK) [256]. Finally detachment of the trailing 
edge occurs after actomyosin contraction, where the protease calpain cleaves focal 
complex components, thereby enabling cell movement [256]. Statins have been 
shown to inhibit cancer cell migration and invasion, possibly through inhibition of the 
geranylgeranylation of Rho GTPases involved in cell motility [238, 257-260]. Statin-
induced RhoA delocalisation from the cell membrane resulted in the disorganisation of 
actin fibres, loss of focal adhesion sites and inactivation of NF-κB, which decreased 
the expression of the proteases MMP2, MMP3, MMP9 and urokinase [224, 240, 258, 
261, 262]. Furthermore, statins have also been demonstrated to inhibit CAMs 
including α-integrins, β-integrins, E-selectin, ICAM-1 and decrease the expression of 
CD44, thus contributing to the loss of cell adhesion [240, 258, 263-265]. Statins have 
also been shown to decrease ovarian clear cell cancer cell invasion by reducing the 
expression of osteopontin, a protein which regulates cell motility, invasiveness and 
growth of various cancers [266]. This was further confirmed in xenograft studies, 
where simvastatin decreased osteopontin expression, significantly delayed tumour 
growth and increased survival compared to control groups [267]. Furthermore, 
Wagner and colleagues reported that simvastatin inhibited ovarian cancer cell 
adhesion to mesothelial cells, a process involved in cancer metastasis to the surface 
of the peritoneum [268]. This was mediated through decreased expression of both 
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VCAM-1 on mesothelial cells and integrin α4β1 on ovarian cancer cells following 
simvastatin treatment [268]. Taken together, statins inhibit cancer cell migration, 
attachment to the ECM and invasion to the basement membrane, which contributes to 
a reduction in tumour metastasis. 
 
1.3.4.5   The Autophagy Pathway 
Autophagy is derived from two Latin words that mean “self” and “eating”. It is a highly 
regulated and evolutionarily conserved process amongst eukaryotic organisms, which 
is involved in the degradation of cellular organelles and proteins during nutrient 
starvation and metabolic stress (figure 1.10) [269-272]. Autophagy can be divided into 
six stages: omegasome formation, phagophore initiation and elongation, 
autophagosome formation, autophagosome-lysosome fusion and degradation as 
detailed below. 
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Figure 1.10: The autophagy pathway in mammalian cells. Nutrient depletion results in 
the activation of autophagy and subsequent formation of autophagosomes containing 
damaged organelles or cellular debris. Autophagosomes fuse with lysosomes, and 
lysosomal enzymes function to degrade damaged cargo. Statins have been reported 
to induce autophagy through the activation of AMP-activated protein kinase (AMPK) 
and the downregulation of Akt (Modified from [273]). 
 
 
Omegasome formation and phagophore initiation 
The autophagosomal membrane originates from cup-shaped protrusions from the 
endoplasmic reticulum, known as omegasomes. The Beclin1-Vps34-Atg14 PI3K 
complex regulates the formation of the omegasome during the initiation of autophagy 
[274]. Following this, an isolation membrane (phagophore) is formed on the inside of 
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the omegasome. The development of the initial phagophore membrane is dependent 
on the Beclin1-Vps34-Atg14 complex. The class III PI3K catalytic subunit Vps34 
generates phosphatidylinositol 3-phosphate (PI3P) which is anchored in place by 
phospholipid-binding effectors (WIPI-1/2) during autophagosome formation [275]. 
PI3P functions to recruit other autophagy-related gene (Atg) products that are 
important in autophagosome formation [276].  
 
Phagophore elongation and autophagosome formation 
The Beclin1-Vps34-Atg14 complex recruits the Atg12-Atg5-Atg16 complex to the 
phagophore [277]. The Atg12-Atg5-Atg16 complex along with Rab32 and Rab33B 
causes the elongation of the isolation membrane in order to engulf damaged contents 
[278-280]. This complex also promotes the recruitment of cytosolic microtubule-
associated protein light chain 3 (LC3-I), and AtgL1 functions to transport LC3-I to the 
phagophore [277]. Atg7, Atg3 and the Atg12-Atg5-Atg16 complex are involved in the 
lipidation of LC3-I, where the C-terminus of LC3-I is conjugated to 
phosphatidylethanolamine (PE) [281]. PE is a component of phospholipid bilayers, 
allowing the lipidated LC3-II to be localised to the autophagosomal membrane [277]. 
Following autophagosome formation, the Atg12-Atg5-Atg16 complex dissociates from 
the phagophore, Atg proteins are recycled in the cytosol and LC3-II remains bound to 
the inner autophagosome membrane [276, 282]. LC3-II also binds to adapter proteins 
including p62, neighbour of BRCA1 gene 1 (NBR1) and calcium binding and coiled-
coil domain 2 (NDP52), which recruit ubiquitinated proteins to the autophagosome to 
enable their degradation [283]. Both p62 and NBR1 may localise to the 
autophagosome formation site independently of LC3 localisation and are 
subsequently degraded during autophagy [284, 285]. 
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Autophagosome-lysosome fusion and degradation 
The fusion of autophagosomes and lysosomes results in the formation of the 
autolysosome. This late stage process is positively regulated by the Beclin1-Vps34-
UVRAG (UV irradiation resistance-associated gene) complex [286, 287]. UVRAG 
activates the GEF for Rab7, Vps34/HOPS (homotypic fusion and vacuole protein 
sorting) complex [288]. The GEF then promotes the activation of Rab7, which results 
in autophagosome tethering, docking, and fusion to lysosomes [289, 290]. Run 
domain protein as Beclin 1 interacting and cysteine-rich containing protein (Rubicon) 
negatively regulates autophagosome maturation by interacting with Vps34 via its RUN 
domain, which serves to inhibit PI3K activity [291]. Other proteins may also be 
involved in the regulation of autophagosome-lysosome fusion including the endosomal 
sorting complex required for transport (ESCRT III), hepatocyte growth factor-regulated 
tyrosine kinase substrate (Hrs), the lysosomal-associated membrane proteins: LAMP1 
and LAMP2, and the soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors: VAMP3 and VAMP7 [292, 293]. Autophagosomes move bidirectionally 
along microtubules, and therefore, fusion with lysosomes may also be dependent on 
microtubules. Two types of fusion have been proposed: one where the 
autophagosome and lysosome completely fuse, and a second where material is 
transferred from the autophagosome to the lysosome whilst keeping both vesicles 
intact [294]. Following autolysosomal formation, the contents of the autophagosome 
are degraded by lysosomal hydrolases including cathepsins, glycolytic enzymes and 
lipases. The vacuolar ATPases (V-ATPases) function as a source of H+ in order to 
maintain a low pH for the activity of lysosomal enzymes. LC3-II localised to the inner 
autophagosome is also degraded by cathepsins during this process, whereas LC3-II 
located on the outer face of the autophagosome is converted back into LC3-I and 
recycled [295]. The metabolites resulting from the digestion of autophagosome 
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contents are released into the cytosol to enable them to be used for energy and 
precursors for other anabolic processes [296]. Following this, the autolysosome is 
elongated to form the protolysosome, which matures and reforms the lysosome [297]. 
 
1.3.4.6   Autophagy and Ovarian Cancer 
Autophagy is increasingly considered to be mechanism of cancer cell survival during 
conditions of metabolic stress. This is supported by the fact that cancer cells can 
withstand a number of different stress conditions including glucose starvation, growth-
factor withdrawal, hypoxia and cytotoxic agents [298, 299]. In ovarian cancer, LC3 
was upregulated in some epithelial subtypes [300], whereas both aplasia ras homolog 
member I (ARHI) [301, 302] and several microRNAs involved in inhibiting the 
expression of Beclin 1 [303] were downregulated. Furthermore, lysophosphatidic acid 
(LPA) secreted by ovarian cancer cells was shown to increase IL-6, which induces 
autophagy in cancer cells and correlates with a poor prognosis [304, 305]. It is 
believed that autophagy can contribute to anti-cancer therapy resistance by facilitating 
the removal of damaged proteins and organelles for energy production and survival 
[298]. Indeed, when drug-induced autophagy was inhibited in ovarian cancer cells, the 
cytotoxic effects of the drugs were enhanced [306, 307].  
 
Autophagy was previously proposed as a mechanism of growth inhibition and non-
apoptotic cell death in cancer cells [308, 309]. It was thought that sustained autophagy 
may exceed the capacity of the cell, leading to the production of a large number of 
autophagosomes and extensive degradation of cytoplasmic proteins and organelles. 
The anti-cancer agent, dasatinib inhibited the growth of ovarian cancer cells through 
an induction in autophagy [310]. Suberoylanilide hydroxamic acid (SAHA) was 
demonstrated to potentiate decitabine-induced autophagy by increasing the 
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expression of a positive regulator of autophagy, ARHI [311]. Furthermore, a 
combination of two autophagy inducers, Rad001 and arsenic trioxide, synergistically 
inhibited the growth of ovarian cancer cells [312]. A number of studies have reported 
that inhibition of autophagy promotes ovarian tumour cell survival. Reductions in 
Beclin 1 and LC3 expression [313, 314], p53 mutations [315], and an upregulation of 
PI3K/Akt/mTOR signalling [316] in ovarian cancer cells can all contribute to an 
inhibition of autophagy and the development of advanced ovarian cancer. Collectively, 
these studies demonstrate that whilst autophagy has an essential role in promoting 
the survival of ovarian cancer cells, the precise function it fulfils may vary depending 
on a number of factors including the type and stage of cancer, genetic aberrations, 
and drug treatments.  
 
1.3.4.7   Autophagy and Statins 
Statins have been shown to induce autophagy in a range of different cancers including 
glioma [317], prostate [318], liver [319], rhabdomyosarcoma [320], mesothelioma 
cancer cells [321], and malignant peripheral nerve sheath cancer cells [322]. 
Furthermore, this was dependent on the inhibition of HMGCR in the mevalonate 
pathway [320], which resulted in the activation of AMP-activated protein kinase 
(AMPK), and the inhibition of Akt and the negative regulator of autophagy, mTOR 
(figure 1.10) [317, 319, 323]. Statins may also activate autophagy through 
extracellular signal-regulated kinase (Erk) and c-Jun N-terminal Kinase (JNK) 
signalling as a result of the production of reactive oxygen species (ROS), although the 
molecular mechanism is not fully understood [324]. Current evidence suggests that 
statin-induced autophagy is a mechanism of cell survival as inhibition of statin-induced 
autophagy using pharmacological agents (e.g. bafilomycin or 3-methyladenine) or 
siRNA against Atg5 resulted in a potentiation of apoptotic cell death [317, 319, 325, 
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326]. A limited number of studies have also suggested that statins may also inhibit 
autophagy. In human papillary thyroid cancer cells, rosuvastatin decreased the 
percentage of cells undergoing autophagy [227]. Furthermore, Wojkowiak and 
colleagues reported that dual exposure of malignant peripheral nerve sheath tumour 
cells to lovastatin and a FT inhibitor aborted autophagy and induced non-apoptotoic 
cell death [327]. Taken together, statins may induce autophagy in cancer cells as a 
mechanism of cell survival, although inhibition of the autophagy pathway cannot be 
excluded.  
 
1.3.4.8   The Apoptosis Pathways 
Apoptosis is a morphologically distinct form of programmed cell death which was first 
described more than 40 years ago [328]. There are currently two main apoptotic 
pathways recognized: the extrinsic (death receptor) pathway and the intrinsic 
(mitochondrial) pathway [329] (figure 1.11).  
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Figure 1.11: The extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is 
initiated by ligands binding to the death receptor which results in the activation of 
caspase-8, and caspases 3 and 7, leading to apoptosis (A). The intrinsic pathway is 
stimulated by DNA damage or endoplasmic reticulum (ER) stress, resulting in the 
activation of Bax and Bak. Subsequent mitochondrial outer membrane 
permeabilization (MOMP) leads to the release of cytochrome c, activation of caspase-
9, followed by caspases 3 and 7, and apoptosis (B). Statins have been reported to 
activate the extrinsic and intrinsic pathways. 
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Extrinsic apoptosis pathway 
The extrinsic apoptosis pathway is activated by the binding of a ligand (e.g. fatty acid 
synthetase ligand (FasL), TNF-α or TNF-related apoptosis-inducing ligand (TRAIL)) to 
the corresponding death receptor in the cell membrane. This leads to the recruitment 
of a cytoplasmic adapter protein such as FAS-associated death domain protein 
(FADD) to the receptor death domain, which associates with procaspase-8 though 
dimerization of the death domain. The resulting death-inducing signalling complex 
(DISC) induces the auto-catalytic activation of procaspase-8. Subsequently, caspase-
8 triggers the execution phase of apoptosis. 
 
Intrinsic apoptosis pathway 
The intrinsic apoptosis pathway is regulated by a range of non-receptor mediated 
stimuli which may activate or inhibit apoptosis. The activation of pro-apoptotic proteins 
including BH3-only proteins (e.g. Bid), and the effectors, Bax and Bak results in the 
loss of the mitochondrial transmembrane potential, mitochondrial outer membrane 
permeabilization (MOMP), and the release of pro-apoptotic proteins including 
cytochrome c. Cytochrome c binds to and activates procaspase-9, leading to the 
formation of an apoptosome and the activation of caspase-9.  
 
Execution pathway 
The extrinsic and intrinsic apoptosis pathways both result in the execution pathway, 
which involves the activation of execution caspases (caspase-3, caspase-6 and 
caspase-7) by the initiator caspases (caspase-8, caspase-9 and caspase-10). 
Execution caspases activate cytoplasmic endonuclease and proteases to degrade 
nuclear material, and cleave various substrates including cytokeratins and PARP. 
Caspase-3 activates Caspase Activated DNAse (CAD) and induces cytoskeletal 
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reorganisation and cellular fragmentation to form apoptotic bodies. Apoptotic cells are 
subsequently recognised and taken up by phagocytes for disposal.  
 
1.3.4.9   Apoptosis and Statins 
Statins have been demonstrated to induce apoptosis, primarily through the 
mitochondrial pathway, in many different cancers including breast [219, 222, 254, 
330], lung [239, 331, 332], prostate [232, 333], liver [221, 334], colon [335, 336], 
ovarian [249, 337, 338], bladder [339], thyroid [227, 340, 341], glioma [342-344], 
lymphoma [220, 236, 345], myeloma [235], osteosarcoma [346], head and neck 
squamous cell [347], and medulloblastoma [225]. These pro-apoptotic effects were 
mediated through the depletion of geranylgeranyl diphosphate in the mevalonate 
pathway [337, 348-350]. Correspondingly, a number of studies have demonstrated 
that statins inhibit the geranylgeranylation of RhoA, Rac1 and Cdc42, and subsequent 
translocation to the plasma membrane [232, 341, 351]. However, instead of the loss of 
prenylation preventing the functions of these Rho GTPases, Zhu and colleagues have 
recently discovered that simvastatin decreased the binding of Rho GTPases with the 
RhoA GDIα, resulting in an increase in the GTP-bound forms of RhoA, Rac1 and 
Cdc42 [352]. Unprenylated yet activated RhoA and Rac1 maintained at least some of 
their functions, as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
was activated, resulting in the generation of ROS following statin exposure [352]. 
Statin-induced ROS can lead to the activation of JNK and p38 MAPK signalling and 
this can contribute to apoptosis [340, 350, 352]. These results are supported by 
previous research where statins induced a paradoxical increase in unprenylated 
RhoA, Rac1 and Cdc42 together with an activation of JNK [220, 338, 353]. JNK 
stimulates Bak activation and inhibits Bcl-2, thereby stimulating pro-apoptotic 
signalling. Nevertheless, there are several examples where Rho GTPase signalling 
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may be impaired by statins. Rho GTPases including Rac can activate the transcription 
factor NF-κB following PI3K stimulation [354-356], and this results in the expression of 
anti-apoptotic mediators including Bcl-2, FLICE-like inhibitory protein (FLIP) and XIAP. 
However, statins reduced NF-κB levels and this is likely to account for the decrease in 
FLIP and Bcl-2 expression also observed after statin exposure [231, 240, 334, 346, 
350, 357-359]. Furthermore, Rho and Rac have also been shown to interact directly 
with PI3K and stimulate Akt, which promotes cell survival independent of NF-κB 
activation [360]. Statins attenuated the activation of PI3K and Akt, possibly through 
the inhibition of Ras and Rho prenylation [220, 249, 335], leading to an increase in 
Bax phosphorylation [334, 350, 361], and an upregulation of Bim expression [338, 
349]. Statin-induced cytochrome c release from the mitochondria stimulated the 
activation of the initiator (caspases 8 and 9) and execution (caspases 3 and 7) 
caspases, PARP cleavage and nuclear degradation, resulting in cell death [220-222, 
239, 334, 337, 341, 345, 350, 362]. Interestingly, activation of the extrinsic pathway 
appears to be tumour specific. Goc and colleagues reported that simvastatin induced 
the activation of caspase-8 in the extrinsic pathway through upregulation of TNF-α 
and FasL in prostate cancer cells, whereas in myeloma cells, statin-induced caspase-
8 activation acted as an amplifier of execution caspases in the intrinsic apoptosis 
pathway [351, 363, 364]. Furthermore, others have suggested that statins may trigger 
an ‘autocrine’ suicide factor, which may serve to amplify apoptotic signalling through 
the extrinsic apoptosis pathway [365]. Taken together, statins induce apoptosis by 
increasing the expression and activation of pro-apoptotic proteins (e.g. Bax and Bim) 
whilst inhibiting anti-apoptotic components (e.g. Bcl-2, Bcl-XL, FLIP and survivin), 
resulting in the loss of the mitochondrial membrane potential [219, 221, 222, 249, 350, 
351, 362], and the release of cytochrome c and smac/DIABLO [239, 333, 334, 337, 
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341, 345, 351], although in some cases, the extrinsic apoptosis pathway may also be 
activated. 
 
 
1.3.5   The Potential of Statins for Cancer Prevention or Treatment 
 
1.3.5.1   Statins and Cancer Incidence 
 
Statins were first associated with an increased risk of cancer in animal studies, where 
lovastatin at high doses increased the incidence of liver and lung cancers [366]. 
Statin-induced carcinogenicity was restricted to pre-clinical studies which utilised 
much higher doses of statins than those used in the clinic [367]. In contrast, the 
administration of lower statin concentrations inhibited the development of various 
cancers including liver [368], colon [369], thyroid [370], and breast [371-373] cancers 
in animal studies.  
 
Several meta-analyses have analysed the cancer risk associated with statin 
administration in human populations with conflicting results. Six meta-analyses found 
no association between statin use and the risk of any cancer (risk ratio (RR) values 
ranged from 0.96 – 1.00 [374-379]. Moreover, meta-analyses evaluating the effect of 
statins on specific cancer risk reported that statins had no significant association with 
breast [376, 378, 380, 381], lung [378, 382, 383], colorectal [376, 384], melanoma or 
non-melanoma [376, 385, 386], bladder [387], renal [388], and pancreatic [389, 390] 
cancers. Conversely, four analyses reported a significant decrease in the risk of 
hepatocellular cancer in patients treated with statins (RR: 0.58 – 0.64; [378, 391-394]. 
This association was observed in Asian and Western populations, and was not 
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affected by the type of statin (hydrophobic versus hydrophilic) or the duration of statin 
treatment [391-393]. Statin treatment also reduced the risk of gastric cancer (RR: 0.56 
– 0.59 [378, 395]) and haematological malignancies (RR: 0.74 – 0.81 [378, 396]). In 
general, statin use had no effect on the risk of prostate cancer [376, 378, 397]. 
However, several recent meta-analyses reported that statin treatment reduced the risk 
of advanced prostate cancer by 20% (RR: 0.8, P<0.001 [398], and improved 
recurrence-free survival in prostate cancer patients treated with radiotherapy [399].  
 
In ovarian cancer, several early studies including a randomised control trial and meta-
analysis indicated that standard doses of statins used for the treatment of 
hypercholesterolemia were not associated with a reduction in the development of 
ovarian cancer or any gynaecological cancer [378, 400, 401]. Despite this, Elmore and 
colleagues reported that in patients with advanced stage or invasive epithelial ovarian 
cancer, statin treatment significantly improved PFS (24 months versus 16 months, P = 
0.007) and OS compared to statin non-users (62 months versus 46 months, P = 0.04 
[402]). This was supported by a recent case-control study, which demonstrated that 
statins were associated with a significantly decreased risk of ovarian cancer and an 
improved survival after diagnosis of ovarian cancer (P = 0.021 [403]). Interestingly, 
whilst there were no overall differences in PFS or disease-specific survival (DSS) in 
ovarian cancer patients taking statins compared to non-statin use, statins appeared to 
improve PFS and DSS specifically in the non-serous papillary subtypes [404]. Taken 
together, a recent meta-analysis incorporating many of these studies reported that 
statin treatment modestly protected against ovarian cancer (RR: 0.79), and long term 
statin use (>5 years) significantly reduced the risk of ovarian cancer (RR: 0.48 [405]. 
These recent results suggest that not only may statins reduce the risk of developing 
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ovarian cancer, but they may also contribute to improved survival in ovarian cancer 
patients.  
 
1.3.5.2   Statins in Clinical Trials for Cancer Treatment 
 
To date, there have been a small number of phase I/II clinical trials evaluating the use 
of statins for the treatment of a range of different cancers. These studies have 
evaluated statins both as single agents and in combinations with standard 
chemotherapeutic options. Furthermore, a limited number of studies have evaluated 
statins at the maximum tolerated dose for up to 7 days. 
 
Several clinical trials have evaluated statins in combination with several 
chemotherapeutic regimens with the aim of establishing a toxicity profile to inform 
future studies. Simvastatin (40 mg/day) plus irinotecan, 5-fluorouracil, and leucovorin 
(FOLFIRI) reported a median survival of 21.8 months in metastatic colorectal patients, 
along with no additional adverse effects as a result of simvastatin addition [406]. This 
was supported by a phase I trial in acute myeloid leukemia patients where pravastatin 
(40-1680 mg/day) in combination with idarubicin and cytarabine did not increase the 
duration of neutropenia or thrombocytopenia, and the overall toxicity profile was 
unchanged compared to chemotherapy alone [407]. However, a recent phase I/II 
clinical trial combining cyclosporin A, pravastatin, etoposide and mitoxantrone in an 
attempt to circumvent drug resistance in acute myeloid leukemia was terminated early 
due to unacceptable toxicity [408]. This highlights the importance of conducting a 
small phase I study and carefully assessing the risk-benefit ratio when evaluating new 
combinations.  
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In non-small lung cancer (NSCLC), several studies by Han and colleagues found that 
the addition of a standard dose of simvastatin (40 mg/daily) to chemotherapy 
(irinotecan and cisplatin or gefitinib) did not significantly improve the time to 
progression or the one-year survival rate [409, 410]. Despite this, patients receiving 
gefitinib and simvastatin had a longer PFS compared to those receiving gefitinib alone 
(3.6 months versus 1.7 months, P = 0.027) in a subgroup of patients with wild-type 
epidermal growth factor receptor (EGFR) non-adenocarcinomas [409]. However, the 
former results were supported by a recent study in advanced pancreatic cancer 
patients, where simvastatin (40mg/daily) in combination with gefitinib afforded no 
additional clinical benefit compared to gemcitabine alone [411]. Standard doses of 
pravastatin (20-40 mg/daily) in patients with hepatocellular cancer significantly 
improved PFS in patients treated with transarterial chemoembolization (TACE) (18 
months versus 9 months, P = 0.006 [412]; 20.9 months versus 12 months, P = 0.003 
[413]). Conversely, pravastatin (40-80mg/daily) alone did not improve the median OS 
compared to patients treated with TACE [414]. Furthermore, no improvement in 
outcome was observed in advanced gastric cancer patients treated with pravastatin 
40 mg/daily in combination with epirubicin, cisplatin and capecitabine [415].  
 
High-dose lovastatin has been evaluated in patients with squamous cell carcinoma of 
the head and neck or of the cervix. This phase I study found that patients tolerated 
doses of up to 7.5 mg/kg/day and approximately a quarter had disease stabilisation 
[416]. These results were in contrast to a previous study where high lovastatin doses 
of 35 mg/kg/day were administered to patients with advanced gastric cancer for 7 
consecutive days (repeated every 28 days) and no response was observed [417]. 
Furthermore, simvastatin (15 mg/kg/day) in combination with vincristine, adriamycin, 
and dexamethasone in patients with myeloma was discontinued due to the poor 
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response as only one patient achieved a partial response [418], although the high 
dose was well tolerated for 7 days [419]. However, a more recent study in patients 
with relapsed and refractory multiple myeloma found that thalidomide, dexamethasone 
and lovastatin (0.5 mg/kg/day) significantly improved PFS compared to patients 
receiving only thalidomide and dexamethasone (33 months versus 16 months, P = 
0.048), with similar side effect profiles in both arms [420]. High-dose fluvastatin (80 
mg/day) was shown to reduce tumour proliferation and induce apoptosis in high-
grade, stage 0/1 breast cancer [421]. Furthermore, fluvastatin (8 mg/kg/day) on days 
1-14 in combination with chemotherapy significantly increased survival, reduced 
tumour volume and increased quality of life in children with brain stem tumours [422]. 
However, at standard doses of fluvastatin (40 mg/day) or atorvastatin (20 mg/day) in 
combination with zoledronate, there was no significant improvement in time to 
progression compared to results from previous studies in patients with renal-cell 
carcinoma and bone metastasis [423]. 
 
Collectively, the clinical trials evaluating statins at standard doses used for the 
treatment of high cholesterol had infrequent beneficial effects and a survival benefit 
has only been demonstrated in two trials in patients with hepatocellular cancer. This 
may reflect the liver-selective uptake of pravastatin by transporters including 
OATP1B1, thereby potentially increasing the concentration of pravastatin in contact 
with the tumour [424]. Despite this poor history of success, the majority of the clinical 
trials ongoing are evaluating statins at these low concentrations for cancer treatment 
[425]. Trials utilising higher doses of statins have generated some positive results, and 
several clinical trials are currently evaluating high doses of statins in combination with 
standard chemotherapeutic agents for the treatment of leukemia, glioma and lung 
cancer [425]. 
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1.4 Ovarian Cancer Experimental Models 
 
1.4.1   Ovarian Cancer Cell Lines 
 
Cell lines were historically the most frequently employed tumour models used to 
evaluate anti-cancer agents in ovarian cancer [426]. Ovarian cancer cell lines can give 
an insight into the molecular diversity and histology of tumours in the clinic, and cell 
lines that have been fully identified by molecular profiling are particularly beneficial for 
the evaluation of anti-cancer therapies which require specific molecular aberrations 
(e.g. PARP inhibitors and BRCA1/2 mutations) [426]. Furthermore, cell lines are 
relatively cheap, easy to manipulate and the culture conditions can be controlled. 
However, cell lines are less heterogeneous populations, and therefore, do not 
represent the whole tumour. Furthermore, cell lines that have been passaged for a 
number of years are likely to have undergone significant evolutionary selection, 
contributing to the inclusion of genomic alterations which are no longer reminiscent of 
the genetic and pathogenic profile of the original tumour cells [427]. Similarly, the drug 
resistance of the cell lines may not correspond to that observed in the parent tumour. 
Ovarian cancer cell lines are frequently grown as a monolayer, which is a flat layer of 
cells attached to the surface of culture vessels. Monolayers are advantageous for 
microscopy and other functional assays, however, this two-dimensional (2D) model is 
generally considered not to be physiologically relevant, and there may be difficulties 
with translation in vivo. This has led to the use of alternative ovarian cancer models, 
including spheroids and xenografts, to further evaluate anti-cancer agents. 
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1.4.2   Ovarian Cancer Spheroid Cultures 
 
Ovarian cancer spheroids can be cultured in vitro by several methods including the 
suspension of ovarian cancer cells in a hanging droplet of medium [428]. Ovarian 
cancer spheroids more accurately represent ovarian tumours as they have been 
shown to exhibit similar cellular, molecular and biochemical properties compared to 
tumours in vivo [428, 429]. For example, cancer spheroids were found to be 
considerably less sensitive to chemotherapy compared to monolayer cultures, 
consistent with the chemoresistance observed in metastatic tumour spheroids [430, 
431]. Cancer spheroids also exhibit oxygen/nutrient and proliferation gradients, where 
central regions may be poorly vascularised, resulting in limited access to essential 
components required for cell growth and the accumulation of catabolites [432, 433]. 
Therefore, ovarian cancer spheroid cultures may go some way to creating a three-
dimensional (3D) microenvironment which more closely represents ovarian cancer in 
a clinical setting. 
 
 
1.4.3   Ovarian Cancer Xenografts 
 
Human ovarian cancer xenografts are used extensively in preclinical drug 
development and commonly incorporate severe combined immunodeficient (SCID) 
mice strains deficient in both B and T lymphocytes to prevent cancer rejection [434, 
435]. Ovarian cancer cells can be implanted into xenograft models either 
subcutaneously, intraperitoneally or orthotopically, although accurate quantification of 
tumour volume can be more readily achieved following subcutaneous implantation 
[426]. Ovarian cancer xenograft models frequently use the Ovcar-3 cell line as many 
characteristics of the primary tumour are retained (e.g. ascites formation, tumour 
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angiogenesis and metastasis), and the histology resembles serous ovarian cancer 
[427, 436-438]. Ovarian cancer xenografts can be used to assess the cytotoxic activity 
of drugs, model biomarker responses in tissue or plasma, and determine toxicity in 
vivo. However, immunodeficient mice cannot recapitulate the effects of a functioning 
immune system on tumour growth, or the interaction between tumour cells and the 
human microenvironment [426]. Furthermore, there may be significant differences in 
drug pharmacokinetics in the xenograft compared to human pharmacokinetics, which 
must be taken into consideration when designing a xenograft study. 
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CHAPTER 2 
 
AIMS AND OBJECTIVES 
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The identification of novel drugs which demonstrate activity in chemorefractory or 
chemoresistant ovarian cancer is a priority in ovarian cancer research, given the poor 
prognosis and low survival rates affecting many patients. Statins have previously been 
shown to have cytotoxic activity in many cancers including some preliminary evidence 
of activity in ovarian cancer. Therefore, the main aim of this research was to 
preclinically evaluate several potent statins in order to support clinical trials of statins 
in ovarian cancer. The following hypotheses were tested.  
 
I.  Simvastatin will have single agent cytotoxic activity dependent on concentration and 
exposure time, and may sensitise ovarian cancer cell lines to carboplatin. Pitavastatin, 
which offers an improved pharmacokinetic profile, will also have single agent cytotoxic 
activity in ovarian cancer cell lines. 
 
II. Statins induce cell death through effects on the apoptosis and autophagy pathways. 
 
III. Potential biomarkers of statin-induced cell death may be identified in the cell 
culture supernatant from cells exposed to statins. 
 
IV. Pitavastatin may sensitise ovarian cancer cells to targeted anti-cancer therapeutics 
including ABT-737, obatoclax, pictilisib or metformin. 
 
To test these hypotheses, this research utilised ovarian cancer cell lines grown both 
as monolayer and spheroid cultures. The results of these in vitro studies prompted the 
evaluation of pitavastatin as a single agent in an ovarian cancer xenograft model. 
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CHAPTER 3 
 
MATERIALS AND METHODS  
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3.1   Ovarian Cancer Cell Lines 
 
Ovarian cancer cell lines were purchased from the American Tissue Culture Collection 
(ATCC).  
 
A2780 and cisA2780 cell lines were derived from a human ovarian carcinoma prior to 
chemotherapy treatment [439]. cisA2780 cells were rendered resistant to cisplatin by 
exposing A2780 cells to increasing concentrations of cisplatin [440]. 
 
The Ovcar-3 cell line was derived from the malignant ascites of a patient with 
progressive ovarian cancer that was resistant to cisplatin [441]. 
 
The Ovcar-4 cell line was derived from the ascites of a patient with ovarian cancer that 
was resistant to cisplatin [442]. 
 
The Ovcar-5 cell line was derived from the ascites of a patient with advanced ovarian 
cancer prior to chemotherapy treatment [442]. 
 
The Ovcar-8 cell line was derived from an ovarian carcinoma that was resistant to 
carboplatin [442]. 
 
The Igrov-1 cell line was derived from an ovarian carcinoma that was sensitive to 
chemotherapy treatment [443].  
 
The Skov-3 cell line was derived from the ascites of a patient with ovarian cancer that 
was resistant to cisplatin [444, 445].  
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PEA1 and PEA2 cells were derived from the ascites or pleural effusion of a patient 
with poorly differentiated cancer. PEA1 was collected prior to treatment and PEA2 
was collected on relapse following cisplatin and prednimustine treatment [446]. 
 
PEO1 and PEO4 cells were derived from the ascites of a patient with poorly 
differentiated serous cancer. PEO1 was collected after treatment with chemotherapy 
and PEO4 was collected after resistance to cisplatin, 5-fluorouracil and chlorambucil 
had developed [446]. 
 
 
3.2   Human Epithelial Cell Lines and Human Foreskin Fibroblasts 
 
Human Ovarian Epithelial (HOE) cells were purchased from Applied Biological 
Materials (ABM) Inc. and were derived from normal ovarian epithelium and 
immortalised using SV40 large T antigen. 
 
Human Bronchial Epithelial (NL20) cells were purchased from the ATCC and were 
derived from normal bronchus epithelium and immortalised using SV40 large T 
antigen. 
 
Primary Human Foreskin Fibroblast (HFF) cells were provided through collaboration 
with Dr. Nicholas Forsyth at the Institution for Science and Technology, Guy Hilton 
Research Centre, Keele University, Staffordshire. 
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3.3   Cell Growth Conditions 
 
Human ovarian cell lines and primary human foreskin fibroblasts were grown in 
Roswell Park Memorial Institute (RPMI 1640; Lonza) medium supplemented with 10% 
fetal bovine serum (FBS; Lonza), 50 µg/mL penicillin/streptomycin (Lonza) and 2 mM 
glutamine (Lonza). For Ovcar-3 cells, the medium was also supplemented with 0.01 
mg/mL insulin (Lonza) and 0.11 g/L sodium pyruvate (Lonza).  
 
The NL20 cell line was grown in Ham’s F12 medium (Lonza) supplemented with 4% 
FBS (Lonza), 1.5 g/L sodium bicarbonate (Sigma-Aldrich), 2.7 g/L glucose (Sigma-
Aldrich), 2 mM glutamine (Sigma-Aldrich), 0.1 mM non-essential amino acids (Sigma-
Aldrich), 0.005 mg/mL insulin (Lonza), 10 ng/mL epidermal growth factor (Lonza), 
0.001 mg/mL transferrin (Sigma-Aldrich) and 500 ng/mL hydrocortisone (Sigma-
Aldrich). 
 
Cells were incubated in a NAPCO water jacketed incubator (Precision Scientific) at 
37°C and in a humidified 5% CO2 atmosphere. cisA2780 cells were exposed to 1 µM 
cisplatin for 1 week every month in order to maintain chemoresistance.   
 
 
3.4   Trypsinisation of Adherent Cells 
 
All cells were routinely sub-cultured when they were more than 80% confluent as 
determined using an Olympus CKX41 light microscope. To detach adherent cells from 
the culture flask for routine passage or experimentation, cells were washed with 1 mL 
phosphate buffered saline (PBS; Lonza) and subsequently exposed to 1 mL 0.01% 
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trypsin (Lonza) in PBS. To encourage detachment, cells were incubated at 37°C and 
gently agitated. Following detachment, the trypsin was neutralised by the addition of 1 
mL RPMI containing 10% FBS and cells were transferred into a sterile 15 mL 
polypropylene tube (Sarstedt). Cells were centrifuged at 150 g for 3 minutes at room 
temperature in a Thermo Scientific Heraeus Megafuge 8 centrifuge. The supernatant 
was carefully aspirated and the cell pellet was re-suspended in fresh cell culture 
medium. For routine passage, cells were transferred to T25 or T75 sterile tissue 
culture flasks (Sarstedt). For experimentation, at least 100 cells were counted using a 
Neubauer haemocytometer to determine cell number and an appropriate number of 
cells were transferred to tissue culture plates (96-well, 48-well, 12-well, 6-well; 
Sarstedt) as described for each experimental procedure. 
 
 
3.5   Cryopreservation of Cells 
 
Cells of a low passage number were collected by trypsinisation (section 3.4) when 
they had reached approximately 50% confluence in a T75 tissue culture flask, to 
ensure that the cells were growing in the logarithmic phase. The cell pellet was re-
suspended in 1.2 mL growth medium containing 10% FBS and 8% dimethyl sulfoxide 
(DMSO, Sigma-Aldrich), and 0.2 mL aliquots were transferred into 2 mL cryovials 
(Triple Red). Cryovials were incubated overnight in a “Mr Frosty” freezing container 
(Nalgene) containing isopropanol (Sigma-Aldrich), at -80°C in a Nuaire -86°C Ultralow 
freezer, and the following day transferred into liquid nitrogen until required. 
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3.6   Reviving Cryopreserved Cells 
 
Frozen cells in a cryovial obtained from the liquid nitrogen were rapidly thawed in a 
Grant JB Series water bath (Grant Instruments) at 37°C and then added to 5 mL pre-
warmed growth medium in a 15 mL polypropylene tube. Cells were then centrifuged at 
150 g for 3 minutes at room temperature and the pellet was re-suspended in 8 mL 
growth medium. The resulting cell suspension was transferred into a T25 tissue 
culture flask and incubated for 24 hours at 37°C. Subsequently, the growth medium 
was replaced to remove residual DMSO and dead cells, and adherent cells were 
grown to an appropriate density for experimentation or sub-culture (section 3.4).   
 
 
3.7   Cytotoxicity Studies 
 
3.7.1   Pharmacological Agents 
 
Compounds were dissolved in DMSO, or PBS for carboplatin, to obtain the following 
concentrations: 10 mM ABT-737 (Abbot Laboratories), 13.5 mM carboplatin (Sigma-
Aldrich), 20 mM doxorubicin (Tocris), 20 mM metformin (Enzo Life Sciences), 5 mM 
obatoclax (GeminX), 10 mM paclitaxel (Sigma-Aldrich), 20 mM pitavastatin calcium 
(Sequoia Research Products), 20 mM pravastatin (Enzo Life Sciences), 20 mM 
simvastatin (Enzo Life Sciences), 0.3 mM topotecan (Tocris), 20 mM pictilisib (LC 
Laboratories), 100 nM bafilomycin A1 (Tocris), 300 mM N-acetylcysteine (NAc; 
Sigma-Aldrich), 20 mM tert-butyl hydroperoxide solution (TBHP; Sigma-Aldrich), 20 
mM farnesol (Sigma-Aldrich), 20 mM geranylgeraniol (Sigma-Aldrich) and 20 mM 
mevalonate (Enzo Life Sciences). 
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Cells were exposed to carboplatin at the IC50, doxorubicin or topotecan at five times 
the IC50, 20-50 nM paclitaxel, and simvastatin or pitavastatin at two to five times the 
IC50, in order to achieve cell death rapidly in vitro. 
 
 
3.7.2   Cell Growth Assays 
 
Following trypsinisation and quantification, cells (5000 cells/well except for A2780, 
cisA2780 and Ovcar-8, where 2000 cells/well were used) were seeded in 96-well 
plates in 80 μL of growth medium. After incubation for 24 hours, 20 μL of 18 different 
concentrations of drug or drug extract at 5 times the required concentration and a drug 
solvent control was added to the cells. For drug combination studies, the cells were 
exposed to either a range of concentrations of two drugs combined in a fixed ratio of 
the two drugs, or in a combination in which the concentration of one drug was held 
constant. (The concentrations are shown in the results section). After incubation for a 
further 72 hours, the growth medium was removed and the cells in each well were 
fixed in 100 μL 10% trichloroacetic acid (TCA, Sigma-Aldrich) on ice for 30 minutes. 
The TCA was then removed by washing the plates three times in water and the cells 
were left to air dry, before staining in 0.4% sulforhodamine B (SRB, Sigma-Aldrich) in 
1% acetic acid (Sigma-Aldrich) for 30 minutes. After removing excess SRB by 
washing the wells three times in 1% acetic acid and drying, the dye was solubilised in 
100 μL 10 mM Tris (pH 10, Sigma-Aldrich) and the absorbance at 570 nm (A570) was 
determined using a BioTek Synergy 2 multi-mode microplate reader. 
 
Cell growth assays, used to determine the potency of pitavastatin in PEA1, PEA2, 
PEO1 and PEO4 cell lines, were conducted by Karen Menezes and Dr Euan Stronach 
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in the Department of Surgery and Cancer at Imperial College London, using the 
method described above.  
 
 
3.7.3   Statistical Analysis to Determine IC50 Value 
 
Data obtained from cell growth assays (section 3.7.2) was analysed using the 
GraphPad Prism software (GraphPad Software, Inc.). Non-linear regression was used 
to fit a four-parameter (Hill-equation) sigmoidal dose-response curve, and 
subsequently, the concentration at which 50% of cell growth was inhibited (IC50) was 
determined. Both the mean average and standard deviation were calculated using 
IC50 values from repeat experiments. 
 
 
3.7.4   Drug Combinations in Cell Growth Assays 
 
For experiments evaluating the effect of altering the schedule of administration of 
combinations of simvastatin with carboplatin, cells were exposed to simvastatin, 
carboplatin or both for 48 hours, after which the drug was washed off the cells using 
PBS. Following this, the cells were incubated for a further 48 hours with drug or 
growth medium containing solvent. Alternatively, cells were exposed to carboplatin or 
simvastatin for 48 hours, before fixing in TCA and staining with SRB (section 3.7.2). 
Scheduling experiments used a fixed ratio of carboplatin and simvastatin 
concentrations based on the respective IC50 values measured in preliminary 
experiments with the single agents. 
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Drug combinations with pitavastatin and either obatoclax or pictilisib were combined at 
a ratio of their IC50 values as determined from single agent studies. ABT-737 is 
insoluble at high concentrations. Therefore, fixed concentrations of ABT-737, which 
had been determined to inhibit cell growth by 5% (A2780, 3 µM; Ovcar-3, 1 µM; 
Ovcar-8, 1 µM; Igrov-1, 0.6 µM), were added to each concentration of pitavastatin. A 
fixed concentration of metformin (15 µM) was also added in combination with varied 
concentrations of pitavastatin, as this is reported to be the highest achievable plasma 
concentration of metformin in vivo [447]. Cells were incubated for 72 hours, then fixed 
in TCA and stained with SRB as described (section 3.7.2).   
 
 
3.7.5   Calculation of Combination Indices and Bliss Independence Criterion 
 
The Combination Index (CI) was first described by Chou and Talalay [448] to provide 
a quantitative estimation of the degree of synergy, additivity or antagonism between 
two drugs. 
 
𝐶𝐼 =  
(𝐷)1
(𝐷𝑥)1
 +  
(𝐷)2
(𝐷𝑥)2
 
 
(D)1 and (D)2 indicate the doses of drug 1 and drug 2 in the combination which inhibit 
cell growth by 𝑥%. (Dx)1 and (Dx)2 indicate the doses of drug 1 and drug 2 alone which 
inhibit cell growth by 𝑥%. If the sum of the two fractions is equal to 1, then the 
interaction between the two drugs is additive. If the CI value is smaller than 1, then the 
interaction is synergistic, whereas if the CI value is greater than 1, then the interaction 
is antagonistic [448]. Results were compared to deviation from unity with a paired t-
test using Welch’s correction. 
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CI values were calculated to measure the combined effect of pitavastatin with ABT-
737, pictilisib, obatoclax or metformin. Dose-response curves were determined for 
each experiment and IC50 values and Hill co-efficients were calculated. CI values were 
quoted at a fraction affected of 0.5 or 0.75, which is the concentration of the drug 
combination that inhibited 50% or 75% of cell growth respectively.  
 
The Bliss independence criterion (which does not require knowledge of the IC50) was 
calculated to compare the observed effect of the drug combination with the expected 
effect.  
 
𝐸𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 =  𝐸𝐴 + 𝐸𝐵 − 𝐸𝐴 ∗ 𝐸𝐵 
 
EA and EB indicate the effects of drug A and drug B alone and are used to calculate 
the expected fractional effect (Eexpected) of the drug combination, which assumes that 
the effects of the two drugs are additive [449]. A paired t-test was used to compare the 
observed effect of the drug combination to the expected effect calculated using the 
Bliss independence criterion. 
 
 
3.7.6   Trypan Blue Cell Viability Assay 
 
Trypan blue is used to differentiate between viable and non-viable cells. The 
chromophore of Trypan blue is negatively charged, which prevents its penetration into 
the cell unless the cell membrane is damaged. Therefore, viable cells exclude the dye 
and have a clear cytoplasm when observed by microscopy, whereas dead cells are 
stained blue. 
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To assess the effect of a drug on cell viability using Trypan blue staining, 2 x 105 cells 
per well of a 12-well plate were incubated with 500 µL growth medium containing 10 
µM simvastatin (Ovcar-8), pitavastatin at a concentration of 5 x IC50 in each cell line 
(1-40 µM) or solvent for 12-96 hours as indicated. In drug combination studies, Ovcar-
3 and Igrov-1 cells (3 x 105 cells per well of a 6-well plate) were incubated with 1 mL 
growth medium containing pitavastatin (6 - 12 µM), ABT-737 (0.6 - 1 µM), obatoclax (2 
- 3 µM), pictilisib (0.7 - 2 µM) or solvent alone or in combination with pitavastatin for 72 
hours. Adherent cells were then collected by trypsinisation (section 3.4) and combined 
with the supernatant containing detached cells. The resulting cell suspension was 
centrifuged at 150 g for 3 minutes before staining with 0.2% Trypan blue (Sigma-
Aldrich) and quantifying live and dead cells using a haemocytometer (section 3.4). 
 
 
3.7.7   Three-Dimensional Spheroid Culture and ATP Assay 
 
Ovarian cancer spheroids/aggregates were used to provide a 3D architecture of 
cancer cells that more closely resemble cancer in vivo. The CellTiter-Glo assay 
(Promega) was used to avoid the issues of reagent penetration into the spheroid 
during the measurement procedure. The CellTiter-Glo reagent lyses the cells in the 
spheroid entirely, and the ATP released results in the mono-oxygenation of luciferin 
and generation of a luminescent signal. The luminescence is proportional to the 
amount of ATP present in the cell culture, which indicates the presence of viable cells. 
 
A2780 (2 x 106 cells/ml), Ovcar-3 (5 x 105 cells/ml), Ovcar-5 (1 x 106 cells/ml), Ovcar-8 
(1.25 x 105 cells/ml) and Igrov-1 (2 x 106 cells/ml) cells were prepared as cell 
suspensions in growth medium (optimal cell concentration for spheroid formation in 
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each cell line was determined previously), using the hanging drop method. One 20 μL 
drop of cell suspension was added to each inner ring of the lids of 48-well plates. 
Outer rings contained a 20 μL drop of growth medium and 300 μL of sterile water was 
added to each well beneath the rings to maintain a humid atmosphere and minimise 
evaporation. The lids were inverted over the plates and incubated for 7 days. After 1 
week, the spheroids were exposed to 5 µL growth medium containing simvastatin, 
pitavastatin or solvent and incubated for a further 72 hours. The spheroids were then 
collected using a wide bore pipette into opaque-walled multiwell plates containing 20 
µL of PBS and an equal volume of CellTiter-Glo reagent was added in order to 
measure ATP. Spheroid lysis was confirmed by microscopy to ensure penetration of 
the reagent into the spheroid. Released cellular ATP was consumed in the luciferase 
reaction to produce a stable luminescence, which was measured using a BioTek 
Synergy 2 multi-mode microplate reader. The data was analysed as previously 
described by using non-linear regression to fit a four-parameter (Hill-equation) 
sigmoidal dose-response curve (section 3.7.3). 
 
 
3.7.8   Caspase 3/7, 8 and 9 Assays 
 
The activities of the initiator caspases, 8 and 9, and the executor caspases, 3 and 7 
were measured using the Caspase-Glo Assay (Promega). The Caspase-Glo reagent 
initially lyses the cells and the released caspases recognise and cleave the 
luminogenic substrate. For example, caspases 3/7 recognise the luminogenic 
substrate containing the tetra peptide sequence DEVD, whereas caspase 8 and 
caspase 9 recognise substrates with the LETD and LEHD sequences respectively. 
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The cleaved substrate results in the luciferase reaction and the production of a 
luminescent signal, which is proportional to the caspase activity present.  
 
Ovcar-8 (2000 cells/well), Ovcar-3 (5000 cells/well) and Igrov-1 (5000 cells/well) cells 
were incubated in 80 µL growth medium in a 96-well plate for 24 hours. Cells were 
then supplemented with 20 µL growth medium containing pitavastatin, paclitaxel or 
solvent. In other studies, cells were exposed to pitavastatin in combination with other 
compounds or extracts as stated. After 48-72 hours, 25 µL of Caspase-Glo 3/7, 8 or 9 
reagent was added and cells were incubated for 30 minutes at room temperature in 
the dark. A BioTek Synergy 2 multi-mode microplate reader was used to measure 
luminescence.  
 
 
3.7.9   Reactive Oxygen Species (ROS) Assay 
 
The fluorogenic dye, 2’,7’-dichlorofluorescin diacetate (DCFDA; Sigma-Aldrich), is 
used to measure reactive oxygen species (ROS) in cells. DCFDA diffuses into the cell 
and is deacetylated by intracellular esterases to the non-fluorescent compound, 2’,7’-
dichlorofluorescin (DCFH), which is trapped in the cell. DCFH is subsequently 
oxidised by a variety of ROS to the fluorescent molecule, 2’,7’-dichlorofluorescein 
(DCF). 
 
Ovcar-3 (5000 cells/well) and Ovcar-8 cells (2000 cells/well) were seeded in 96-well 
plates in 80 μL of growth medium and incubated for 24 hours. The cells were then 
washed with growth medium containing no FBS (FBS-free medium) and stained with 
25 µM DCFDA in FBS-free medium for 45 minutes at 37°C. Several wells containing 
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cells were left unstained as a control to assess auto-fluorescence. After a second 
wash with FBS-free medium, cells were exposed to 100 µL FBS-free medium 
containing solvent or drug as stated, and incubated for 48 hours. After 45 hours, 50 
µM TBHP was added to several wells containing stained cells and incubated for the 
final 3 hours. Fluorescence was measured at an excitation of 485 nm and emission of 
535 nm using a BioTek Synergy 2 multi-mode microplate reader. Auto-fluorescence 
from the unstained cells was subtracted from the data obtained.  
 
 
3.7.10   Cell Migration Scratch Assay 
 
The “scratch assay” can be used to measure cell migration in vitro. A “scratch” is 
made in a cell monolayer and images are captured both at the beginning and at time 
points during cell migration. The images can be compared in order to determine the 
migration of the cells.  
 
Ovcar-8 cells (1 x 106 cells/well) were plated in 6-well plates in 2 mL of growth 
medium and incubated for 24 hours. The cell monolayer was then scraped down the 
centre of each well using a P200 pipet tip to create a “scratch”. The debris was 
removed by washing the cells twice with 1 mL of PBS. The cells were then exposed to 
growth medium containing pitavastatin (0.1-0.2 µM) or solvent for a further 36 hours. 
Reference points were made on the base of each well and images of the scratch at 
the reference points were acquired at various time points using an Olympus CKX41 
light microscope. Images were analysed using ImageJ (Wayne Rasband, National 
Institutes of Health, USA). The pre-migration area (before drug was added) and post-
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migration area (36 hours of drug exposure) of the scratch was determined and used to 
calculate % closure using the equation below: 
 
 
% 𝐶𝑙𝑜𝑠𝑢𝑟𝑒 =  (
𝑃𝑟𝑒­𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑟𝑒𝑎 − 𝑃𝑜𝑠𝑡­𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑟𝑒𝑎 
𝑃𝑟𝑒­𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑟𝑒𝑎
) ∗ 100 
 
 
3.8   Small Interfering RNA (siRNA) Transfections 
 
Lipofection is a widely employed technique that uses liposomes to transport genetic 
material into a cell. Liposomes are cationic lipids which bind to the surface of the 
negatively charged phospholipid bilayer and are endocytosed. The lipid-based 
transfection reagent, DharmaFECT 1 (Thermo Scientific), is efficient and has a low 
toxicity, and was used to introduce small interfering RNA (siRNA) into ovarian cancer 
cell lines. The optimum transfection conditions have been determined in previous 
studies [450], and demonstrated more than 95% transfection efficiency. 
 
Cells were seeded in 96 well plates (2000-5000 cells/well) in 80 µL antibiotic-free 
growth medium and incubated overnight. After 16 hours, 1% DharmaFECT 1 was 
prepared in Optimum (Invitrogen) and incubated for 5 minutes at room temperature. 
The siRNA was also diluted in Optimum at 10 times the final concentration required 
and then added to the 1% DharmaFECT 1 solution. The siRNA and DharmaFECT 1 
solution was incubated for 20 minutes at room temperature to enable the siRNA to 
form a complex with the liposomes. The growth medium on the cells was replenished 
with 80 µL of fresh antibiotic-free growth medium, and 20 µL of the siRNA and 
DharmaFECT 1 solution was added to each well containing cells (details of the siRNA 
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used is described in appendix 1). A non-targeting siRNA control was included in all 
transfections to establish any off-target effects on gene expression (off-target gene 
silencing). The cells were incubated for a further 24 hours at 37°C, before the growth 
medium was replenished with 80 µL of fresh growth medium and the cells were 
exposed to a range of concentrations of simvastatin or pitavastatin. Cell growth 
assays or caspase 3/7 assays were completed as previously described (sections 3.7.2 
and 3.7.8). Knockdown of gene expression was confirmed by western blotting (section 
3.9.3).  
 
 
3.9   Molecular Biology Methods 
 
3.9.1   Isolation, Purification and Quantification of Mitochondrial DNA from Cell 
Lines 
 
Mitochondrial DNA was extracted and purified from cell lines using a QIAamp DNA 
Mini Kit (QIAGEN) and all steps were completed as per kit instructions. All reagents 
were incubated to room temperature before use. 
 
Ovcar-8 cells (5 x 106 cells) and Ovcar-3 cells (2 x 106 cells) in T75 tissue culture 
flasks, previously exposed to pitavastatin or solvent as described, were washed in 
PBS and collected by trypsinisation (section 3.4), followed by centrifugation at 200 g 
for 5 minutes. The supernatant was discarded and the cell pellet was re-suspended in 
200 µL PBS. The cell suspension was then combined with 20 µL proteinase K, and 
200 µL Buffer AL was added, before vortexing for 15 seconds to ensure a 
homogenous solution for efficient cell lysis. The suspension was incubated at 56°C for 
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10 minutes, and then centrifuged briefly to collect the condensation inside the lid. 
Subsequently, 200 µL 99% ethanol (Sigma-Aldrich) was added to the suspension and 
vortexed for 15 seconds to precipitate the DNA. After a brief centrifugation, all of the 
suspension was transferred to a QIAamp Mini spin column in a collection tube and 
centrifuged at 6000 g for 1 minute in an Eppendorf 5415R centrifuge to remove the 
lysate. The precipitated DNA was adsorbed onto the QIAamp silica membrane during 
centrifugation. The bound DNA was then washed with 500 µL Buffer AW1, and 
centrifuged at 6000 g for 1 minute to remove residual contaminants and improve the 
purity of the DNA. The DNA was washed a further time with 500 µL Buffer AW2, 
before centrifuging at 10,000 g for 3 minutes. Purified DNA was eluted from the 
QIAamp Mini spin column by incubating the column at room temperature for 5 minutes 
with 200 µL Buffer AE, and then collecting the DNA into a clean microcentrifuge tube 
by centrifugation at 6000 g for 1 minute.  
 
A NanoDrop 2000 spectrophotometer (Thermo Scientific) was used to determine the 
concentration and purity of the DNA in each sample. The NanoDrop 2000 uses a 
patented sample retention system which automatically optimises the path length 
depending on the DNA concentration. The absorbance of the DNA is measured at 260 
nm (A260) as DNA absorbs light most strongly at this wavelength. The absorbance 
generated is used to estimate the concentration of DNA in the sample, assuming that 
the A260 of 1.0 = 50 µg/mL pure double-stranded DNA. The A260 measurement is also 
adjusted for turbidity by deducting the absorbance measured at 320 nm. The DNA 
concentration is often overestimated as other molecules have absorbance values at 
260-280 nm, including RNA and aromatic amino acids in proteins, and these can 
contribute to the total A260. The purity of the DNA is calculated by taking the ratio of 
the absorbance at 260 nm and 280 nm (A280), after correcting for turbidity. A ratio of 
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1.7-2.0 indicates relatively pure DNA, whereas lower ratios suggest the presence of 
contaminants. The NanoDrop 2000 was blanked with Buffer AE before measuring the 
A260 and A280 of 1 µL aliquots of each sample.  
 
 
3.9.2   Quantitative Polymerase Chain Reaction 
 
Polymerase chain reaction (PCR) is a process involved in amplifying DNA sequences 
of interest from small quantities of starting product. PCR involves three main stages. 
The reaction is started with a temperature increase to 95°C, where double-stranded 
DNA is denatured into single strands. The temperature is then reduced to around 
60°C and two oligonucleotide primers bind to their complementary sequences on 
opposite ends of the desired DNA sequence. The Taq polymerase then binds and 
extends the DNA sequence between the primers. This process is repeated up to 40 
times to give billions of copies of the DNA of interest. Real-time quantitative PCR 
(qPCR) monitors this process in ‘real-time’ as the amount of DNA synthesised can be 
detected using fluorescent dyes. SYBR green is a fluorescent dye which binds to 
double-stranded DNA, allowing the production of DNA to be monitored by measuring 
an increase in fluorescence throughout the cycles. An amplification plot can be 
generated from the increasing fluorescence signal and used to quantitate the amount 
of DNA.  
 
 Real-time qPCR reactions were carried out by first preparing the reaction mixture 
containing 1 X ABsolute SYBR Green ROX mix (Thermo Scientific), 167 nM forward 
and reverse primers (appendix 2, [451]) and double-distilled water (ddH2O). Aliquots 
of 7.5 µL reaction mixture were added to individual wells of optical 8-tube strips 
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(Applied Biosystems), and then 5 µL of each DNA sample or a ddH2O control was 
added to each well in duplicate. The reaction mixture in each strip was briefly vortexed 
to remove any air bubbles and collect the liquid at the bottom of the wells.  
 
 Table 3.1: Thermal profile for qPCR  
 
 
The reaction cycles (table 3.1) were carried out using a Stratagene Mx3005P thermal 
cycler (Agilent Technologies). The dissociation curve at the end of the reaction cycles 
was evaluated to confirm that only one amplicon had been detected. Contaminating 
DNA or primer dimers are illustrated by a peak additional to the amplicon peak.  
 
Data was analysed by the comparative cycle threshold (CT) method which compares 
the CT value of one gene to the CT value of a reference gene (usually a 
housekeeping gene such as β-actin). The CT value is the point at which the threshold 
line intersects the amplification curve, and gives a relative measurement of the DNA in 
the reaction. The efficiencies of both the target and control gene amplifications were 
first confirmed by measuring the CT values of 4 serial 5-fold dilutions of DNA samples 
using qPCR. The standard curve produced from this data was analysed by linear 
 
Segment 1 Segment 2 Segment 3 
Denaturation of the 
two DNA strands at 
95°C for 15 minutes 
Denaturation at 95°C 
for 30 seconds 
For the dissociation 
curve: 95°C for 1 
minute, 55°C for 30 
seconds and 95°C 
for 30 seconds 
Primer annealing at 
60°C for 30 seconds 
DNA strand 
elongation at 68°C 
for 30 seconds 
Cycle Number 1 40 1 
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regression, and then used to calculate the efficiency of each primer using the following 
equation. The gradient is determined from the slope of the line of best fit.  
 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 10−1/𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡 
 
An efficiency of 100% indicates that two copies of DNA were produced in each 
amplification cycle. Following this, the ΔΔCT was calculated using the following 
equation: 
 
𝑅𝑎𝑡𝑖𝑜 =  
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑇𝑎𝑟𝑔𝑒𝑡)𝐶𝑇 (𝑇𝑎𝑟𝑔𝑒𝑡,𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)−𝐶𝑇(𝑇𝑎𝑟𝑔𝑒𝑡,𝑇𝑟𝑒𝑎𝑡𝑒𝑑)
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙)𝐶𝑇(𝐶𝑜𝑛𝑡𝑟𝑜𝑙,𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)−𝐶𝑇(𝐶𝑜𝑛𝑡𝑟𝑜𝑙,𝑇𝑟𝑒𝑎𝑡𝑒𝑑)
 
 
The target and control refer to the gene of interest and the control gene respectively. 
The treated and untreated refer to DNA samples extracted from cells that have been 
exposed to pitavastatin or solvent respectively.  
 
 
3.9.3   Immunodetection of Proteins using SDS-PAGE and Western Transfer 
 
The separation and detection of numerous intracellular proteins from ovarian cancer 
cells was achieved by western blotting. First the cells are lysed to release intracellular 
proteins and then the protein concentration of the lysate is determined. Following this, 
known amounts of each lysate are loaded onto a polyacrylamide gel and using gel 
electrophoresis, the mixture of proteins is separated based on molecular weight. The 
separated proteins are subsequently transferred onto a membrane, where primary 
antibodies can be used to bind to a specific protein. Unbound primary antibody is 
washed off, leaving antibody bound to the protein required. Secondary antibodies 
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conjugated to horseradish peroxidase (HRP) bind to the primary antibody and in the 
presence of chemiluminescent substrate, HRP catalyses the oxidation of luminol, with 
the emission of light. CCD camera imaging can be used to detect this light which 
corresponds to the protein band.  
 
Cells were exposed to drugs as described, washed in PBS and lysed in 1 mL (per 100 
cm2 growth area) RIPA (“Radio-Immunoprecipitation Assay”) buffer containing 
proteases and protease inhibitors (20 mM Hepes (CalbioChem), 150 mM sodium 
chloride (NaCl, Sigma-Aldrich), 2 mM ethylene-diamino-tetraacetic acid (EDTA, 
Sigma-Aldrich), 0.5% sodium deoxycholate (Sigma-Aldrich), 1% NP40 (Sigma-
Aldrich), 120 µM leupeptin (Sigma-Aldrich), 10 µM pepstatin (Sigma-Aldrich) and 1 
mM phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich)). The cell lysate 
suspension was centrifuged at 10,000 g for 10 minutes at 4°C, and the supernatant 
containing the cellular proteins was collected. Protein lysates were stored at -80°C.  
 
The protein concentration was determined using the Bicinchoninic acid (BCA) protein 
assay kit (Sigma-Aldrich). Bovine serum albumin (BSA, Sigma-Aldrich) standards 
were prepared at concentrations between 0.1 and 2 mg/mL. BCA reagent was 
prepared by adding 4% copper (II) sulphate pentahydrate solution (Sigma-Aldrich) to 
BCA solution (bicinchoninic acid, sodium carbonate, sodium tartate and sodium 
bicarbonate in 0.1 M sodium hydroxide) in the ratio of 1:50, and 100 µL of the reagent 
was added to either 10 µL of each BSA standard or 5 µL of each lysate diluted in 5 µL 
RIPA buffer. Lysates were incubated for 30 minutes at 37°C and then the A570 was 
determined using a spectrophotometer. A protein standard calibration curve was 
prepared from the BSA standard A570 values and fit using linear regression. The 
calibration curve was used to calculate the protein concentration in each lysate. 
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Prior to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 5-
15 µg protein from each cell lysate was added to NuPAGE sample buffer (Invitrogen) 
containing 5% β-mercaptoethanol (Sigma-Aldrich), and denatured at 70°C for 15 
minutes. A 4-20% NuView Tris-Glycine polyacrylamide gradient gel (Nusep) in an 
XCell SureLock Mini Cell (Invitrogen) with hepes running buffer (100 mM hepes, 100 
mM Tris and 1% sodium dodecyl sulphate (SDS, Sigma-Aldrich)) was used to 
fractionate the denatured protein from each cell lysate. PageRuler Plus Prestained 
Protein Ladder (Thermo Scientific) was included on each gel to estimate the size of 
immunodetected proteins. Separated proteins were subsequently transferred onto 
Amersham Hybond P 0.45 µm polyvinylidene difluoride (PVDF) membrane (GE 
Healthcare Life Sciences) in transfer buffer (25 mM Tris, 200 mM glycine (Sigma-
Aldrich), 0.075% SDS and 10% methanol (Sigma-Aldrich)) at 25 V for 1.5 hours. 
Following this, the membrane was incubated with Tris Buffered Saline with Tween 
(TBST) buffer (50 mM Tris hydrochloride (Tris HCl, pH 7.4, Sigma-Aldrich), 150 mM 
NaCl, 0.1% Tween 20) containing 5% skimmed milk powder for 1.5 hours with gentle 
rocking on a Stuart Scientific Platform Shaker STR6 at room temperature for blocking. 
The membrane was then incubated in primary antibody for 16 hours at 4°C overnight 
with gentle rocking. Following five washes in TBST, the membrane was incubated in 
secondary antibody for 1 hour at room temperature with gentle rocking. The 
antibodies and corresponding dilutions used are described in appendix 3. After a 
further five washes in TBST, protein bands were visualised using UptiLight HRP 
chemiluminescent substrate (Uptima) and a FluorChem M Imager. Bands were 
quantified by using AlphaView SA software (Protein Simple) to measure the total 
number of pixel grey levels in the selected band area and then normalised to the 
loading control, glyceraldehde-3-phosphate dehydrogenase (GAPDH).  
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3.9.4   Detection of Proteins using SDS-PAGE and Silver Staining or Coomassie 
Brilliant Blue 
 
An additional method by which separated cellular proteins can be detected is by 
staining the polyacrylamide gel with either silver nitrate or Coomassie Brilliant Blue. 
Both detect total protein which enables visualisation of the protein pattern in the gel. 
After gel electrophoresis, proteins are fixed into the gel using an acid or alcohol wash. 
Exposure to the stain allows the Coomassie dye or silver ions to diffuse into the gel 
and bind to the proteins. Destaining removes excess stain from the gel matrix 
background and allows better detection of the protein bands.  
 
The silver and Coomassie Brilliant Blue stains were used to detect proteins released 
from cells into the growth medium both before and after exposure to drug. Ovcar-8, 
Ovcar-3, HOE and HFF cells (2 x 105 cells/mL) were exposed to 1-8 µM pitavastatin, 
2-10 µM simvastatin, 2-10 µM pravastatin, 70 μM carboplatin (1 x IC50 in Ovcar-8 
only), 21 nM paclitaxel (3 x IC50 in Ovcar-8 only), 1 µM doxorubicin (5 x IC50 in Ovcar-
8 only), 50 nM topotecan (5 x IC50 in Ovcar-8 only) or solvent for 48 hours at 37°C. 
Cells were subsequently washed three times in FBS-free growth medium, after which 
the experimental drugs were re-added to the cells in FBS-free growth medium. After 
incubation for a further 24 hours, the growth medium on the cells was collected and 
centrifuged at 10,000 g for 10 minutes to remove debris prior to gel electrophoresis 
and staining. The supernatant was collected and stored at -80°C. 
 
For protein supernatant samples analysed by Coomassie Brilliant Blue staining or 
western blotting, Ovcar-8 and Ovcar-3 cells (4 x 106) were plated in T75 tissue culture 
flasks prior to drug addition in order to maximise protein concentration. The 
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supernatant collected after centrifugation was transferred to a Vivaspin 20 10 kDa 
sample concentrator (Fisher Scientific) and centrifuged at 1000 g for 1 hour. Each 
concentrated supernatant sample was made up to a final volume of 1 mL using FBS-
free growth medium. An equal volume of each supernatant sample was resolved by 
Tris-Glycine SDS-PAGE, using a 4-20% polyacrylamide gradient gel (Nusep) for silver 
staining or an 8% polyacrylamide resolving gel (8% protogel (acrylamide and bis-
acrylamide in the ratio of 37.5:1, Fisher Scientific), 2 M Tris (5% Tris HCl, 20% Tris, 
pH 8.8), 0.06% N,N,N’,N’-tetramethylethylenediamine (TEMED, Sigma-Aldrich), 0.1% 
SDS, 0.025% ammonium persulfate (APS, Sigma-Aldrich)) for Coomassie Brilliant 
Blue staining, as described in section 3.9.3.  
 
For silver staining, the polyacrylamide gel was washed in deionised water to remove 
running buffer from the gel matrix. The gel was then fixed (40% ethanol (Sigma-
Aldrich) and 10% acetic acid) for 1.5 hours with rocking, washed (5% ethanol and 5% 
acetic acid) with rocking four times for 1 hour, and sensitised using 0.02% sodium 
thiosulphate (Fisher Scientific) for 2 minutes. Following this, the gel was washed in 
deionised water three times for 15 minutes, stained (0.2% silver nitrate (BDH Lab 
Supplies) and 0.076% formaldehyde (Sigma-Aldrich)), and washed in deionised water 
a further two times for 2 minutes before developing (6% sodium carbonate (BDH Lab 
Supplies), 0.05% formaldehyde and 0.0004% sodium thiosulphate). After the required 
staining intensity had been reached, the reaction was stopped by replacing the 
developing solution with 5% acetic acid, and the gel was imaged using a FluorChem 
M Imager. 
 
For Coomassie Brilliant Blue staining, the polyacrylamide gel was fixed and stained in 
a solution containing 0.1% Coomassie Brilliant Blue (Sigma-Aldrich), 10% methanol 
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and 10% acetic acid for 16 hours with rocking at room temperature, and destained 
using multiple 6% acetic acid washes for a further 24 hours with rocking until protein 
bands were visible. The gel was imaged using a FluorChem M Imager, before 
excising bands for mass spectrometry analysis.  
 
 
3.9.5   In-Gel Digestion of Excised Protein Bands and Protein Identification by 
Mass Spectrometry 
 
Throughout the last 30 years, mass spectrometry has become the key method used to 
identify proteins from complex biological mixtures. Proteins separated by gel 
electrophoresis can be identified by mass spectrometry, following several stages of 
sample extraction and preparation that are critical for high-quality results.  
 
Protein bands are first excised from the gel and destained to remove the Coomassie 
stain. Following this, the disulfide bonds on the cysteine residues are reduced, and the 
remaining free sulfhydryl groups are irreversibly alkylated to prevent disulfide 
reformation. The proteins are subsequently hydrolysed by trypsin on the C-terminal 
side of lysine and arginine. The resulting peptides are extracted from the gel matrix 
and prepared for mass spectrometry.  
 
Sample preparation and mass spectrometry analysis was completed by Dr Elzbieta 
Piatkowska and Dr Sarah Hart at the School of Life Sciences, Keele University, 
Staffordshire. Excised protein bands from Coomassie Brilliant Blue stained gels were 
cut into small cubes and destained in 25 mM ammonium bicarbonate (Fisher 
Scientific) in 50% acetonitrile (Sigma-Aldrich) with occasional vortexing for 10 
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minutes. After discarding the supernatant, destaining was repeated a further two 
times, before incubating in 100% acetonitrile for 15 minutes to dehydrate the gel 
pieces. The resulting white gel pieces were dried in a Thermo SPD SpeedVac linked 
to a Savant Refrigeration Condensation Trap and High Vacuum Pump at room 
temperature for 30 minutes. Gel pieces were subsequently reduced in 25 mM 
ammonium bicarbonate and 10 mM dithiothreitol (DTT, Sigma-Aldrich) for 45 minutes 
at 56°C with rocking, and after discarding the supernatant, alkylated in 25 mM 
ammonium bicarbonate and 55 mM iodoacetamide for 1 hour at room temperature in 
the dark. Following this, gel pieces were washed in 25 mM ammonium bicarbonate 
and dried in a SpeedVac at room temperature for 20 minutes. Gel pieces were then 
digested in 20 µg/mL trypsin in 25 mM ammonium bicarbonate overnight at 37°C. 
After 16 hours, extraction buffer (50% acetonitrile and 0.1% trifluroacetic acid (TFA, 
Sigma-Aldrich)) was added to the gel pieces for 10 minutes to neutralise remaining 
trypsin activity and the supernatant was collected. The addition of extraction buffer to 
the gel pieces was repeated and the supernatant from both extractions was pooled, 
before being dried in a SpeedVac at room temperature to complete dryness. 
 
Following digestion and extraction, peptides were added to 10 mg/mL α-Cyano-4-
hydroxycinnamic acid (in 0.1% TFA and 80% acetonitrile, Sigma-Aldrich) in a 1:1 ratio 
(v/v) on a stainless steel Matrix Assisted Laser Desorption/Ionization (MALDI) target 
plate. A MALDI time-of-flight (TOF/TOF) instrument (MALDI 4800, AB Sciex, 
Warrington, Cheshire) was used to acquire data in a positive reflector mode in the 
mass range of 700-3,600 m/z, and 800-1,000 laser shots were collected during survey 
scan acquisition. Cal Mix 5 (a mixture of the 5 protein standards: bradykinin, 
angiotensin, P14R, ACTH fragment 18-39 and glufibrinopeptide, Sigma-Aldrich) was 
used to externally calibrate all spectra.  
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A 1 kV collision energy profile with air as a collision gas was used to analyse the 
manually generated list of precursors for tandem mass spectrometry (MS/MS). The 
isolation width was -1 to +2 amu around the precursor ion mass. Furthermore, 4000 
laser shots were acquired for each spectrum, with a signal-to-noise ratio (S/N) of at 
least 20 for spectrum acceptance. 
 
Plain text Mascot generic files (.mgf) were produced using the Macro tool in 4000 
Series Explorer software (Export_to_MGF_file.ExportMascotPeakList available from 
Matrix Science). All product ion spectra generated for each excised gel band 
underwent a single Mascot search using Mascot Daemon (Matrix Science, London). 
The data were searched against the MSDB database with the following search 
parameters: enzyme trypsin; 1 miscleavage allowed; fixed modification: cysteine 
carbamidomethylation; variable modifications: methionine oxidation; peptide tolerance 
200 ppm and MS/MS tolerance ± 0.6 Da.   
 
 
3.9.6   M30 CytoDeath ELISA  
 
During apoptosis, caspases cleave cellular proteins including the intermediate filament 
protein cytokeratin 18 (CK18). Caspases 3, 7 and 9 cleave CK18 after aspartic acid 
residue 396 and the resulting neo-epitope is recognised by the M30 antibody. The 
M30 CytoDeath solid phase sandwich enzyme-linked immunosorbent assay (ELISA) 
is used to measure the levels of soluble caspase-cleaved CK18 (ccCK18) in epithelial 
cells. The solid phase capture antibody, M6, binds to ccCK18 in the sample (figure 
3.1). The M30 antibody then recognises and binds to the CK18Asp396 neo-epitope 
present only on ccCK18 (figure 3.1). Unbound conjugate is removed by washing and 
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subsequently, HRP linked to the M30 antibody catalyses the conversion of the 
chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB), to a measurable 
coloured product. 
 
 
Figure 3.1: M30 CytoDeath ELISA. Cytokeratin 18 is cleaved by caspases during 
apoptosis to yield a CK18Asp396 neo-epitope, which is recognised by the M30 
antibody in the ELISA [452]. 
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Ovcar-8, Ovcar-3, Igrov-1 and Skov-3 cells (5000 cells/well except for Ovcar-8, 2000 
cells/well) were incubated in 100 µL growth medium in a 96-well plate for 24 hours 
and then exposed to pitavastatin at five times the IC50 measured in cell growth assays 
(1-20 μM), carboplatin at the IC50 in each cell line (4-70 μM), paclitaxel (50 nM) or 
solvent. After 72 hours, the supernatant was collected and centrifuged at 10,000 g for 
10 minutes at 4°C. The M30 CytoDeath ELISA (Peviva) was completed following the 
manufacturer’s instructions. All reagents were incubated to room temperature before 
use. 25 µL of each supernatant was transferred in duplicate to the ELISA plate and 75 
µL of monoclonal M30 antibody conjugated with HRP was immediately added to each 
well containing sample. The wells were incubated at room temperature with gentle 
rocking for 4 hours. The wells were then washed five times using wash solution to 
remove unbound conjugate. Subsequently, TMB substrate was added to each well 
and incubated at room temperature in the dark with gentle rocking for 20 minutes. 
Colour development was proportional to the amount of ccCK18 bound, and was 
stopped by the addition of 1 M sulphuric acid. A450 (nm) was measured using a BioTek 
Synergy 2 multi-mode microplate reader. 
 
 
3.9.7   Flow Cytometry  
 
Flow cytometry is used to analyse the characteristics of single cells in liquid 
suspension as they pass through a beam of light. Organelles and DNA can be labelled 
with fluorescent probes including MitoTracker for detecting active mitochondria and 
propidium iodide (PI) for labelling DNA and RNA.  
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MitoTracker Green probe diffuses across the plasma membrane of live cells and is 
sequestered in active mitochondria. Once in the lipid environment of the mitochondria, 
MitoTracker Green binds to the mitochondrial lipids and is converted to a fluorescent 
probe, which can be detected by flow cytometry or fluorescence microscopy. 
 
PI intercalates between the nucleotide bases in both DNA and RNA. Ribonuclease 
(RNase) is used to enzymatically remove RNA to enable the specific staining of DNA 
for cell cycle analysis. Cells in G2 and M phases of the cell cycle contain double the 
amount of DNA compared to cells in G1. Apoptotic cells (subG1) have less DNA due to 
DNA degradation by endogenous nucleases and diffusion out of the cell. The DNA 
content of cells during S phase lies between that for G1 and G2 phases. Fluorescence 
emission from PI is proportional to the cellular DNA content. Therefore, flow cytometry 
was used to measure progression through the cell cycle, in addition to the detection of 
mitochondria using MitoTracker Green. 
 
Ovcar-8 and Ovcar-3 cells (5 x 105 cells/well) were seeded in 6-well plates and 
incubated for 24 hours at 37°C, before exposure to 1-20 µM pitavastatin or solvent for 
48 hours. Adherent cells were then trypsinised and combined with the supernatant 
containing the detached cells, centrifuged at 150 g for 3 minutes, and re-suspended in 
FBS-free medium containing 100 nM MitoTracker Green FM (Invitrogen). Cells were 
incubated for 30 minutes at 37°C, after which the cells were centrifuged at 150 g for 3 
minutes and re-suspended in 0.5 mL PBS.  
 
For PI staining, after cell collection and centrifugation as described above, Ovcar-3 
cells were re-suspended in 500 µL cold PBS and fixed by the drop wise addition of 5 
mL cold 70% ethanol whilst vortexing the cell suspension. The cell suspension was 
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incubated at 4°C for 24 hours, and subsequently centrifuged at 200 g for 10 minutes 
at 4°C using an IEC Centra-8R centrifuge. The supernatant containing ethanol was 
removed and the cell pellet was washed in 1 mL cold PBS by centrifugation a further 
two times. Cells were re-suspended in 500 µL cold PBS and stained with 50 µL 
PI/RNase staining solution (500 µg/mL PI (Sigma-Aldrich) and 0.5 mg/mL heat treated 
RNase (Sigma-Aldrich)) for 30 minutes at room temperature in the dark.  
 
A Beckman Coulter Cytomics 500 flow cytometer with CXP software was used to 
acquire data. The forward scatter versus side scatter plot was used to identify and 
gate the cell population and, after exclusion of doublets (identified using a peak pulse 
height versus integral fluorescence (area) plot), fluorescence data was collected in the 
FL1 (MitoTracker Green FM staining) and FL3 (PI staining) channels. Data acquired 
for unstained cells was used to eliminate auto fluorescence. Flow cytometry data was 
analysed using Flowing Software (Perttu Terho, Turku Centre for Biotechnology, 
University of Turku, Finland). 
 
 
3.9.8   Fluorescence Microscopy 
 
Immunofluorescence is commonly used to label a specific protein with an antibody, 
which is then conjugated to a fluorophore and detected using fluorescence 
microscopy. This technique can be employed to determine the abundance or cellular 
localisation of a protein. The development of fluorescent probes which can pass 
through viable cell membranes has enabled the monitoring of proteins and organelles 
in live cells by fluorescent microscopy.   
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Ovcar-8 cells (7 x 105 cells/well) were grown on sterile glass coverslips in 6-well plates 
for 24 hours, before exposure to 3-10 μM simvastatin or solvent for a further 24 hours. 
Cells were then exposed to growth medium or PBS supplemented with simvastatin or 
solvent for 2 hours, before fixing in 3% paraformaldehyde (Sigma-Aldrich) for 20 
minutes at room temperature. Cells were permeabilised with 0.4% Triton X-100 
(Sigma-Aldrich) in PBS for 10 minutes, and then blocked in PBS supplemented with 
1% BSA for 30 minutes. Cells were subsequently incubated with anti-Rab7 and anti-
LC3 antibodies diluted in PBS supplemented with 1% BSA for 1 hour at room 
temperature (antibody dilutions are described in appendix 3). This was followed by 
three washes in PBS and incubation in Alexa Fluor 568 anti-rabbit antibody or Cy2 
anti-mouse antibody diluted in PBS supplemented with 1% BSA for 1 hour at room 
temperature in the dark (antibody dilutions are described in appendix 3). After a 
further three washes in PBS, Fluoro-Gel mounting medium (Interchim) containing 4’,6-
diamidino-2-phenylindole (DAPI) was used to mount the glass coverslips onto slides 
and stain the nuclei. Images were captured using a Nikon Eclipse Ti-S fluorescence 
microscope. 
 
For live cell imaging, Ovcar-8 and Ovcar-3 cells in 6-well plates were exposed to drug 
as described in section 3.9.7 and incubated with 100 nM MitoTracker Green FM and 5 
µg/mL Hoechst 33258 solution (Sigma-Aldrich) for 30 minutes at 37°C. Images were 
captured using a Nikon Eclipse Ti-S fluorescence microscope. 
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3.10   Tumour Xenograft Studies 
 
Xenograft studies were completed by Charles River Discovery Research Services in 
Morrisville, North Carolina. Female CB17 severe combined immunodeficiency (SCID) 
mice at an age of 8-12 weeks were subcutaneously injected in the flank with 1 mm3 
Ovcar-3 tumour fragments propagated from Ovcar-3 cells (ATCC). Drug treatment 
was started when tumours had reached an average size of 80-120 mm3. Pitavastatin 
calcium was prepared in 0.5% carboxymethyl cellulose in sterile water. Vehicle 
consisted of 0.5% carboxymethyl cellulose in sterile water. In a maximum tolerated 
dose (MTD) study, mice were treated with 26.32 mg/kg, 39.47 mg/kg, 52.63 mg/kg, 
78.95 mg/kg or 157.89 mg/kg pitavastatin every 12 hours for 14 days (5 mice in each 
group). In the subsequent xenograft study, mice were treated with 78.95 mg/kg 
pitavastatin (MTD) or vehicle alone every 12 hours orally for 33 days (10 mice in each 
group). Mice were monitored on a daily basis, and body weight and tumour size were 
measured twice a week. The endpoint of the study was 33 days, after a mean tumour 
weight of 1000 mm3 in the control group had been reached. At the end of the study, all 
mice were euthanized. Tumour samples were taken from three mice in both the 
control and pitavastatin-treated groups and stored at -80°C. 
 
 
3.11   Detection of Proteins in Tumour Tissues 
 
Approximately 50-100 mg of each tumour sample was cut into small pieces and 
homogenised in 60 µL (per 5 mg tumour tissue) RIPA buffer containing proteases and 
protease inhibitors (20 mM Hepes, 150 mM NaCl, 2 mM EDTA, 0.5% sodium 
deoxycholate, 1% NP40, 120 µM leupeptin, 10 µM pepstatin, 1 mM PMSF, 20 µg/mL 
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soybean trypsin inhibitor (SBTI, Sigma-Aldrich) and 0.05 TIU/mL aprotinin (Sigma-
Aldrich)) using a dounce homogeniser to a liquid consistency. Tissue lysates were 
incubated at 4°C with rocking for a further 2 hours to allow complete cell lysis. The 
tissue lysate suspension was centrifuged, the supernatant collected, and the protein 
concentration determined as previously described in section 3.9.3. Proteins in the 
tissue lysate were separated and detected by western blotting (section 3.9.3). 
 
 
3.12   Pitavastatin Extraction from Tumour Tissues 
 
A sensitive method for the estimation of pitavastatin in biological samples using Solid 
Phase Extraction (SPE) and liquid chromatography has previously been developed 
[453]. SPE is a form of chromatography used to isolate an analyte from a solution. 
Reversed phase SPE involves a polar mobile phase and a nonpolar stationary phase. 
The solid phase is composed of silica packing modified with hydrophobic alkyl and 
aryl groups. Retention of pitavastatin from the polar lysis buffer is achieved through 
van der Waals or dispersion forces acting between carbon-hydrogen bonds in the 
analyte and the nonpolar groups on the silica surface. Furthermore, polar interactions 
(for example, hydrogen bonding) between residual unreacted silanols on the solid 
phase and hydroxyl groups of pitavastatin can also contribute to retention, and 
therefore, an acidic conditioning solution (0.5 M monobasic potassium phosphate) has 
previously been used to optimise the retention of pitavastatin [453]. A more polar 
solvent (methanol) is used to disrupt the hydrogen bonding and van der Waals forces 
to elute pitavastatin from the column. Pitavastatin can then be analysed by high-
performance liquid chromatography (HPLC).  
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Approximately 50-200 mg of each tumour sample was cut into small pieces and 
homogenised in 200 µL PBS to a liquid consistency using a dounce homogeniser. The 
resulting suspension was centrifuged at 10,000 g for 10 minutes at 4°C and the 
supernatant was collected. A Supelclean LC-18 SPE tube (SupelCo) for each 
suspension was conditioned with 3 mL 99% methanol, followed by 3 mL deionised 
water, and then 3 mL 0.5 M monobasic potassium phosphate (Sigma-Aldrich), 
allowing each solution to pass through the matrix using positive pressure. The sample 
was then transferred to the tube, and once in the matrix, the tube was washed with 3 
mL 0.5 M monobasic potassium phosphate, followed by 3 mL deionised water to 
remove weakly retained materials. Pitavastatin was then eluted from the matrix by the 
addition of 3 mL 99% methanol to the tube. The eluate was collected and dried in a 
SpeedVac at 45°C to complete dryness. The resulting residue was re-suspended in 
100 µL 99% methanol for HPLC analysis or growth medium for cell growth assays 
(section 3.7.2).  
 
HPLC analysis was completed by Dr Clare Hoskins at the School of Pharmacy, Keele 
University, Staffordshire. Pitavastatin standards were prepared in 100% acetonitrile at 
concentrations between 1 and 50 µg/mL. Samples were diluted 10-100 times in 100% 
acetonitrile and a 20 µL aliquot of standard or sample was introduced through an 
injector valve. Separation was achieved on a reversed-phase C18 column (Metlab 
Supplies) at room temperature with a mobile phase of acetonitrile:water with 0.1% 
formic acid (65:35) and a flow rate of 1 mL/minute. Pitavastatin was detected with an 
excitation of 245 nm and an emission of 420 nm using a JASCO PU-980 HPLC pump 
coupled to a JASCO FP-920 fluorescence detector (JASCO). Data was acquired 
using Azur 5.0 software (Datalysis) by measurement of the peak areas. A standard 
calibration curve was prepared from the pitavastatin standard peak areas and fit using 
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linear regression. The calibration curve was used to calculate the pitavastatin 
concentration in each extract sample.  
 
Alternatively, a bioassay was performed in which a range of concentrations of the 
extract samples, as estimated by the HPLC method, were added to Ovcar-8 cells, and 
the potency of the extracts were determined by cell growth assays (section 3.7.2). The 
dose-response curve for authentic pitavastatin was used as a calibration curve, and 
an equipotent dose was used to determine the concentration of pitavastatin in each 
sample.  
 
 
3.13   Extraction of Lipids from Foodstuffs 
 
Eight foodstuffs were obtained for the purposes of extracting lipids. The three 
organisations which donated mouse chow included Lab Diet NIH 31 0045117 from 
Charles River in North Carolina, Special Diets Services 801960 BK001(E) from Keele 
University in the United Kingdom and Open Source Diets D11112201 from University 
of British Columbia in Canada. Four oils and food replacement drinks obtained in the 
United Kingdom included Tesco Pure Sunflower Oil produced in the United Kingdom, 
Sainsbury’s Olive Oil produced in Spain, Ensure Plus Raspberry Flavour Drink 
produced in the European Union and Fresubin 2 kcal Vanilla Flavour Drink produced 
in Germany. Japonica polished rice (Kinuhikari) was obtained from Japan.  
 
The method used for extracting lipids from foodstuffs is a modification of the “gold 
standard” methods by Folch [454] and Bligh and Dyer [455] for the isolation of lipids, 
and is described by [456].  
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For each foodstuff, 50 g was transferred to a mortar and manually homogenised using 
a pestle in 30 mL 99% methanol and extracted by further additions of 30 mL 100% 
chloroform (Sigma-Aldrich) and 30 mL 99% methanol. Japonica polished rice was first 
homogenised to a fine powder in a Tesco Jug Blender before extraction as described 
above. The resulting extracts were filtered through fluted filter paper to remove any 
solid and evaporated to dryness in a round bottom flask using an RE100 rotary 
evaporator (Fisher Scientific). Liquid foodstuffs were transferred to a separating funnel 
and extracted with 60 mL 99% methanol and 30 mL 100% chloroform. The lower lipid 
phase was evaporated to dryness as previously described. 
 
Residues were dissolved in 25 mL 99% ethanol and 25 mL 5 M potassium hydroxide 
(Sigma-Aldrich) was added for alkaline hydrolysis. The alkaline solution was incubated 
with stirring at 56°C for 1 hour, and after cooling, neutralised with approximately 25 
mL 5 M hydrochloric acid (Sigma-Aldrich). The resulting solution was partitioned with 
120 mL 95% n-hexane (Fisher Scientific), 30 mL water and an additional 30 mL 99% 
ethanol, and the upper organic phase was evaporated to dryness in a pre-weighed 
round bottom flask using a rotary evaporator. The mass of the extract was determined 
using a Mettler AE 200 balance before dissolving in DMSO. 
 
Ovcar-3 and Ovcar-8 cells were exposed to the extracts (0.15 mg/mL sunflower oil 
extract, 0.03 mg/mL olive oil extract, 0.55 mg/mL polished rice extract, 0.04 mg/mL 
Lab Diet chow extract, 0.02 mg/mL Special Diets chow extract, 0.02 mg/mL Open 
Source Diets chow extract, 0.03 mg/mL Ensure Plus extract or 0.03 mg/mL Fresubin 
extract), or 10 µM geranylgeraniol, either alone or in combination with pitavastatin in 
cell growth assays (section 3.7.2) or caspase 3/7 assays (section 3.7.8), as previously 
described.  
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CHAPTER 4 
 
PRECLINICAL EVALUATION OF 
SIMVASTATIN AS A TREATMENT FOR 
OVARIAN CANCER 
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4.1   Introduction 
 
Hypercholesterolemia was identified as a risk factor for the development of coronary 
heart disease during the middle of the last century and with this came the search for 
novel drugs that could be utilised to lower plasma cholesterol. Cholesterol is 
synthesised by the mevalonate pathway, as discussed in chapter 1, in which the 
enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyses the 
synthesis of mevalonate from 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA). 
Mevalonate is then converted into isopentenes (5 carbon atoms), which are 
subsequently conjugated to form farnesyl diphosphate (FPP, 15 carbon atoms) and 
geranylgeranyl diphosphate (GGPP, 20 carbon atoms). Cholesterol is synthesised 
from FPP via a series of biochemical steps [457]. HMGCR is the rate-limiting enzyme 
in the mevalonate pathway, and therefore, was a target for the development of 
inhibitors of this pathway. Lovastatin was isolated from a fermentation broth of 
Aspergillus terreus in 1978, and developed as the first clinically available inhibitor of 
HMGCR [457]. Simvastatin was developed in the early 1990’s as a semi-synthetic 
derivative of lovastatin, containing an additional side chain methyl group. Simvastatin 
has been demonstrated to reduce total cholesterol by 19-36%, low-density lipoprotein 
(LDL) cholesterol by 26-47%, triglycerides by 12-24%, and increase high-density 
lipoprotein (HDL) cholesterol by 8-12% [458]. Furthermore, simvastatin was the first 
statin to show a significant reduction in cardiac-related mortality [459]. 
 
In addition to the anti-hypercholesterolemia effects, simvastatin has also been shown 
to inhibit the growth and proliferation of breast [460], melanoma [263], colon [358], 
lung [461], pancreatic [462], hepatic [229], prostate [463], renal [464], glioma [465], 
head and neck squamous [466], Hodgkin’s lymphoma [467], myeloma [468], Barret’s 
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adenocarcinoma [469], cervical [470], and ovarian [337] cancer cells through their 
additional effects on isopentenes including FPP and GPP. Both are lipid products in 
the mevalonate pathway that are used by prenyltransferases to post-translationally 
modify several proteins including the small GTPases, Ras, Rho and Rab. Prenylation 
increases the affinity of these proteins for cellular membranes. The membrane 
localisation of these proteins is essential for many biological functions, which include 
regulating cell cycle progression, cell signalling and membrane integrity. The inhibition 
of the membrane localisation and function of these GTPases by statins is thought to 
contribute to the anti-cancer effects of statins, including cell cycle arrest, induction of 
apoptosis, reduction in metastasis and inhibition of angiogenesis (discussed in 
chapter 1 and reviewed by [471]).  
 
The mechanisms by which simvastatin induces cancer cell death have not been fully 
determined. Simvastatin induces apoptosis in myeloma [235, 351, 468], lymphoma 
[350], Hodgkin’s lymphoma [467], glioma [342], osteosarcoma [346], breast [330, 472, 
473], prostate [232, 364, 474], melanoma [230], Barrett's esophageal [475], colon 
[336, 358, 476], ovarian [267, 337, 477], lung [331, 461], hepatic [229, 478], 
cholangiocarcinoma [479], and renal [464] cancer cells through the intrinsic apoptosis 
pathway, and in some cases through activation of the extrinsic apoptosis pathway. 
 
Autophagy is a process where cellular organelles and proteins are degraded and 
recycled during conditions of nutrient starvation and metabolic stress. The function of 
autophagy in cancer is currently under investigation. High levels of autophagy may 
promote cancer cell death and this is supported by studies demonstrating that agents 
which induce autophagy potentiate cancer cell death [308, 309]. However, there is 
increasing research that supports the hypothesis that cancer cells undergo autophagy 
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as a mechanism of cell survival during stress conditions such as exposure to 
chemotherapy. Indeed, the inhibition of cisplatin-induced autophagy using 3-
methyladenine or chloroquine increased the sensitivity of ovarian cancer cells to 
cisplatin [307, 480]. Furthermore, inhibition of the autophagic response in glioma cells 
sensitised cells to simvastatin-induced apoptosis [317]. An induction in autophagy in 
response to simvastatin exposure has been reported in several cancer cell lines 
including human rhabdomyosarcoma cells [481], and glioma cells [317], but not 
hepatoma cells [481]. There are at least two possible explanations for this as statin-
induced autophagy may contribute to either cancer cell survival or death. Further 
research is required to determine the effects of simvastatin on autophagy and its 
contribution to cell death in ovarian cancer cells.  
 
Clinical trials evaluating simvastatin for the treatment of cancer have had varied 
outcomes. In non-small lung cancer, several studies by Han and colleagues found that 
adding standard dose simvastatin (40 mg/daily) to chemotherapy did not improve 
either the time to progression (TTP) or the one-year survival rate [409, 410]. More 
recently, the addition of simvastatin 40 mg once daily to gemcitabine in patients with 
advanced pancreatic cancer did not improve TTP or expected one-year survival rates 
[411]. Standard doses of simvastatin have previously been observed to provide 
plasma concentrations (Cmax ~10 nM [424]) that are significantly below the drug 
concentration required for anti-cancer activity in preclinical laboratory studies. This 
may go some way to explaining why clinical trials utilising standard doses of 
simvastatin have been unsuccessful. When the pharmacokinetics of simvastatin were 
evaluated at the maximum tolerated dose (MTD, 7.5 mg/kg twice daily) in patients with 
refractory and relapsed chronic lymphocytic leukemia (CLL), the peak plasma 
concentrations ranged from 0.08 - 2.2 µM [482]). These concentrations are 
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significantly lower than those required for anti-cancer activity in CLL in vitro, (10 - 50 
µM [483]) and may limit the success of simvastatin in clinical trials. A previous study, 
where the MTD of simvastatin was administered combination with chemotherapy to 
patients with myeloma, was discontinued due to poor response [418]. One possibility 
is that the short half-life of simvastatin (2-3 hours) may allow the synthesis of 
isoprenoids in the mevalonate pathway in between simvastatin doses, thereby 
overcoming the anti-cancer activity of the statin. Increasing the frequency of 
simvastatin dosing or use of an alternative statin with a longer half-life would be 
required to overcome this.  
 
Clinical trials of novel anti-cancer agents are generally conducted using either the 
drug as a single agent or in combination with existing therapy. Previous studies have 
reported that statins are synergistic with cisplatin in ovarian cancer cell lines [337, 
484]. However, tumour resistance to cisplatin is common and therefore, simvastatin 
should also be evaluated in combination with the first line chemotherapeutic agents, 
carboplatin and paclitaxel. 
 
 
4.2   Aims 
 
The research in this chapter aimed to evaluate the activity of simvastatin as a single 
agent in a panel of ovarian cancer cell lines, to further understand the mechanism by 
which simvastatin elicits anti-cancer activity including the impact on the autophagy 
pathway, and to determine if simvastatin should be used in combination with 
carboplatin. 
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4.3   Results 
 
4.3.1   Statins inhibit the growth of ovarian cancer cell lines 
 
Cell proliferation assays were used to determine the concentration of drug at which 
50% of cell growth was inhibited (IC50) as a measure of potency. Results obtained 
previously by Mandrita Nandi suggested that the lipophilic statins, fluvastatin and 
simvastatin, were consistently more potent than statins that were more water soluble. 
In seven ovarian cancer cell lines, fluvastatin and simvastatin had IC50 values ranging 
between 1 µM and 20 µM, whereas rosuvastatin and atorvastatin had slightly greater 
IC50 values of between 3 µM and 32 µM (figure 4.1, results obtained as part of an MSc 
project by Mandrita Nandi). 
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Figure 4.1: The activity of four statins in a panel of ovarian cancer cell lines. (IC50, 
mean ± S.D., n = 3-7). Increasing lipophilicity is represented by the triangle showing 
increasing logP. Data obtained as part of an MSc project by Mandrita Nandi. 
 
 
To determine if the anti-proliferative activity of simvastatin had resulted from inhibition 
of HMGCR, Ovcar-8 cells exposed to simvastatin were supplemented with 
mevalonate, farnesol or geranylgeraniol. The addition of mevalonate to Ovcar-8 cells 
significantly inhibited the anti-growth effects of simvastatin (figure 4.2). Furthermore, 
supplementing simvastatin-treated cells with geranylgeraniol but not farnesol also 
prevented growth inhibition (figure 4.2). These results suggested that the anti-
proliferative activity of simvastatin was mediated though the inhibition of 
geranylgeranylation. 
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Figure 4.2: Prevention of the anti-growth effects of simvastatin. Ovcar-8 cells were 
exposed to different concentrations of simvastatin for 72 hours in the presence of 100 
μM mevalonate, 10 μM farnesol, 10 μM geranylgeraniol or solvent. The data was 
represented as a fraction of the top of the curve which was identified by curve fitting 
(mean ± S.D., n = 3). “C” represents the control cells exposed to solvent alone. 
 
 
The anti-growth effects of simvastatin have previously been evaluated in monolayer 
cell cultures. In order to determine the anti-cancer activity of simvastatin in a more 
physiologically relevant model, ovarian cancer spheroids or aggregates were 
produced from five ovarian cancer cell lines: A2780, Ovcar-3, Ovcar-5, Ovcar-8 and 
Igrov-1 (figure 4.3). 
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Figure 4.3: Phase contrast microscopy images of ovarian cancer spheroids grown for 
7 days. The mean diameter of the spheroid/aggregate is reported below each image 
(mean ± S.D., n = 3).  
 
 
The ability of statins to cause cell death in ovarian cancer spheroids was evaluated by 
measuring ATP in cells exposed to increasing concentrations of simvastatin. The 
dose-response curves for each ovarian cancer cell line showed a striking decrease in 
ATP of more than 75% at the highest simvastatin concentrations tested. This was 
observed in all ovarian cancer cell lines that were tested and suggested a reduction in 
cell viability (figure 4.4). 
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Figure 4.4: Simvastatin dose-response curves in ovarian cancer spheroids. A2780, 
Ovcar-3, Ovcar-5, Ovcar-8 and Igrov-1 spheroids were exposed to the indicated 
concentrations of simvastatin for 72 hours and total ATP was measured. The data was 
represented as a fraction of the top of the curve which was identified by curve fitting 
(mean ± S.D., n = 5). “C” represents the control samples exposed to solvent alone. 
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The potency (IC50) of simvastatin in each cell line was compared to the potency 
previously measured in cell monolayers. The anti-cancer activity of simvastatin was 
retained in spheroid models, with IC50 values ranging between 1 µM and 15 µM (figure 
4.5), which in most cases were comparable to the potency measured with cell 
monolayers. However, the IC50 of simvastatin measured in Igrov-1 spheroids and 
particularly in A2780 spheroids was significantly higher than the respective values in 
monolayer cultures (figure 4.5). 
 
 
 
Figure 4.5: The potency of simvastatin in A2780, Ovcar-3, Ovcar-5, Ovcar-8 and 
Igrov-1 spheroids compared to monolayer cultures (mean IC50 ± S.D., n = 5). The 
duration of simvastatin exposure in monolayer and spheroid cultures was the same 
(72 hours), however the analysis methods varied (spheroids, ATP assay; monolayer, 
SRB assay). The IC50 was significantly increased in A2780 and Igrov-1 spheroids 
compared to monolayer cultures (*, paired t-test, P<0.05). 
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To determine if there was a correlation between ovarian cancer cell sensitivity to 
simvastatin and chemotherapeutic agents, the IC50 of carboplatin was also determined 
in ovarian cancer cell monolayers and spheroids. Simvastatin retained potency in cells 
that were relatively resistant to carboplatin (figure 4.6). Furthermore, there was no 
significant correlation between the sensitivity of ovarian cancer cells to simvastatin 
and carboplatin (figure 4.6). This raises the possibility that simvastatin may have 
activity in chemoresistant disease. This prompted the evaluation of statins in paired 
cell lines, which were obtained from ovarian cancer patients both before and after the 
development of resistance to chemotherapy (chapter 5).  
 
 
 
 
Figure 4.6: The potency of simvastatin versus carboplatin compared between cell 
lines in both monolayer (left) and spheroid (right) cultures. There was no significant 
linear correlation between simvastatin and carboplatin activity (Monolayer R² = 0.1, 
mean IC50 ± S.D., n = 3-7 and spheroid R² = 0.007, mean IC50 ± S.D., n = 5).  
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4.3.2   Kinetics of simvastatin-induced cell death 
 
Simvastatin has a relatively short half-life of around 2-3 hours, and therefore, single 
daily dosing in patients may allow the plasma concentration of simvastatin to fall 
below that required for anti-cancer activity. These studies aimed to model the 
cytotoxic effects of a single daily dose of simvastatin in vitro and also determine how 
long exposure to simvastatin must be maintained in order to induce cell death. Ovcar-
8 cells were exposed to simvastatin, at 5 times the IC50 measured in cell growth 
assays, for up to 96 hours. Cell death was determined every 24 hours by quantifying 
the number of cells that failed to exclude Trypan blue. 
 
Cell death observed after 48 hours of simvastatin exposure was almost undetectable 
(figure 4.7), however morphological changes were present after 24 hours as some 
cells had begun to round and detach from the plate (figure 4.8). Significant cell death 
(figure 4.7) and detachment from the plate (figure 4.8) was observed after 72 or 96 
hours of continuous exposure to simvastatin, indicating that prolonged exposure to 
simvastatin was required for cell death. The commitment to cell death did not occur 
before 48 hours exposure, because 48 hours exposure to simvastatin followed by 48 
hours without simvastatin did not result in significant cell death. 
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Figure 4.7: Ovarian cancer cell death induced by simvastatin. The number of dead 
Ovcar-8 cells was determined by Trypan blue staining, after exposure to drug solvent 
or 10 µM simvastatin (5 x IC50) exposure for 24-96 hours. Alternatively cells were 
exposed to simvastatin for 48 hours, then culture medium (“washout”) for a further 48 
hours. The results (mean ± S.D., n = 4) are expressed as a proportion of the total cell 
number at each time point. After exposure to simvastatin for 72 hours or 96 hours, the 
number of dead cells was significantly increased compared to cells treated with 
solvent or to cells exposed to simvastatin for 48 hours followed by solvent for an 
additional 48 hours (1-Way ANOVA, P<0.0001; *, Tukey's Multiple Comparison Test, 
P<0.001). 
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Figure 4.8: Phase contrast microscopy images of ovarian cancer cells exposed to 
simvastatin. Ovcar-8 cells were exposed to solvent or 10 µM simvastatin (5 x IC50) 
either continuously for 24-96 hours (h), or pulsed daily (simvastatin for 12 hours 
followed by no drug for 12 hours) for 96 hours (representative of 3 experiments). 
 
 
To simulate (in a somewhat crude fashion) patient exposure to simvastatin in a clinical 
setting, Ovcar-8 cells were exposed to 10 μM simvastatin every 12 hours followed by 
12 hours of culture medium without simvastatin. This cycle was repeated for 96 hours 
or 192 hours.   
 
Cell death occurred in Ovcar-8 cells continuously exposed to simvastatin for 4 days, 
whereas cells that had been exposed to simvastatin in a pulsatile fashion every 12 
hours for a total of 4 days retained viability (figure 4.9) and continued to proliferate 
(figure 4.8). Ovcar-8 cells were also exposed to pulsed simvastatin for 8 days to 
ensure that the total exposure to pulsed statin was equivalent to 4 days of continual 
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exposure. No additional cell death was observed after exposing cells to simvastatin in 
a pulsatile fashion for 8 days (figure 4.9). These results indicate that continuous 
blockade of HMGCR is required to cause cell death. 
 
 
Figure 4.9: The kinetics of simvastatin-induced cell death. The number of dead 
Ovcar-8 cells was determined by Trypan blue staining after exposure to 10 µM 
simvastatin (5 x IC50) either continuously or alternating between 12 hour drug 
exposure and 12 hour no drug (“pulsed”) for 4-8 days. The number of dead cells 
(mean ± S.D., n = 4) was significantly increased in cells exposed to simvastatin 
continuously compared to cells treated with solvent or pulsed simvastatin (1-Way 
ANOVA, P<0.0001; *, Tukey's Multiple Comparison Test, P<0.001). 
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4.3.3   The contribution of autophagy to simvastatin-induced cell death 
 
Apoptosis has previously been identified as one mechanism of simvastatin-induced 
cell death in ovarian cancer cell lines [337, 338, 485]. To further identify additional 
mechanisms by which statins may cause cell death, the autophagy pathway was 
investigated. Previous studies have reported either an induction or inhibition of 
autophagy following statin exposure, which may have resulted in cell death [317, 318, 
322, 327]. These conflicting results prompted further research into the effects of 
simvastatin on autophagy in ovarian cancer cell lines. 
 
Statins have been proposed to stimulate autophagy, because they cause an increase 
in the synthesis of LC3-II. However, LC3-II can also be increased when autophagy is 
inhibited because the turnover of LC3-II is prevented. To address this, p62 was also 
measured, as p62 accumulation is a marker of autophagy inhibition [486]. Simvastatin 
exposure for 8-48 hours resulted in an accumulation of both LC3-II and p62 in a panel 
of four ovarian cancer cell lines, suggesting an inhibition of autophagy (figure 4.10). 
However, after 24 hours of simvastatin treatment, a modest reduction in p62 was 
observed in several cell lines (Ovcar-8 and Ovcar-5), consistent with the turnover of 
p62 through autophagy, which may be accompanied by a reduction in p62 synthesis. 
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Figure 4.10: The effects of simvastatin on the autophagy pathway. A panel of four 
ovarian cancer cell lines were exposed to 10 μM simvastatin (5 x IC50) or solvent (-) 
for 8–48 hours (h). The levels of LC3-II and p62 were measured by western blotting. 
GAPDH was used as a loading control (n = 3). 
 
 
It was necessary to determine if the increase in LC3-II observed following simvastatin 
exposure was due to an induction or inhibition of autophagy, and therefore, a principle 
method involving the autophagy inhibitor, bafilomycin, was used to measure LC3-II 
turnover [487]. Bafilomycin inhibits lysosome acidification, which blocks the 
degradation of LC3-II, and leads to an accumulation of LC3-II [487]. Drugs which 
further increase LC3-II in the presence of bafilomycin are considered to stimulate 
autophagy [487]. It was important to achieve full inhibition of autophagy with 
bafilomycin to ensure that any additional increase in LC3-II following simvastatin 
exposure could be attributed to an induction in autophagy, rather than an 
accumulative inhibition. Therefore, the bafilomycin concentration required to 
completely block autophagy was first determined in a dose-response study. 
 
Preliminary studies demonstrated that Ovcar-8 cells required 30 nM bafilomycin for 2 
hours in order to achieve full blockade of the autophagy pathway. No further 
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accumulation of LC3-II was observed following exposure to higher concentrations of 
bafilomycin (figure 4.11).  
 
 
Figure 4.11: The inhibition of autophagy in ovarian cancer cells using bafilomycin. 
Ovcar-8 cells were exposed to increasing concentrations of bafilomycin (1-200 nM) or 
solvent (-) for 2 hours, before determining LC3-II levels by western blotting. GAPDH 
was used as a loading control (n = 2). 
 
 
When autophagy was maximally inhibited with bafilomycin in Ovcar-8 cells, 
simvastatin caused a small but significant increase in LC3-II. This was confirmed by 
quantification of the immunoblot images (figure 4.12). These observations suggest 
that simvastatin can stimulate the autophagy pathway in Ovcar-8 cells. 
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Figure 4.12: The effects of simvastatin on the autophagy pathway in the presence of 
bafilomycin. Ovcar-8 cells were exposed to 10 μM simvastatin (5 x IC50) or solvent (-) 
for 48 hours, followed by solvent or 30 nM bafilomycin for 2 hours. LC3-II levels (n = 
3) were significantly increased in cells exposed to both simvastatin and bafilomycin 
compared to cells exposed to only simvastatin (*, paired t-test, P<0.005). GAPDH was 
used as a loading control. 
 
 
The mechanism by which simvastatin effects autophagy was further explored by 
supplementing statin-treated Ovcar-8 cells with mevalonate, farnesol or 
geranylgeraniol. The addition of either mevalonate or geranylgeraniol reversed the 
increase in LC3-II and p62, suggesting that effects on the autophagy pathway were 
mediated though inhibition of HMGCR (figure 4.13). 
 
126 
 
 
 
Figure 4.13: Prevention of the effects of simvastatin on the autophagy pathway. 
Ovcar-8 cells were exposed to 10 μM simvastatin (+, sim, 5 x IC50) or solvent (-) for 48 
hours either in the presence of solvent, 100 μM mevalonate (M), 10 μM farnesol (F) or 
10 μM geranylgeraniol (G). The levels of LC3-II and p62 were significantly decreased 
in cells exposed to simvastatin and mevalonate or geranylgeraniol compared to cells 
exposed to simvastatin alone (1-Way ANOVA, P<0.05; *, Tukey's Multiple 
Comparison Test, P<0.05). GAPDH was used as a loading control (n = 3). 
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The Rab7 GTPase is essential for the regulation of autophagosome trafficking during 
autophagy, and knockdown of Rab7 resulted in impaired epidermal growth factor 
receptor degradation and autophagy inhibition [488]. Rab7 geranylgeranylation is 
required for membrane localisation to late endosomes, and subsequent regulation of 
autophagy [489, 490]. This raised the possibility that statins may block autophagy by 
inhibiting the prenylation and function of Rab7. Simvastatin decreased the total 
amount of Rab7 in Ovcar-5 and Ovcar-8 cells after 24-48 hours of continuous 
exposure (figure 4.14). Despite this, in A2780 and Igrov-1 cells, Rab7 levels were 
initially increased, followed by a subsequent reduction after 32-48 hours. This may 
reflect an initial increase in the synthesis of Rab7, possibly due to a reduction in the 
amount of Rab7 in the membrane [491]. Rab7 was restored in Ovcar-8 cells following 
the addition of mevalonate, and modestly, but nevertheless significantly, rescued by 
geranylgeraniol, suggesting that inhibition of prenylation may have resulted in the 
reduction in Rab7 (figure 4.14). 
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Figure 4.14: The effect of simvastatin on the level of Rab7. A panel of four ovarian 
cancer cell lines were exposed to 10 μM simvastatin (5 x IC50) or solvent (-) for 8–48 
hours (h). The level of Rab7 was measured by western blotting (n = 3). Ovcar-8 cells 
were also exposed to 10 μM simvastatin (+, sim) or solvent (-) for 48 hours either in 
the presence of solvent, 100 μM mevalonate (M), 10 μM farnesol (F) or 10 μM 
geranylgeraniol (G). The level of Rab7 was significantly increased in cells exposed to 
simvastatin and mevalonate or geranylgeraniol compared to cells exposed to 
simvastatin alone (1-Way ANOVA, P<0.05; *, Tukey's Multiple Comparison Test, 
P<0.05). GAPDH was used as a loading control (n = 3). 
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Immunocytochemistry confirmed the reduction in Rab7. There was a significant 
decrease in the number of cells with punctate Rab7 staining following simvastatin 
exposure (figure 4.15). Although the number of cells with punctate LC3-II staining did 
not significantly change, the intensity of LC3-II staining increased in cells treated with 
simvastatin, corresponding to the increase in LC3-II previously observed by western 
blotting (figure 4.15). Furthermore, induction of autophagy by nutrient deprivation for 2 
hours failed to restore Rab7. These results suggested that simvastatin inhibited 
autophagy by preventing Rab7 activation, and subsequently, autophagosome 
degradation.  
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Figure 4.15: The effects of simvastatin on Rab7 and LC3-II immunofluorescence. 
Ovcar-8 cells were exposed to 3 μM or 10 μM simvastatin (1.5 and 5 x IC50) or solvent 
for 24 hours (n = 3), and stained for LC3-II (green) or Rab7 (red). Nuclei were stained 
with DAPI (blue). Other cells were exposed to 3 μM or 10 μM simvastatin for 22 hours, 
then PBS supplemented with simvastatin or solvent for a further 2 hours. The number 
of cells with punctate LC3-II or Rab7 staining was quantified in blinded 
immunofluorescent images (mean ± S.D., n = 3, >100 cells counted per experiment). 
Rab7 punctate staining was decreased following simvastatin treatment compared to 
cells treated with solvent (*, paired t-test, P<1×10−6), and this was not reversed by 
nutrient deprivation (#, paired t-test, P<0.01). 
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The conflicting effects of statins on autophagy (apparently both stimulating and 
inhibiting different stages of autophagy) raised the possibility that this contributed to 
the cytotoxicity of statins. Atg5 is necessary for autophagy as it forms part of a 
complex which is involved in autophagosome elongation and LC3-II formation [277]. 
To assess the contribution of autophagy to the cytotoxic effects of simvastatin, Atg5 
expression was inhibited by RNA interference (RNAi). Atg5 siRNA was used at a 
concentration which on its own did not significantly reduce cell viability alone. 
Knockdown of Atg5 and autophagy inhibition was confirmed by western blotting. Atg5 
knockdown somewhat increased the sensitivity of Ovcar-8 cells to simvastatin at high 
statin concentrations (figure 4.16). Despite this, the IC50 of simvastatin after Atg5 
knockdown was not significantly lower compared to cells exposed to non-targeting 
siRNA.  
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Figure 4.16: The effects of autophagy inhibition by Atg5 knockdown on the potency of 
simvastatin. Ovcar-8 cells were transfected with Atg5 SMARTpool (20 nM) or non-
targeting (NT) SMARTpool for 24 hours, followed by exposure to simvastatin at a 
range of concentrations for 72 hours. The data was represented as a fraction of the 
top of the curve which was identified by curve fitting (mean ± S.D., n = 4). “C” 
represents the control cells exposed to solvent alone. Western blotting (inset) 
confirmed knockdown of Atg5 and inhibition of autophagy. GAPDH was used as a 
loading control. Atg5 knockdown increased Ovcar-8 sensitivity to simvastatin at the 
indicated simvastatin concentrations (*, paired t-test, P<0.05). 
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In contrast, inhibition of Beclin 1, an additional protein involved in the initiation of 
autophagy, did not sensitise Ovcar-8 cells to simvastatin (figure 4.17). There was no 
significant difference in the potency of simvastatin in cells exposed to Beclin 1 siRNA 
compared to non-targeting siRNA.  
 
 
Figure 4.17: The effects of Beclin 1 knockdown on the potency of simvastatin. Ovcar-
8 cells were transfected with Beclin 1 SMARTpool (20 nM) or non-targeting (NT) 
SMARTpool for 24 hours, followed by exposure to simvastatin at a range of 
concentrations for 72 hours. The data was represented as a fraction of the top of the 
curve which was identified by curve fitting (mean ± S.D., n = 4). “C” represents the 
control cells exposed to solvent alone. Western blotting (inset) confirmed knockdown 
of Beclin 1. GAPDH was used as a loading control. 
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4.3.4   Simvastatin in combination with chemotherapy 
 
In previous studies, ovarian cancer cell lines were simultaneously exposed to 
simvastatin and either carboplatin or paclitaxel, combined at a ratio of their single 
agent IC50 values. The combinations were additive or mildly antagonistic (combination 
index >1), however the antagonism was only statistically significant in one cell line 
(results obtained as part of an MPharm project by Laurelle Wilkinson). Varying the 
schedule of drug addition may dramatically influence whether synergy is observed. 
Witham et al reported that ABT-737 was more effective at sensitising ovarian cancer 
cells to carboplatin when administered after chemotherapy [450]. Therefore, cells 
were sequentially exposed to simvastatin and carboplatin for 48 hours, or treated with 
both simvastatin and carboplatin simultaneously for 48 hours, followed by recovery for 
a further 48 hours. In each case, the cells were exposed to either drug at a fixed 
concentration ratio equal to the ratio of the IC50s of the single agents. 
 
The exposure of three ovarian cancer cell lines to simvastatin for 48 hours prior to 
treatment with carboplatin was profoundly antagonistic compared to treatment with 
either carboplatin followed by simvastatin or both drugs simultaneously (figure 4.18). 
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Figure 4.18: Scheduled combinations of simvastatin and carboplatin. Three ovarian cancer cell lines were exposed to a range of 
concentrations of carboplatin and simvastatin at a ratio of their single agent IC50s. The data was represented as a fraction of the top of the 
curve which was identified by curve fitting (mean ± S.D., n = 3). “C” represents the control cells exposed to solvent alone. The schedule of 
drug exposure comprised of treatment with carboplatin for 48 hours then simvastatin for 48 hours, or simvastatin for 48 hours then 
carboplatin for 48 hours, or simvastatin and carboplatin for 48 hours then no drug for 48 hours. Ovcar-8 cells were also exposed to 
carboplatin or simvastatin for 48 hours, followed by a further 48 hours in growth medium containing solvent. Alternatively, Ovcar-8 cells 
were exposed to carboplatin or simvastatin for 48 hours, before fixing in trichloroacetic acid. 
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This made it important to understand if patients already receiving statins for the 
treatment of hypercholesterolemia (typical dose is 40 mg of simvastatin) had a 
reduced response to chemotherapy for ovarian cancer. The maximum plasma 
concentration achieved following a standard 40 mg dose of simvastatin or atorvastatin 
for the treatment of high cholesterol is approximately 10-50 nM [424]. However, in the 
previous experiments, a fixed ratio of carboplatin and simvastatin were used. The 
concentration at which antagonism was evident (>1 µM) was considerably greater 
than the plasma concentration obtained in patients receiving a 40 mg daily dose of 
statin. Therefore, the experiments were repeated with a fixed concentration of statin 
(100 nM) which is closer to the concentration likely to occur in patients treated for 
hypercholesterolemia. These studies used the two commonly prescribed statins, 
simvastatin and atorvastatin.  
 
Pre-treatment of three ovarian cancer cell lines with 100 nM simvastatin or 100 nM 
atorvastatin for 48 hours prior to carboplatin had no effect on the sensitivity of the cells 
to carboplatin (figure 4.19). Furthermore, these low statin concentrations have no 
effect on ovarian cancer cell growth and proliferation. 
 
 
 
 
 
 
 
 
 
137 
 
 
 
Figure 4.19: Carboplatin in combination with low concentrations of statins. Three 
ovarian cancer cell lines were pre-treated with 100 nM simvastatin, 100 nM 
atorvastatin or solvent for 48 hours, then washed, and exposed to a range of 
concentrations of carboplatin. The data was represented as a fraction of the top of the 
curve which was identified by curve fitting (mean ± S.D., n = 3). “C” represents the 
control cells exposed to solvent alone. 
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4.4   Discussion 
 
A range of statins have previously been evaluated in a panel of ovarian cancer cell 
lines, demonstrating that the lipophilic statins (simvastatin and fluvastatin) were more 
potent than the hydrophilic alternatives (e.g. rosuvastatin). This inhibition of cell 
growth was reversed by the addition of mevalonate or geranylgeraniol, suggesting that 
these effects were mediated through inhibition of HMGCR. Simvastatin was found to 
be the most potent statin across most cell lines and was therefore chosen for further 
analysis. Simvastatin has previously been shown to inhibit the proliferation of cancer 
cell lines and induce apoptotic cell death (reviewed by [471]). Despite this, clinical 
trials evaluating both standard doses of simvastatin, used for the treatment of 
hypercholesterolemia, and the MTD of simvastatin have not been successful at 
improving patient survival. The studies presented here aimed to evaluate simvastatin 
as a therapy for the treatment of ovarian cancer, and determine how statins can be 
used more successfully in the clinic than has been achieved in clinical trials to date. 
 
The cytotoxic activity of simvastatin was confirmed in a spheroid model. Ovarian 
cancer spheroids are a three-dimensional architecture of cancer cells that potentially 
more closely resembles cancer in a physiological setting. Simvastatin retained anti-
cancer activity in this cellular model, with IC50 values similar to those obtained in 
monolayer cultures, thereby supporting the use of simvastatin in vivo. Modest, but 
nevertheless significant, increases in the IC50 of simvastatin in A2780 and Igrov-1 
spheroid cultures compared to monolayer cultures could reflect the inability of 
simvastatin to affect cells contained within the spheroid core. These ovarian cancer 
spheroids may be more resistant to anti-cancer agents compared to monolayer 
cultures, which may be due to limited drug penetration into the spheroid and reduced 
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proliferation of cells contained within the spheroid core [430]. This leaves unanswered 
the question why simvastatin could (presumably) penetrate the core of the other 
spheroids. 
 
Further kinetic studies on cell monolayers demonstrated that prolonged and 
continuous exposure to high concentrations of simvastatin for 72-96 hours was 
required to achieve cell death. This period may be required to allow the turnover of 
proteins which are already prenylated before cell death can occur. However, there 
was no significant cell death after cells were exposed to simvastatin for 48 hours, 
followed by a further 48 hours without simvastatin. This is in contrast to previous 
research, which reported a significant increase in caspase 3/7 activity in ovarian 
cancer cells exposed to simvastatin after 48 hours [492], and suggests that cells can 
recover from caspase-3 activation. This is supported by increasing evidence which 
demonstrates that upon removal of the apoptotic stimuli, cells can reverse apoptosis 
and survive, even after caspase activation and DNA damage [493, 494]. Furthermore, 
minority mitochondrial permeabilization can lead to limited caspase activation, which 
results in DNA damage that can promote cellular transformation, but is insufficient to 
trigger cell death [495]. Therefore, 3-4 days of continuous statin exposure may be 
required for complete mitochondrial permeabilization and commitment to cell death. 
This has a number of implications for the use of simvastatin in a clinical setting. 
Simvastatin has a considerably short half-life of approximately 2-3 hours [424], and 
therefore, single daily dosing with this statin may allow a period of time when the 
synthesis of isoprenoids could occur. This is likely to prevent the anti-cancer activities 
of simvastatin by enabling cancer cells to survive and proliferate. Indeed, ovarian 
cancer cells exposed to simvastatin in a pulsatile fashion every 12 hours for more than 
1 week failed to undergo cell death. This may partially explain the lack of clinical 
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success that has been achieved with statins to date. Instead, patients may require 
either several daily doses of simvastatin or continuous infusion to ensure constant 
inhibition of HMGCR. Alternatively, statins with a longer half-life may be used, which 
allow less frequent dosing. However, the choice of statin is problematic, because data 
presented here suggest that lipophilic statins are notably more potent. The commonly 
prescribed statins that have long half-lives tend to be more hydrophilic compared to 
simvastatin. The recently developed statin, pitavastatin, is both lipophilic and affords a 
substantially improved half-life of 11 hours [496]. This may significantly improve drug 
exposure compared to simvastatin. Pitavastatin is evaluated in chapter 5.  
 
The concentrations of simvastatin required to induce cell death in vitro (2-15 µM in 
ovarian cancer cell lines) are considerably greater than those achieved in the plasma 
following a 40 mg dose of simvastatin for the treatment of high cholesterol (7.6 - 16.5 
nM [424]). Despite this, several clinical trials have evaluated simvastatin at standard 
doses (40 mg daily) with chemotherapy in patients with non-small lung cancer without 
success [409, 410]. The plasma concentration obtained in patients following 
administration of simvastatin at the MTD (7.5 mg/kg twice daily) was 0.08 - 2.2 µM 
[482], closer to the concentration required for anti-cancer activity in vitro. These doses 
were administered orally for 7 consecutive days during 21-day cycles without 
significant toxicity [419, 482, 497]. Several studies have reported side effects including 
fatigue, gastrointestinal symptoms and neutropenia following administration of high 
statin doses, however these were manageable or tolerable over the short treatment 
period [419, 497]. Several clinical trials are evaluating high doses of statins for the 
treatment of cancer [425], although these trials do not currently address the issue of 
the short half-life of simvastatin. Instead, clinical trials should evaluate simvastatin at 
high doses with a dosing frequency to maintain suppression of HMGCR. 
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Novel therapeutic agents are often evaluated in combination with existing 
chemotherapeutic therapies in oncology. In the case of simvastatin, a synergistic 
interaction with first line therapy for ovarian cancer (carboplatin and paclitaxel) could 
lower the concentrations of statin required to cause cell death. These concentrations 
may be more achievable in patients, and therefore, clinical trials using high doses of 
simvastatin are more likely to be successful. This may also facilitate the use of lower 
doses of statins, thereby minimising the adverse effects. However, previous studies 
have demonstrated additive or modest antagonistic interactions in ovarian cancer cells 
simultaneously exposed to simvastatin and carboplatin or paclitaxel [492]. In dose 
scheduling experiments, profound antagonism was observed when cells were 
exposed to high concentrations of simvastatin prior to carboplatin. One possible 
explanation is that inhibition of HMGCR by statins results in cell cycle arrest [229, 
235], which may render ovarian cancer cells refractory to carboplatin. Chemotherapy 
is generally considered to be most potent in cells which are proliferating. Carboplatin 
causes the accumulation of ovarian cancer cells in S- and G2/M phase of the cell cycle 
[498], and therefore, prolonged G1 arrest induced by simvastastin may blunt the pro-
apoptotic effect of carboplatin. Taken together, these results suggest that simvastatin 
(or another statin) is best evaluated in clinical trials as a single agent. Trials could be 
carried out as “consolidation therapy” in patients who have completed and responded 
to chemotherapy. Furthermore, simvastatin displayed anti-cancer activity in ovarian 
cancer cell lines which were relatively resistant to chemotherapy, suggesting that 
simvastatin could also be used in patients with chemotherapy resistant disease. It is 
worthwhile noting that in situations where the cancer is advanced, it may be difficult to 
show a therapeutic benefit following high dose simvastatin treatment.  
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The significant antagonism observed in cells exposed to simvastatin followed by 
carboplatin raised the concern that standard doses of statins for the treatment 
hypercholesterolemia could antagonise chemotherapy prescribed for the treatment of 
ovarian cancer. The potential impact of this is that patients may benefit from having 
their statin therapy withdrawn prior to receiving chemotherapy. However, the plasma 
concentration of statin achieved from a standard dose of simvastatin or atorvastatin is 
not sufficient to antagonise the anti-cancer effect of carboplatin in vitro, suggesting 
that existing statin therapy should not be an issue.  
 
The mechanism by which statins inhibit growth and induce cell death has previously 
been explored in ovarian cancer cells. Statins induce G1 cell cycle arrest [484], 
apoptosis [337, 338, 485], and more recently, autophagy in other cancer types [317, 
322]. In ovarian cancer cells, simvastatin increased the level of LC3-II even when the 
autophagy pathway was fully blocked with bafilomycin, supporting previous reports 
that statins stimulate autophagy. P62 was also evaluated as a marker of autophagy, 
as p62 has been shown to accumulate when autophagy was inhibited [486]. 
Simvastatin caused an initial accumulation of p62 in all cell lines tested, consistent 
with autophagy inhibition and a reduction in the turnover of p62. However, this 
increase in p62 may also reflect an increase in the synthesis of p62. Evidence for p62 
induction at the transcriptional level by oxidative stress conditions has been reported 
[499]. The GTPase Rab7 is essential for the late stages of autophagosome maturation 
as knockdown of Rab7 has been shown to inhibit autophagy [488]. Prenylation and 
membrane recruitment is required for the activation of Rab7 [489, 490], raising the 
possibility that statins may block autophagy through the inhibition of Rab7 activation. 
Simvastatin significantly decreased the level of Rab7 and this was moderately 
reversed by the addition of geranylgeraniol, suggesting that statins may block the later 
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stages autophagy by inhibiting the prenylation and membrane translocation of Rab7. 
Statin-mediated inhibition of Rab geranylgeranylation has also been demonstrated for 
Rab5 and Rab6 GTPases [322, 327, 500, 501]. These studies also reported that the 
addition of geranylgeranyl diphosphate to statin-treated cells restored prenylation and 
active Rab proteins in several different cancer cell lines [500, 501]. However, two 
groups reported an induction in autophagy following statin exposure, despite a 
reduction in Rab5 prenylation [322, 327]. Therefore, it is also possible that statins may 
only be capable of partially blocking the activity of Rab GTPases, and that remaining 
prenylated Rab5 or Rab7 may be sufficient to sustain autophagy. This incomplete 
inhibition of autophagy could account for the modest reduction in p62 levels in several 
cell lines after 48 hours of simvastatin exposure. Taken together, these results raise 
the possibility that statins may simultaneously stimulate and inhibit autophagy at 
different points on the autophagic pathway. Futile cycles have been linked to cell 
death [502], and this may contribute to the cytotoxic effects of statins. Indeed, 
inhibition of autophagy using siRNA against Atg5, an essential autophagy-related 
protein involved in the early stages of autophagosome formation, modestly sensitised 
cells to simvastatin. Furthermore, another study reported that co-treatment with 
lovastatin and a farnesyltransferase inhibitor resulted in an inhibition of autophagy and 
cell death [327]. Conversely, autophagy inhibition using siRNA against Beclin 1 (Atg6), 
a protein also involved in autophagosome formation, had no significant effects on the 
sensitivity of cells to simvastatin. Beclin 1 knockdown has previously been reported to 
inhibit drug-induced apoptosis, and this could go some way to explaining why 
attenuation of Beclin 1 had no overall effect on cells exposed to simvastatin [503, 
504]. In conclusion, whilst the effects of statins on the autophagy pathway may 
contribute to cell death, it is likely that there are additional mechanisms involved in the 
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cytotoxicity of statins in ovarian cancer, which are also mediated through the inhibition 
of HMGCR. 
 
In summary, these results suggested that simvastatin should be evaluated in clinical 
trials at high concentrations, with an appropriate dosing schedule, which will enable 
continual inhibition of HMGCR. The short half-life of simvastatin may require a 
frequent and inconvenient dosing schedule, and therefore, this has led to the pre-
clinical evaluation of an alternative statin (pitavastatin) with a longer half-life. 
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CHAPTER 5 
 
PRECLINICAL EVALUATION OF 
PITAVASTATIN AS A TREATMENT FOR 
OVARIAN CANCER 
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5.1   Introduction 
 
Pitavastatin (NK-104) is a synthetic statin synthesised by Nissan Chemical Industries 
and developed by Kowa at the beginning of the century [505]. The structure of 
pitavastatin retains the dihydroxy-heptanoic acid chain, which is responsible for 
binding to the active site of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCR) [506]. Furthermore, the abundance of hydrophobic moieties in the 
compound allows the formation of van der Waals interactions with the enzyme [163]. 
The unique cyclopropyl group may also contribute to effective inhibition of HMGCR. 
Pitavastatin is moderately lipophilic (n-octanol/water partition coefficient (logP) of 1.49) 
compared to other statins including simvastatin (logP = 1.6) and fluvastatin (logP = 
1.27) [162], and this may support passive diffusion across plasma membranes into the 
cellular cytosol. In addition, pitavastatin is a substrate of organic anion-transporting 
polypeptide 1B (OATP1B), which also mediates the translocation of pitavastatin into 
cells located in the liver, kidney and brain [507]. The OATP transporters play a crucial 
role in hepatic uptake mechanisms, and statins utilise these carriers to gain entry to 
the liver and inhibit cholesterol synthesis [507]. Pitavastatin has been shown to reduce 
low density lipoprotein cholesterol to a level comparable to that achieved by 
simvastatin [508], in addition to increasing high density lipoprotein cholesterol levels 
[509]. In conjunction with these impressive cholesterol-lowering effects, pitavastatin 
has also been demonstrated to exhibit cholesterol-independent or “pleiotropic” effects 
including anti-cancer activity.  
 
Following the success in reducing cholesterol levels, initial studies in the oncology 
field focussed on the evaluation of pitavastatin in colon or liver tumorigenesis. 
Pitavastatin inhibited proliferation and induced apoptosis in cholangiocarcinoma cells, 
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as demonstrated by G0/G1 phase cell cycle arrest and an increase in cleaved caspase 
3 levels [218]. Furthermore, pre-treatment of these cells with 20 µM pitavastatin for 48 
hours prior to gemcitabine, cisplatin or 5-fluorouracil exposure resulted in a synergistic 
reduction in cell proliferation [218]. However, results from the combination 
experiments were not compared to the response to single agent pitavastatin, and 
therefore, the anti-proliferative effects could be attributed to pitavastatin alone. Low 
concentrations of pitavastatin (0.1-1 µM) decreased tumour necrosis factor-alpha 
(TNF-α)-induced NF-κB activation, resulting in reduced expression of the pro-
inflammatory cytokine, interleukin 6 (IL-6), in breast and liver cancer cells [510, 511]. 
These effects also contributed to the inhibition of cancer cell growth and proliferation.  
 
Pitavastatin has also been evaluated in vivo for the treatment of obesity-related 
cancers. Pitavastatin significantly inhibited the development of drug-induced liver or 
colonic preneoplastic lesions in mice [512, 513]. Pitavastatin-induced apoptosis in vivo 
was confirmed by an increase in single-stranded DNA (ssDNA)-positive nuclei [514], 
increased levels of the pro-apoptotic protein, Bad, and decreased expression of Bcl-2 
mRNA [512]. Furthermore, a decrease in the expression of TNF-α, IL-6 and IL-8 was 
reported, suggesting a reduction in inflammation and an activation of AMP-activated 
protein kinase (AMPK), all of which can inhibit lipid accumulation [512, 513]. 
Pitavastatin exposure did not result in significant liver toxicity at the relatively low 
concentrations used (10 ppm) [512]. In a similar study, pitavastatin decreased drug-
induced intestinal polyp formation in mice, possibly by decreasing the expression of 
cyclooxygenase-2, IL-6, inducible nitric oxide, monocyte chemoattractant protein-1, 
and plasminogen activator inhibitor-1 mRNA in intestinal nonpolyp areas [515]. 
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More recently, pitavastatin has been evaluated both in vitro and in xenograft studies in 
human breast and brain cancer [516, 517]. Pitavastatin inhibited the proliferation of 
cancer cells, induced G1/S phase cell cycle arrest, and increased the autophagy 
protein, LC3-II, which could be attributable to an induction or inhibition of autophagy. 
Jiang and colleagues also reported that pitavastatin did not induce apoptosis [517], 
however this may reflect the short duration of exposure to pitavastatin, as cells are 
likely to require the turnover of prenylated proteins before cell death occurs (chapter 
4). Furthermore, pitavastatin significantly inhibited the growth of glioblastoma tumours 
in xenograft models when administered intraperitoneally [516]. Interestingly, the 
growth of these tumours was not significantly inhibited by pitavastatin administered by 
oral gavage, suggesting that the formulation and dose may require careful 
optimisation. Pitavastatin also inhibited drug exclusion by the multi-drug resistant 
protein, MDR-1, and this may contribute to the potentiation of other chemotherapeutic 
agents [517].  
 
Whilst all statins inhibit HMGCR, they have distinct pharmacokinetic properties. Most 
statins have short half-lives of between 0.5 and 3 hours, with the exception of 
atorvastatin, pitavastatin and rosuvastatin (chapter 1, [162]). Previous research 
demonstrated that continued inhibition of HMGCR was necessary to cause cell death, 
suggesting that several daily doses of simvastatin would be required in order to 
effectively treat cancer (chapter 4). Pitavastatin has a half-life of 11 hours [162], which 
may prolong exposure to statin and thereby reduce the dosing frequency required. 
Thus, the promising anti-cancer activity of pitavastatin in cancer cell lines and 
xenografts, together with an extended half-life, make pitavastatin an ideal candidate 
for evaluation in ovarian cancer.  
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To conduct clinical trials evaluating pitavastatin for the treatment of ovarian cancer, 
biomarkers of statin-induced cell death are required to confirm the cytotoxic effects of 
statins on cancer cells. Clinical trials have previously estimated HMGCR inhibition as 
an indicator of statin activity. This has been achieved by measuring plasma 
cholesterol levels, urinary mevalonate excretion, and by measuring the degree of 
inhibition of a standard amount of HMGCR present in a rat microsomal preparation 
[407, 416, 421, 518]. However, cholesterol and mevalonate markers are not always 
correlated to statin cytotoxicity and therefore, may not be adequate biomarkers of 
statin-induced cell death in vivo. Additional biomarkers which may be used to predict 
response to statin therapy include markers of apoptosis. Immunostaining tumour 
tissue for the cell proliferation marker, Ki-67, and the apoptosis marker, cleaved 
caspase-3, before and after statin treatment revealed a significant decrease in Ki-67, 
and an induction in apoptosis in high-grade breast tumours [421]. Furthermore, 
cytokeratin 18 is cleaved by caspases during apoptosis to form caspase-cleaved 
cytokeratin 18 (ccCK18), which is released from cells, and can be detected in the 
plasma of patients exposed to chemotherapy [519]. Alternatively, proteins released 
from cells exposed to pitavastatin can be analysed by gel electrophoresis and mass 
spectrometry [520], with the aim of identifying proteins which are predominantly 
released from cancer cells compared to normal cells. 
 
 
5.2   Aims 
 
The research in this chapter aimed to evaluate the activity of pitavastatin as a single 
agent in a panel of ovarian cancer cell lines, to further understand the mechanism by 
which pitavastatin induces cytotoxic activity, to identify biomarkers of statin-induced 
150 
 
death, and to evaluate pitavastatin activity in a xenograft study. The results of this 
research will inform clinical trials of pitavastatin in ovarian cancer, and establish novel 
biomarkers which could be utilised to confirm response to pitavastatin in the clinic. 
 
 
5.3   Results 
 
5.3.1   HMGCR levels in epithelial, fibroblast and ovarian cancer cell lines 
 
HMGCR has previously been described as a metabolic oncogene, as ectopic 
expression of HMGCR contributed to anchorage-independent growth and cellular 
transformation [137]. Furthermore, overexpression of HMGCR in oesophageal 
squamous cell carcinoma cells increased cell growth and migration [146]. Therefore, 
HMGCR protein level was determined in a panel of ovarian cancer cell lines, and 
compared to the HMGCR level in three normal cell lines. HMGCR protein level was 
increased in all ovarian cancer cell lines compared to normal ovarian epithelial (HOE) 
cells, lung epithelial (NL20) cells and fibroblasts (HFF) (figure 5.1). Quantification of 
HMGCR protein level confirmed that this was significant (P<0.05) in A2780, cisA2780, 
Ovcar-3 and Ovcar-8 cell lines compared to HOE cells (figure 5.1). These results 
raised the possibility that an increase in HMGCR may contribute to the development 
of ovarian cancer, and therefore, provided a rationale for the evaluation of pitavastatin 
in ovarian cancer. 
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Figure 5.1: HMGCR levels in a panel of ovarian cancer cell lines and normal cells 
including human foreskin fibroblasts (HFF), human bronchial epithelial cells (NL20) 
and human ovarian epithelial cells (HOE) (n = 3-4). GAPDH was used as a loading 
control. HMGCR levels were normalised to GAPDH and significantly increased 
compared to HOE cells where indicated (*, paired t-test, P<0.05). 
 
 
5.3.2   Pitavastatin inhibits the growth of ovarian cancer cell lines 
 
The activity of pitavastatin in cell growth assays was determined in a panel of ovarian 
cancer cell lines, normal cells and ovarian cancer spheroids. In eight ovarian cancer 
cell lines grown as monolayers, pitavastatin exhibited IC50 values ranging between 0.2 
µM and 8 µM (figure 5.2). Pitavastatin had the most potent activity in Ovcar-8 cells 
(IC50 = 0.2 ± 0.05 µM), but also demonstrated activity in normal ovarian epithelial cells 
and in fibroblasts (IC50 ~ 1 µM; figure 5.2). To evaluate the activity of pitavastatin in a 
3-dimensional culture, the effect of pitavastatin on ovarian cancer spheroids was 
evaluated by measuring ATP in cells exposed to increasing concentrations of 
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pitavastatin. The activity of pitavastatin in ovarian cancer spheroids was comparable 
to that determined in cell monolayers with IC50 values ranging between 0.6 µM and 4 
µM (figure 5.2). However, the IC50 values in A2780 spheroids and Ovcar-8 spheroids 
(2 µM and 0.6 µM) were notably increased compared to the IC50 values in respective 
monolayer cultures (0.7 µM and 0.2 µM).  
 
 
Figure 5.2: The potency of pitavastatin in normal cell monolayers (human ovarian 
epithelial (HOE) cells or human foreskin fibroblasts (HFF)), eight ovarian cancer cell 
monolayers (mean IC50 ± S.D., n = 3-4), and in five ovarian cancer spheroids (mean 
IC50 ± S.D., n = 4-5). IC50 values were significantly increased in spheroid cultures 
compared to monolayer cultures where indicated (*, paired t-test, P<0.01). 
 
 
Simvastatin was previously found to have cytotoxic activity in ovarian cancer cells that 
were resistant to carboplatin, suggesting that statins may have activity in cancers 
resistant to chemotherapy (chapter 4). Therefore, the anti-growth activity of 
pitavastatin was evaluated in several paired cell lines (PEA1/PEA2 and PEO1/PEO4), 
which have been obtained from ovarian cancer patients both before and after the 
development of clinical resistance to chemotherapy. Pitavastatin IC50 values in the 
153 
 
paired cell lines (1 μM – 3.5 μM) were comparable to those obtained in ovarian cancer 
cell lines (figure 5.3, data obtained by Dr Euan Stronach and Karen Menezes at 
Imperial College, London). Interestingly, PEA2 and PEO4 cells derived from 
chemoresistant and relapsed tumours appeared modestly more sensitive to 
pitavastatin compared to their paired chemosensitive cell lines. 
 
 
Figure 5.3: The potency of pitavastatin in paired ovarian cancer cell lines. The paired 
cell lines PEA1 and PEA2, and PEO1 and PEO4 were exposed to the indicated 
concentrations of pitavastatin for 72 hours. The data was represented as a fraction of 
the top of the curve which was identified by curve fitting (mean ± S.D., n = 6-9). “C” 
represents the control cells exposed to solvent alone. Data was obtained from Dr 
Euan Stronach and Karen Menezes at Imperial College, London.  
 
 
To confirm the anti-growth activity of pitavastatin had resulted from inhibition of 
HMGCR, Ovcar-8 and Ovcar-3 cells exposed to pitavastatin were supplemented with 
farnesol or geranylgeraniol, or both. The addition of geranylgeraniol but not farnesol to 
Ovcar-8 and Ovcar-3 cells significantly suppressed the anti-growth effects of 
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pitavastatin (figure 5.4). Furthermore, supplementing pitavastatin-treated cells with 
both geranylgeraniol and farnesol also significantly suppressed the inhibition of the 
growth of Ovcar-8 cells, although this occurred to a lesser degree in Ovcar-3 cells 
(figure 5.4). These results suggested that the anti-growth activity of pitavastatin was 
mediated though the inhibition of geranylgeranylation. 
 
 
 
Figure 5.4: Prevention of the anti-growth effects of pitavastatin. Cells were exposed to 
1 μM (Ovcar-8) and 20 μM (Ovcar-3) pitavastatin (pit, 5 x IC50) for 72 hours in the 
presence of 10 μM farnesol (F), 10 μM geranylgeraniol (G) or solvent. The number of 
cells surviving (mean ± S.D., n = 3) was expressed as a fraction of those surviving in 
samples treated with solvent alone. The number of cells were significantly increased 
compared to pitavastatin where indicated (*, paired t-test, P<0.01). 
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5.3.3   Pitavastatin has no significant effects on cell migration 
 
Statins have also been shown to inhibit cancer cell migration and invasion through 
inhibition of HMGCR (chapter 1). Therefore, the effects of pitavastatin on ovarian 
cancer cell migration were determined. Ovcar-8 cells were grown to confluence, the 
monolayer was wounded, and cell migration was measured after 36 hours in medium 
supplemented with pitavastatin at concentrations up to the IC50. These concentrations 
were chosen to avoid significant cell detachment. Pitavastatin had no effect on the 
relative migration of Ovcar-8 cells after 36 hours (figure 5.5), suggesting that inhibition 
of cell migration is unlikely to contribute to the anti-cancer effects of pitavastatin on 
ovarian cancer cells.  
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Figure 5.5: The effects of pitavastatin on cell migration. Analysis of Ovcar-8 migration 
after exposure to 0.1 µM or 0.2 µM pitavastatin (0.5 and 1 x IC50), or solvent by phase 
contrast microscopy immediately after wounding or after 36 hours (h) (mean ± S.D., n 
= 3). Relative migration was calculated as described in chapter 3. 
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5.3.4   Pitavastatin induces cell cycle arrest and apoptotic cell death 
 
Next, experiments were completed to identify the mechanisms by which pitavastatin 
inhibited the growth of cultures of ovarian cancer cells. Exposure of Ovcar-3 cells to 
pitavastatin resulted in a decrease in the fraction of cells in G2/M phase(s) of the cell 
cycle and an increase in subG1 (figure 5.6).  
 
 
Figure 5.6: The effects of pitavastatin on the cell cycle. Flow cytometry analysis of the 
DNA content in Ovcar-3 cells exposed to 12 μM pitavastatin (3 x IC50) or solvent for 48 
hours (mean ± S.D., n = 3). The percentage of pitavastatin-treated cells in G2/M 
phase(s) of the cell cycle was significantly decreased compared to cells exposed to 
solvent alone, together with a significant increase in subG1 phase where indicated (*, 
paired t-test, P<0.01). 
 
 
The increase in subG1 phase following pitavastatin exposure may indicate an increase 
in apoptosis. This prompted further studies to confirm that cell death contributed to the 
reduced growth of monolayer cultures of ovarian cancer cells. To quantify cell death 
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induced by pitavastatin, a panel of eight ovarian cancer cell lines were exposed to 
pitavastatin at 5 times IC50 for 96 hours, and the number of cells that failed to exclude 
Trypan blue were determined. Cell death was significantly increased in every cell line 
exposed to pitavastatin (figure 5.7). Notably, almost all A2780, cisA2780 and Ovcar-3 
cells were dead after 96 hours.  
 
Trypan Blue Cell Viability Assay 
 
 
Figure 5.7: Ovarian cancer cell death induced by pitavastatin. The number of dead 
ovarian cancer cells was determined by Trypan blue staining after exposure to solvent 
(-) or pitavastatin (+) at 5 x IC50 for 96 hours (mean ± S.D., n = 3). The percentage of 
dead cells after exposure to pitavastatin was significantly increased compared to the 
solvent alone for all cell lines (*, paired t-test, P<0.0005). 
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Apoptosis has previously been identified as one mechanism of statin-induced cell 
death in ovarian cancer cell lines [337, 338, 485]. To confirm that pitavastatin also 
induced apoptosis in ovarian cancer cell lines, several markers of apoptosis including 
caspases 3, 7, 8, 9 and poly (ADP) ribose polymerase (PARP) cleavage were 
measured in cells exposed to pitavastatin. Pitavastatin significantly increased caspase 
3/7 activity in all cell lines tested, indicating the induction of apoptotic cell death (figure 
5.8). This was confirmed by an increase in PARP cleavage in pitavastatin-treated 
Ovcar-8 cells (figure 5.8). Furthermore, the cleavage of PARP was fully reversed by 
the addition of mevalonate or geranylgeraniol, suggesting that the pro-apoptotic 
activity of pitavastatin was mediated through inhibition of HMGCR.  
 
The activation of apoptosis can occur through the extrinsic (death receptor) pathway 
or the intrinsic (mitochondrial) pathway (chapter 1). Statins have predominantly been 
shown to induce apoptosis through the mitochondrial pathway; however one study 
reported an increase in death receptor ligands, and subsequent activation of the 
extrinsic apoptotic pathway following simvastatin exposure [338, 364]. In order to 
further elucidate the pathway by which pitavastatin induced apoptosis in ovarian 
cancer cells, the activities of the initiator caspases were also determined. Caspase-8 
is activated following the binding of ligands to the death receptor and activation of the 
death-inducing signalling complex in the extrinsic apoptosis pathway, whereas 
caspase-9 is activated by Bax/Bak-mediated cytochrome c release from the 
mitochondria in the intrinsic apoptotic pathway. Pitavastatin significantly increased the 
activity of both caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) in 
most cell lines tested, suggesting that both the extrinsic and intrinsic apoptosis 
pathways were activated during pitavastatin-induced apoptosis (figure 5.8).  
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Figure 5.8: The effects of pitavastatin on the apoptosis pathway. Caspase 8, 9 and 
3/7 activities were measured in Ovcar-3, Igrov-1 and Ovcar-8 cells following exposure 
to 20 µM (Ovcar-3), 10 µM (Igrov-1) and 1 µM (Ovcar-8) pitavastatin (5 x IC50), 50 nM 
paclitaxel or solvent for 48 hours. Caspase activity was expressed as a fraction (mean 
± S.D., n = 3) of the activity measured in cells exposed to paclitaxel. Relative caspase 
activity was significantly increased following pitavastatin exposure (*, paired t-test, 
P<0.05) compared to cells treated with solvent where indicated. Ovcar-8 cells were 
also exposed to 1 μM pitavastatin or solvent for 48 hours either in the presence of 100 
μM mevalonate (M), 10 μM farnesol (F), 10 μM geranylgeraniol (G) or solvent, and 
PARP cleavage was determined by western blotting. GAPDH was used as a loading 
control (n = 3). 
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FLICE-like inhibitory protein (FLIP) negatively regulates the extrinsic apoptosis 
pathway by inhibiting the cytoplasmic adaptor protein and caspase-8 complex, and 
has previously been implicated in drug resistance in ovarian cancer [521, 522]. This 
raised the possibility that FLIP knockdown may sensitise ovarian cancer cells to 
apoptosis induced by pitavastatin. FLIP expression was inhibited by siRNA which 
recognised the long form of FLIP (FLIP#4), and both the long and short isoforms of 
FLIP (FLIP#18). FLIP siRNA was used at a concentration which did not significantly 
reduce cell viability alone [522].  
 
FLIP SMARTpool and FLIP#4 siRNA did not have a significant effect on the sensitivity 
of Ovcar-3 cells to pitavastatin (figure 5.9). FLIP#18 siRNA modestly decreased the 
potency of pitavastatin in Ovcar-3 cells (IC50 = 5.6) compared to cells transfected with 
non-targeting siRNA (IC50 = 7.4, figure 5.9), although this was not statistically 
significant. Knockdown of FLIP, as evaluated by western blotting, was incomplete, and 
this may have contributed to the lack of any significant changes in sensitivity to 
pitavastatin (figure 5.9).  
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siRNA IC50 (µM) 
NT SMARTpool 7.0 ± 0.8 
FLIP SMARTpool 6.9 ± 1.0 
NT #1 7.4 ± 1.9 
FLIP #4 7.3 ± 0.4 
FLIP #18 5.6 ± 1.1 
 
Figure 5.9: The effects of FLIP knockdown on the potency of pitavastatin. Ovcar-3 
cells were transfected with FLIP SMARTpool (0.3 nM), FLIP #4 (25 nM) or FLIP #18 
(3 nM) and the corresponding non-targeting (NT) siRNA for 24 hours, followed by 
exposure to pitavastatin at a range of concentrations for 72 hours. The data was 
represented as a fraction of the top of the curve which was identified by curve fitting 
(mean ± S.D., n = 3). “C” represents the control cells exposed to solvent alone. 
Western blotting (inset) confirmed knockdown of FLIP. GAPDH was used as a loading 
control. The IC50 values were calculated from the dose-response curves (mean ± S.D., 
n = 3).  
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5.3.5   The contribution of autophagy to pitavastatin-induced cell death 
 
To further identify additional cellular pathways which may affect statin-induced cell 
death, autophagy was investigated. Previous studies demonstrated that simvastatin 
may simultaneously induce and inhibit the autophagy pathway at different points, and 
this could contribute to the cytotoxic effects of statins (chapter 4). To confirm this, the 
effects of pitavastatin on autophagy were also determined.  
 
An accumulation of LC3-II can result from an induction or inhibition of autophagy, 
whereas an increase in p62 is often a marker of autophagy inhibition. Pitavastatin 
exposure resulted in an accumulation of LC3-II and p62 in Ovcar-8 cells after 48 
hours, suggesting that pitavastatin inhibited autophagy (figure 5.10). However, this 
could also be representative of autophagy induction, as p62 synthesis can be 
increased in response to autophagy stimulation [486]. The geranylgeranylated 
GTPase Rab7 is essential for the late stages of autophagosome maturation [488]. 
Pitavastatin reduced the level of Rab7, raising the possibility that inhibition of the 
prenylation of Rab7 promotes its turnover (figure 5.10). Whatever the explanation for 
the pitavastatin-induced decrease in Rab7, these data suggest that pitavastatin may 
block the late stages of autophagy. Notably, the effects on LC3-II, p62 and Rab7 were 
reversed by the addition of either mevalonate or geranylgeraniol to pitavastatin-treated 
cells, suggesting that effects on the autophagy pathway were mediated through 
HMGCR inhibition (figure 5.10).  
 
Atg5 is involved in the early stages of autophagosome formation and LC3-II 
production [277]. To determine if autophagy contributed to the pro-apoptotic effects of 
pitavastatin, Atg5 expression was inhibited using Atg5 siRNA at a concentration which 
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did not significantly induce apoptosis alone (figure 5.10). Knockdown of Atg5 and 
autophagy inhibition was confirmed by western blotting. Atg5 knockdown modestly, 
but significantly, increased the sensitivity of Ovcar-8 cells to apoptotic cell death 
induced by pitavastatin (figure 5.10). 
 
 
Figure 5.10: The effects of pitavastatin on the autophagy pathway. Ovcar-8 cells were 
exposed to 1 μM pitavastatin (5 x IC50) or solvent for 48 hours either in the presence 
of 100 μM mevalonate (M), 10 μM farnesol (F), 10 μM geranylgeraniol (G) or solvent. 
The levels of LC3-II and p62 were measured by western blotting (n = 3). Ovcar-8 cells 
were also transfected with Atg5 SMARTpool (20 nM) or non-targeting (NT) 
SMARTpool for 24 hours followed by exposure to solvent or 2 μM pitavastatin (10 x 
IC50) for 48 hours. Western blotting (inset) confirmed knockdown of Atg5 and inhibition 
of autophagy. GAPDH was used as a loading control. Caspase 3/7 activity (mean ± 
S.D., n = 3) was expressed as a fraction of the activity in cells exposed to NT siRNA 
and solvent. Atg5 knockdown significantly increased pitavastatin-induced apoptosis in 
Ovcar-8 cells (*, paired t-test, P<0.05). 
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5.3.6   Increased reactive oxygen species (ROS) production is not a mechanism 
of pitavastatin-induced cell death 
 
Deregulation of autophagy has been correlated with increases in reactive oxygen 
species (ROS), and in some cases, increased mitochondrial content; mitochondria are 
the major cellular source of ROS (reviewed by [295]). The effects of both simvastatin 
(chapter 4) and pitavastatin on the autophagy pathway prompted further investigations 
on the effects of pitavastatin on mitochondrial content and ROS in ovarian cancer 
cells.  
 
Mitochondrial turnover (mitophagy) relies on the autophagy pathway and defective 
autophagy can result in alterations in mitochondrial number or function [295]. 
Therefore, mitochondrial content was estimated in Ovcar-8 and Ovcar-3 cell lines 
using MitoTracker Green FM dye, which binds to mitochondrial proteins predominantly 
in the inner mitochondrial membrane in viable cells. Pitavastatin significantly 
increased the mitochondrial content in Ovcar-8 and Ovcar-3 cells, as indicated by a 
significant increase in mitochondrial fluorescence (figure 5.11). Furthermore, the 
majority of cells exposed to pitavastatin exhibited an increase in mitochondrial staining 
as observed by fluorescence microscopy. Collectively, these results suggest that 
pitavastatin may inhibit mitochondrial turnover.  
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Figure 5.11: The effects of pitavastatin on mitochondrial content. Ovcar-8 and Ovcar-
3 cells exposed to 1 μM and 20 μM pitavastatin (5 x IC50) respectively or solvent for 48 
hours. Mitochondria were stained using 100 nM MitoTracker Green FM and 
fluorescence was determined by flow cytometry (mean ± S.D., n = 3). Relative 
fluorescence was significantly increased in pitavastatin-treated cells compared to cells 
exposed to solvent alone (*, paired t-test, P<0.05). Mitochondria were also visualised 
by fluorescence microscopy (green). Nuclei were stained with Hoechst 33258 (blue). 
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To confirm the increase in mitochondrial content in ovarian cancer cells exposed to 
pitavastatin, the cellular mitochondrial DNA (mtDNA) content was measured. The 
mitochondrial NADH dehydrogenase 1 (ND1) gene is located exclusively in mtDNA. 
Therefore, ND1 and an internal reference gene, β-actin, were used to quantify the 
relative mtDNA content (chapter 3). There was a significant increase in relative 
mtDNA content in Ovcar-8 cells exposed to pitavastatin, consistent with the increase 
in mitochondrial content (figure 5.12). However, there was no difference in mtDNA 
content in Ovcar-3 cells exposed to pitavastatin compared to the solvent control 
(figure 5.12). This may reflect the accumulation of mitochondria containing damaged 
mtDNA in pitavastatin-treated Ovcar-3 cells. 
 
 
Figure 5.12: The effects of pitavastatin on mitochondrial DNA (mtDNA). Ovcar-8 and 
Ovcar-3 cells were exposed to 1 μM and 20 μM pitavastatin (5 x IC50) respectively or 
solvent for 48 hours. ND1 content was determined by qPCR and normalised to β-actin 
content, as described in chapter 3 (mean ± S.D., n = 3). Relative mtDNA (ND1) 
content was significantly increased in Ovcar-8 cells exposed to pitavastatin (*, paired 
t-test, P<0.05). 
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Mitochondria are the major intracellular producers of ROS, and increased 
mitochondrial content has previously been linked to elevated ROS [523, 524]. 
Furthermore, statins have been reported to increase ROS in colon cancer cells and 
lymphoma cells [350, 352]. To determine if the increase in mitochondria in ovarian 
cancer cells was accompanied by an increase in ROS, 2’,7’-dichlorofluorescin 
diacetate (DCFDA) was used to measure ROS in Ovcar-3 and Ovcar-8 cells exposed 
to pitavastatin.  
 
A significant increase in ROS was detected in Ovcar-3 cells exposed to pitavastatin, 
and this was inhibited by the ROS scavenger, N-acetylcysteine (NAc) (figure 5.13). 
Conversely, there was no increase in ROS in Ovcar-8 cells after exposure to 
pitavastatin for 48 hours compared to the solvent control (figure 5.13). Tert-butyl 
hydroperoxide (TBHP) can decompose to alkoxyl and peroxyl radicals, resulting in the 
generation of hydrogen peroxide, and therefore, TBHP can be used to generate 
oxidative stress in vitro. TBHP significantly induced ROS in both Ovcar-3 and Ovcar-8 
cells (figure 5.13).  
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Figure 5.13: The effects of pitavastatin on reactive oxygen species (ROS) production. 
Ovcar-8 and Ovcar-3 cells were exposed to 1 μM and 20 μM pitavastatin (5 x IC50) 
respectively or 50 µM tert-butyl hydroperoxide (TBHP) to generate ROS, either in the 
presence of solvent or 0.5 mM N-acetylcysteine (NAc) for 48 hours (3 hours for 
TBHP). ROS were measured using 2’,7’-dichlorofluorescin diacetate (DCFDA) and 
expressed as a fraction of the activity in cells exposed solvent (mean ± S.D., n = 3). 
ROS were significantly increased in ovarian cancer cells exposed to pitavastatin or 
TBHP where indicated (*, paired t-test, P<0.05).  
 
 
The generation of superoxide in simvastatin-treated colon cancer cells was 
demonstrated to induce activation of the JNK pathway, resulting in the expression of 
the pro-apoptotic protein Bim and subsequent apoptosis [352]. Furthermore, 
suppression of ROS using superoxide scavengers attenuated apoptosis, suggesting 
that superoxide was important for simvastatin-induced apoptosis in colon cancer cells 
[352]. To evaluate whether the increase in ROS in ovarian cancer cells contributed to 
apoptosis induced by pitavastatin, Ovcar-3 and Ovcar-8 cells were exposed to 
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pitavastatin alone, or in combination with the superoxide scavenger, N-acetylcysteine 
(NAc), and caspase 3/7 activity was determined.  
 
Inhibition of ROS in Ovcar-3 and Ovcar-8 cells exposed to pitavastatin had no 
significant effect on caspase 3/7 activity, suggesting that ROS production is not likely 
to be a major mechanism contributing to pitavastatin-induced apoptosis in these 
ovarian cancer cell lines (figure 5.14). Notably, induction of ROS using TBHP 
modestly induced apoptosis in Ovcar-8 cells but not Ovcar-3 cells, and this was 
somewhat reversed by the addition of NAc, indicating that Ovcar-8 cells may be 
sensitive to ROS-induced cell death (figures 5.13 and 5.14). 
 
 
 
Figure 5.14: The effects of reactive oxygen species (ROS) inhibition on pitavastatin-
induced apoptosis. Ovcar-8 and Ovcar-3 cells were exposed to 1 μM and 20 μM 
pitavastatin (5 x IC50) respectively or 50 µM tert-butyl hydroperoxide (TBHP), either in 
the presence of solvent or 0.5 mM N-acetylcysteine (NAc) for 48 hours or 3 hours for 
TBHP. Caspase 3/7 activity was measured and expressed as a fraction of the activity 
in cells exposed solvent (mean ± S.D., n = 3).  
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5.3.7   Biomarkers of pitavastatin treatment 
 
Cytokeratin 18 is cleaved by caspases during apoptosis to produce ccCK18, which is 
released into the extracellular environment and can be detected in the plasma of 
breast cancer patients treated with chemotherapy [519]. To determine if ccCK18 was 
elevated in response to statin treatment, ccCK18 was measured in cell culture 
medium taken from ovarian cancer cells which had been exposed to pitavastatin for 
72 hours. 
 
A significant amount of ccCK18 was detected in the medium taken from Ovcar-3 and 
Ovcar-8 cells, but not Igrov-1 or Skov-3 cells exposed to pitavastatin for 72 hours, 
suggesting that ccCK18 may only be useful as a biomarker of pitavastatin-induced cell 
death in a subset of patients (figure 5.15).  
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Figure 5.15: Caspase-cleaved cytokeratin 18 (ccCK18) released from ovarian cancer 
cells exposed to pitavastatin. Ovarian cancer cells were exposed to 1 μM (Ovcar-8), 
10 μM (Igrov-1), 18 μM (Skov-3) and 20 μM (Ovcar-3) pitavastatin (5 x IC50), 50 nM 
paclitaxel (Ovcar-3) or solvent for 72 hours. ccCK18 levels were measured in 
supernatant samples and expressed as a fraction of the ccCK18 from Ovcar-3 cells 
exposed to paclitaxel (mean ± S.D., n = 3). ccCK18 was significantly increased in 
Ovcar-3 and Ovcar-8 cells exposed to pitavastatin (*, paired t-test, P<0.005). 
 
 
To identify additional novel biomarkers which were predominantly released from 
cancer cells in response to statin-induced cell death, ovarian cancer cells and normal 
cells were exposed to a panel of chemotherapeutic drugs or statins, and the proteins 
released into the cell culture medium were detected by silver staining of SDS-PAGE 
gels.  
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There were generally more proteins released into the medium from ovarian cancer 
cells exposed to simvastatin, pitavastatin or paclitaxel compared to cells exposed to 
solvent, pravastatin, carboplatin, doxorubicin or topotecan (figure 5.16). Furthermore, 
the profiles of proteins released from Ovcar-8 and Ovcar-3 cell lines were different 
compared to the protein profiles from HOE cells and fibroblasts (figure 5.16). This 
enabled the identification of seven protein bands, which were detected specifically in 
the supernatant of ovarian cancer cells exposed to pitavastatin or simvastatin, and 
were present at lower levels in the silver stains of normal cells or ovarian cancer cells 
exposed to solvent or pravastatin (marked with arrows in figures 5.16 and 5.17). 
These protein bands were extracted from a gel stained with Coomassie Brilliant Blue 
and provisionally identified by tryptic peptide sequencing using mass spectrometry in 
collaboration with Dr Elzbieta Piatkowska and Dr Sarah Hart at Keele University 
(figure 5.17; appendix 4). 
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Silver Staining 
 
Figure 5.16: The proteins released from normal cells and ovarian cancer cells 
exposed to statins and chemotherapeutic agents. Ovcar-8 cells and human foreskin 
fibroblasts (HFF) were exposed to 1 μM pitavastatin (5 x IC50) or 10 μM simvastatin (5 
x IC50) or pravastatin; human ovarian epithelial cells (HOE) were exposed to 2 μM 
pitavastatin (2 x IC50), simvastatin or pravastatin; Ovcar-3 cells were exposed to 8 μM 
pitavastatin (2 x IC50), simvastatin or pravastatin, or solvent as indicated for 72 hours 
(n = 3). Ovcar-8 cells were also exposed to 70 μM carboplatin (1 x IC50), 1 μM 
doxorubicin (5 x IC50), 21 nM paclitaxel (3 x IC50) and 50 nM topotecan (5 x IC50). 
Proteins in supernatant samples were separated by gel electrophoresis and visualised 
by silver staining. Protein sizes were estimated using the protein markers (kDa) on the 
left. Black arrows indicate the protein bands that were excised from a gel stained with 
Coomassie Brilliant Blue (figure 5.17) for mass spectrometry analysis. 
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Coomassie Brilliant Blue Staining 
 
Figure 5.17: The identification of nine proteins released from ovarian cancer cells 
exposed to pitavastatin. Ovcar-8 cells were exposed to 1 μM pitavastatin (5 x IC50) or 
solvent for 72 hours. Proteins in supernatant samples were separated by gel 
electrophoresis and visualised by Coomassie Brilliant Blue staining. The bands 
indicated by black arrows were excised, and proteins were identified by mass 
spectroscopy sequencing by Dr Elzbieta Piatkowska and Dr Sarah Hart at Keele 
University. The peptide sequences identified are detailed in appendix 4. Protein sizes 
were estimated using the protein markers (kDa) on the left. Heat shock protein 90, 
HSP90; glyceraldehyde-3-phosphate dehydrogenase, GAPDH.  
 
 
To confirm the identity of the proteins identified by mass spectrometry, the cell culture 
medium taken from Ovcar-8 and Ovcar-3 cells exposed to pitavastatin for 72 hours 
was analysed by western blotting (figure 5.18). Medium from cells exposed to 
pitavastatin contained an increase in each protein, suggesting that these proteins had 
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been accurately identified by mass spectrometry, and they may be novel biomarkers 
of statin-induced cell death (figure 5.18).  
 
Western Blotting 
 
Figure 5.18: Validation of the release of nine proteins from ovarian cancer cells 
exposed to pitavastatin. Ovcar-8 and Ovcar-3 cells exposed to 1 μM (5 x IC50) or 8 μM 
(2 x IC50) pitavastatin (+) respectively, or solvent (-) for 72 hours. Proteins in 
supernatant samples, previously identified by mass spectroscopy sequencing, were 
increased in cells exposed to pitavastatin (n = 3). Heat shock protein 90, HSP90; 
pyruvate kinase isoform M1 or M2, PK M1/M2; glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH. 
 
 
5.3.8   Pitavastatin modestly inhibits the growth of Ovcar-3 tumour xenografts 
 
To determine whether pitavastatin could inhibit the growth of tumour cells in vivo, 
Ovcar-3 xenografts were established in nude mice (these studies were performed by 
Charles River Discovery Research Services, North Carolina). The maximum tolerated 
dose (MTD) of 78.95 mg/kg, orally, every 12 hours was determined in an initial study 
which evaluated a range of doses of pitavastatin in mice (26.32 – 157.89 mg/kg every 
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12 hours). Subsequently, mice were treated with either pitavastatin at the MTD or 
vehicle alone for 33 days. Pitavastatin treatment was well tolerated with less than 5% 
decrease in mean body weight throughout the experiment. Pitavastatin marginally 
reduced tumour volume after 25 days compared to tumours treated with vehicle alone, 
although the overall reduction in tumour volume was not statistically significant (figure 
5.19). 
 
 
Figure 5.19: The effects of pitavastatin on the growth of Ovcar-3 xenografts in SCID 
mice. Mice were treated with 78.95 mg/kg pitavastatin or vehicle alone every 12 hours 
orally for 33 days (10 animals per group). Tumour volume was measured twice a 
week (mean ± S.E.M., n = 10). This xenograft study was completed by Charles River 
Discovery Research Services in Morrisville, North Carolina. 
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Pitavastatin was previously shown to cause apoptosis in ovarian cancer cell lines 
(figure 5.8). Furthermore, simultaneous induction and inhibition of the autophagy 
pathway following pitavastatin exposure may contribute to these cytotoxic effects. In 
order to determine if pitavastatin had any effects on apoptosis or autophagy in the 
tumour xenografts after 33 days of pitavastatin exposure, six representative tumours 
were homogenised and the levels of LC3-II, p62, Rab7, and PARP cleavage were 
determined.  
 
PARP cleavage was possibly increased in two of the tumours treated with pitavastatin, 
suggesting that pitavastatin may have contributed to an increase in apoptosis in these 
tumours (figure 5.20). Furthermore, there was an increase in LC3-II or p62 in two 
pitavastatin-treated tumours, and a reduction in the level of Rab7 in all tumours 
exposed to pitavastatin (figure 5.20). Taken together, these results are reminiscent of 
those obtained in vitro, and the effects of pitavastatin on both apoptosis and 
autophagy may have contributed to the modest reduction in tumour volume. 
 
HMGCR has been reported to be upregulated in response to statin treatment, and this 
may contribute to resistance to the cytotoxic effects of statins [173, 525]. This raised 
the possibility that an increase in HMGCR in the statin-treated xenograft tumours may 
have overcome the cytotoxic effects of pitavastatin, resulting in only a modest 
reduction in tumour growth. Therefore, the level of HMGCR was determined in the six 
representative tumours. The level of HMGCR did not differ significantly between 
tumours treated with pitavastatin or vehicle, suggesting that this is not likely to have 
contributed to resistance to pitavastatin (figure 5.20). 
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Figure 5.20: The effects of pitavastatin on HMGCR and proteins involved in 
autophagy and apoptosis in Ovcar-3 xenograft tumours. Six Ovcar-3 tumours from 
xenograft studies were lysed (group 1 = vehicle, group 2 = pitavastatin). PARP 
cleavage, HMGCR, Rab7, LC3-II and p62 levels were determined by western blotting. 
GAPDH was used as a loading control (n = 3). 
 
 
To further understand why pitavastatin only modestly inhibited tumour growth in vivo, 
the concentration of pitavastatin in each tumour was determined. Solid phase 
extraction (SPE) was used to extract pitavastatin from homogenised tumours, and the 
concentration of pitavastatin in each tumour was determined by high-performance 
liquid chromatography (HPLC). HPLC was completed by Dr Clare Hoskins at Keele 
University. 
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Xenograft tumours treated with vehicle contained no pitavastatin, whereas tumours 
exposed to pitavastatin contained between 32 µM and 114 µM pitavastatin, thereby 
suggesting that pitavastatin had penetrated the tumours (table 5.1). To further confirm 
the presence of pitavastatin in the tumours, Ovcar-8 cells were exposed to a range of 
concentrations of the pitavastatin extracts from each tumour, and the effect on cell 
growth was determined. Extracts from xenograft tumours treated with vehicle had no 
effect on the growth of Ovcar-8 cells. However, tumour extracts from pitavastatin-
treated tumours were approximately 10-fold less potent than authentic pitavastatin. 
Furthermore, when the potency of each tumour extract in the bioassay was compared 
to that of authentic pitavastatin, the pitavastatin concentration in the tumour extracts 
was approximately 5-fold lower than that measured by HPLC (table 5.1). These data 
support the presence of pitavastatin in the xenograft tumours treated with pitavastatin, 
however the reduction in potency compared to authentic pitavastatin suggests that 
either the pitavastatin concentration in the tumour extracts was less than that 
measured by HPLC, or there were other factors inhibiting pitavastatin activity. 
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Ovcar-3 tumour 
xenograft 
Pitavastatin concentration 
in tumour extract (HPLC) 
(µM) 
Pitavastatin concentration 
in tumour extract 
(bioassay) (µM) 
Group 1    #1-3 0 0 
Group 2    #1 106 17 
Group 2    #2 32 8 
Group 2    #3 114 22 
 
Table 5.1: Determination of the concentration of pitavastatin in Ovcar-3 xenograft 
tumours. Pitavastatin was extracted from six Ovcar-3 tumour samples from xenograft 
studies (group 1 = vehicle, group 2 = pitavastatin) and quantified using HPLC (data 
was obtained from Dr Clare Hoskins at Keele University). Alternatively, a bioassay 
was performed in which a range of concentrations of the tumour extracts, as 
estimated by the HPLC method, were added to Ovcar-8 cells in vitro and the potency 
of the extracts were compared to that of authentic pitavastatin. 
 
 
An additional factor that could have contributed to the insufficient reduction in tumour 
growth in xenografts treated with pitavastatin was the presence of geranylgeraniol in 
the mouse chow. Nomura and colleagues reported that a high-fat diet restored tumour 
growth in mice deficient in monoacylglycerol lipase, a lipolytic enzyme which promotes 
tumour growth and invasion [526]. This raised the possibility that exogenous sources 
of lipids may have blocked the cytotoxic effects of the statins. Lipids were extracted 
from the Lab Diet mouse chow used in the xenograft study along with two other 
mouse chows, Special Diets and Open Source Diets, and a selection of foodstuffs 
(table 5.2).  
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Foodstuff 
Documented fat content 
in foodstuff 
Mass of lipid extract 
obtained 
Tesco pure sunflower oil 100 g in 110 mL 608 mg 
Sainsbury’s olive oil 92 g in 100 mL 388 mg 
Japonica polished rice 
(Kinuhikari) 
Not Available 510 mg 
Lab Diet NIH 31 0045117 
chow 
5 g in 100 g 928 mg 
Special Diets Services 
801960 BK001(E) chow 
Not Available 198 mg 
Open Source Diets 
D11112201 chow 
7 g in 100 g 340 mg 
Ensure Plus drink 5 g in 100 mL 10 mg 
Fresubin 2 kcal drink 8 g in 100 mL 10 mg 
 
Table 5.2: Yields of lipid extracts obtained from foodstuffs. Lipids were extracted from 
a range of mouse chow diets, sunflower oil, olive oil, rice, and several food 
replacement drinks. Lipids were extracted from 50 g of each foodstuff. The fat content 
in each foodstuff is also given where available. 
 
 
These extracts were added to ovarian cancer cells exposed to pitavastatin to 
determine if they could suppress the cytotoxic effects of the statins. The extracts on 
their own had no significant effect on cell growth or apoptosis (figures 5.21 and 5.22). 
However, when Ovcar-8 and Ovcar-3 cells exposed to pitavastatin were 
supplemented with the extracts from the mouse chow used in the xenograft study (Lab 
Diet) and the Special Diets mouse chow, there was a modest but significant inhibition 
of the anti-growth and pro-apoptotic effects of pitavastatin (figures 5.21 and 5.22). 
Furthermore, the Open Source Diets mouse chow also prevented the anti-growth 
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effects of pitavastatin in ovarian cancer cell lines, although only modestly inhibited 
caspase 3/7 activity (figures 5.21 and 5.22). 
 
These data made it important to determine if other foodstuffs, which would 
presumably be consumed by patients treated with statins during clinical trials, also 
contained lipids that may inhibit the cytotoxic activity of pitavastatin. Extracts were 
also prepared from various foods, and their ability to suppress the cytotoxic effects of 
pitavastatin was determined. Previous studies have reported the presence of 
geranylgeraniol, geranylgeranyl diphosphate or geranylgeranyl esters in foodstuffs 
including Kinuhikari polished rice [456], sunflower oil [527], olive oil [527], and virgin 
olive oil [528]. Extracts from sunflower oil and Kinuhikari polished rice significantly 
prevented the anti-growth and pro-apoptotic effects of pitavastatin in Ovcar-8 or 
Ovcar-3 cell lines (figures 5.21 and 5.22). Notably, sunflower oil extract almost 
completely inhibited pitavastatin-induced apoptosis in both cell lines (figure 5.22). 
Extracts from olive oil also modestly inhibited the effects of pitavastatin on cell growth 
and apoptosis (figures 5.21 and 5.22). However, extracts from olive oil and rice did not 
appear to prevent the anti-growth effects of pitavastatin in Ovcar-8 and Ovcar-3 cells 
respectively, despite modestly decreasing pitavastatin-induced apoptosis in these cell 
lines. This may reflect lower concentrations of lipids in these extracts, which may only 
partially reverse the effects of pitavastatin.  
 
These studies highlighted the need for a food that patients could consume during a 
clinical trial of pitavastatin, which would not suppress the drug’s pro-apoptotic effect. 
Lipids were also extracted from two food replacement drinks, Ensure Plus and 
Fresubin (table 5.2). These food replacement drinks have less fat / mL compared to 
the sunflower and olive oils (table 5.2). The extracts from Ensure Plus and Fresubin 
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had no effect on the anti-growth and pro-apoptotic effects of pitavastatin, suggesting 
that these food replacement drinks could be used as an alternative diet in studies 
evaluating pitavastatin for the treatment of cancer in vivo (figures 5.21 and 5.22).
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Figure 5.21: The effects of lipids extracted from various foodstuffs on the anti-growth effects of pitavastatin. Ovcar-8 and Ovcar-3 cells 
were supplemented with lipids extracted from 8 foodstuffs (sunflower oil, olive oil, polished rice, Lab Diet chow, Special Diets chow, Open 
Source Diets chow, Ensure Plus and Fresubin) or 10 µM geranylgeraniol (G), either in the presence of 0.4 µM (Ovcar-8) or 8 µM (Ovcar-
3) pitavastatin (2 x IC50) or solvent for 72 hours. The number of cells surviving (mean ± S.D., n = 3-5) was expressed as a fraction of 
those surviving in samples treated with solvent alone. The number of cells was significantly increased compared to cells exposed to 
pitavastatin alone where indicated (*, paired t-test, P<0.05; #, paired t-test, P<5×10−5). 
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Figure 5.22: The effects of lipids extracted from various foodstuffs on the pro-apoptotic effects of pitavastatin. Ovcar-8 and Ovcar-3 cells 
were supplemented with lipids extracted from 8 foodstuffs (sunflower oil, olive oil, polished rice, Lab Diet chow, Special Diets chow, Open 
Source Diets chow, Ensure Plus and Fresubin) or 10 µM geranylgeraniol (G), either in the presence of 0.4 µM (Ovcar-8) or 8 µM (Ovcar-
3) pitavastatin (2 x IC50) or solvent for 72 hours. Caspase 3/7 activity was expressed as a fraction (mean ± S.D., n = 3) of the activity 
measured in cells exposed to geranylgeraniol. Caspase 3/7 activity was significantly decreased compared to cells exposed to pitavastatin 
alone where indicated (*, paired t-test, P<0.05; #, paired t-test, P<0.01). 
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5.4   Discussion 
 
This chapter aimed to evaluate pitavastatin in ovarian cancer, because this statin has 
an improved half-life of around 11 hours, and previous results demonstrated that a 
statin with a longer half-life than simvastatin (2-3 hours) may be required to improve 
drug exposure (chapter 4). 
 
HMGCR has been labelled as a metabolic oncogene as overexpression was 
correlated with cell growth, transformation and migration, and a poor prognosis in 
breast cancer patients [137, 146]. Furthermore, the TP53 tumour suppressor gene is 
mutated in most ovarian cancers, and mutant p53 can associate with sterol gene 
promoters including SREBP, resulting in the expression of genes involved in the 
mevalonate pathway [148]. In the studies presented here, HMGCR was significantly 
increased in ovarian cancer cell lines compared to normal ovarian epithelial cells. The 
cells tested all lack wild-type p53, raising the possibility that the increased expression 
may be driven by mutant p53/SREBP. The description of HMGCR as a metabolic 
oncogene in breast cancer suggests that it may have a similar role in ovarian 
tumorigenesis. In any event, these findings provide a rationale for the evaluation of 
HMGCR inhibitors, statins, in ovarian cancer. The lipophilic statin, simvastatin was 
previously shown to have cytotoxic activity in ovarian cancer cell lines (chapter 4). 
However, simvastatin has a short half-life (2-3 hours), and therefore, repeated dosing 
is likely to be necessary for continual inhibition of HMGCR and the cytotoxic effects of 
simvastatin (chapter 4). Pitavastatin has a considerably longer half-life of 11 hours, 
and therefore, twice daily dosing may be adequate to maintain suppression of 
HMGCR. The data presented here aimed to evaluate pitavastatin as a therapy for the 
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treatment of ovarian cancer, and to identify novel biomarkers of statin-induced cell 
death which could be used to predict response to statins in clinical trials.  
 
Pitavastatin was found to be more potent than simvastatin in a panel of ovarian cancer 
cell lines. Reminiscent of simvastatin, the inhibition of cell growth by pitavastatin was 
reversed by simultaneous exposure to geranylgeraniol, suggesting that these effects 
were mediated through inhibition of HMGCR. Pitavastatin also demonstrated anti-
growth activity in paired ovarian cancer cell lines, some of which had developed 
resistance to chemotherapy, reaffirming that statins could be used in chemotherapy 
resistant disease. Clinical trials with pitavastatin could be carried out in patients with 
advanced chemoresistant ovarian cancer, although it may be difficult to show a 
therapeutic benefit in this subset of patients. Pitavastatin also significantly inhibited the 
growth of normal human ovarian epithelial cells and human foreskin fibroblasts with a 
similar potency to that observed in some ovarian cancer cell lines. This suggests that 
the cytotoxic effects of statins may also affect normal cells, independent of the level of 
HMGCR. Conversely, other studies reported that statins had no cytotoxic effect on 
other normal cell lines including mesothelial cells [321], mammary epithelial cells 
[254], embryonic stem cells [529], and primary tissue cultures established from normal 
ovarian epithelium [337], suggesting that normal cells exhibit varying sensitivities to 
statins. Furthermore, despite the potential cytotoxic effects of statins on normal human 
cells, clinical trials have administered high doses of statins in patients without 
considerable toxicity [419, 497]. One possible interpretation is that the evaluation of 
toxicity in vitro is a poor predictor of clinical activity. Immortalised “normal” cells in vitro 
proliferate continually, a feature that is not shared by most cells in vivo.  
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The activity of pitavastatin was confirmed in an ovarian cancer spheroid model. 
Pitavastatin reduced ATP in cancer spheroids, although there was a significant 
decrease in potency in A2780 and Ovcar-8 spheroids compared to the respective 
monolayer cultures. Reminiscent of the activity of simvastatin in ovarian cancer 
spheroids, these differences could reflect limited drug penetration or reduced 
proliferation of cells in the spheroid core (chapter 4). Furthermore, the different 
analytical methods used to estimate the IC50 in cell monolayers versus spheroids 
could have contributed to the variation in drug potency.  
 
Further studies on cell monolayers demonstrated that pitavastatin significantly induced 
cell death in a panel of ovarian cancer cell lines. Notably, after 96 hours of continuous 
exposure to pitavastatin at 5 times the IC50, more than 75% of A2780, cisA2780, 
Ovcar-3 and Ovcar-8 cells were dead when assessed by Trypan blue exclusion, 
suggesting that several days of high concentrations of pitavastatin may be necessary 
to induce cell death. This has several implications for clinical trials evaluating 
pitavastatin in ovarian cancer. The maximum tolerated dose (MTD) of pitavastatin in 
humans is 64 mg daily and this achieves a maximum plasma concentration (Cmax) of 
approximately 2.7 µM (calculated based on linear pharmacokinetics and previously 
reported data from [530-532]). This concentration is representative of the IC50 of 
pitavastatin in most of the ovarian cancer cell lines evaluated. Furthermore, 
pitavastatin can be administered at the MTD for up to two weeks without significant 
myotoxicity [533]. Taken together, this suggests that pitavastatin administered at the 
MTD could achieve plasma concentrations comparable to those required for anti-
cancer activity in vitro, and these high concentrations can be maintained for several 
weeks to allow the turnover of proteins which are already prenylated before cell death 
can occur.  
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To further justify a clinical trial of pitavastatin in ovarian cancer, an Ovcar-3 xenograft 
study was conducted with the MTD of pitavastatin in mice (78.95 mg/kg, orally, every 
12 hours) administered for 33 days. The MTD was predicted to achieve a Cmax of 
approximately 56 µM in the mice (calculated based on linear pharmacokinetics and 
previously reported data from [161]), which is well above the concentration required 
for cytotoxicity in vitro. Furthermore, based on a half-life of 7 hours in rats, the 
pitavastatin concentration was estimated to be approximately 17 µM 12 hours after a 
single administration, suggesting that adequately high concentrations would be 
maintained over 12 hours, and this should allow continual inhibition of HMGCR. 
Despite this, pitavastatin only marginally reduced tumour volume compared to mice 
treated with vehicle alone after 33 days. This was supported by a small increase in 
PARP cleavage in two representative pitavastatin-treated tumours, suggestive of an 
induction in apoptosis. Furthermore, pitavastatin also increased the autophagy 
proteins, LC3-II and p62, in two tumours exposed to pitavastatin and this may 
contribute to an inhibition of autophagy, which may increase the sensitivity of ovarian 
cancer cells to apoptosis. The geranylgeranylated GTPase, Rab7 is required for 
autophagosome maturation and trafficking during autophagy [488], and statins were 
shown to reduce Rab7 in ovarian cancer cells in vitro. Pitavastatin was also modestly 
decreased Rab7 in three tumours, providing confidence that pitavastatin had reached 
the tumours. One pitavastatin-treated tumour displayed no increase in PARP cleavage 
despite an apparent increase in both LC3-II and p62, suggesting that there may have 
been other factors which prevented pitavastatin-induced apoptosis. Therefore, it was 
necessary to determine the reasons for the limited activity observed in the Ovcar-3 
xenograft study, before pitavastatin could be evaluated in further xenograft studies or 
clinical trials. HMGCR is upregulated in response to statin exposure and this can 
contribute to resistance to the effects of statins, presumably by overcoming the 
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inhibition of HMGCR [173, 525]. The level of HMGCR was similar in both drug- and 
placebo-treated tumours, suggesting that this was not likely to be a mechanism of 
resistance to pitavastatin in this study. Alternatively, pitavastatin may not have 
penetrated the tumours in sufficient concentrations to cause cell death. To assess 
this, the drug was extracted from the tumours and its concentration measured by 
HPLC. Pitavastatin concentrations in drug-treated tumours ranged from 32 µM to 114 
µM, which was anticipated to be more than adequate to induce apoptosis in ovarian 
cancer cell lines. To confirm the HPLC results, a bioassay was performed in which the 
tumour extracts were added to ovarian cancer cells in vitro and the potency of the 
extract was compared to that of authentic pitavastatin. When ovarian cancer cells 
were exposed to pitavastatin extracted from drug-treated tumours, using the HPLC 
estimation of pitavastatin concentration, the extracts were approximately 10-fold less 
potent than authentic pitavastatin. There are several possible explanations for this 
discrepancy. The concentration of pitavastatin measured by HPLC may have been 
higher than the actual concentration in the extracts. This is surprising because SPE of 
pitavastatin followed by detection by HPLC has previously been reported to be a 
sensitive and accurate method for the quantitative analysis of pitavastatin in biological 
samples [453, 534]. Another explanation is that the tumour extracts contained 
compounds related to geranylgeraniol. The reversed phase SPE process includes a 
nonpolar solid phase composed of silica packing modified with hydrophobic alkyl and 
aryl groups. This might retain geranylgeraniol, which could suppress the activity of the 
pitavastatin in the tumour extract, and make it appear less potent. Nonetheless, it was 
still surprising that pitavastatin had little effect because even if the bioassay was a 
more accurate measure of pitavastatin than the HPLC method, the concentration of 
drug in the tumour extracts would have ranged from 8-22 µM, 2-5 fold above the IC50 
measured in vitro. Taken together, these data suggest that a significant amount of 
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pitavastatin reached the tumour and that a further explanation for the lack of efficacy 
was necessary. 
 
The possibility that the mice had a dietary source of geranylgeraniol was considered. 
It was noted that the mouse chow used in the xenograft study contained fat, which 
may encompass geranylgeranyl-related lipids. Nomura and colleagues reported that 
mouse chow containing elevated amounts of fatty acids restored tumour growth in 
mice deficient in monoacylglycerol lipase, a lipolytic enzyme which promotes tumour 
growth and invasion [526]. Notably, lipids extracted from the mouse chow used in the 
xenograft study modestly, but nevertheless significantly, inhibited the effects of 
pitavastatin on Ovcar-8 and Ovcar-3 cell growth and apoptosis, suggesting that the 
consumption of mouse chow containing these lipids could have suppressed the 
cytotoxic effects in the xenograft study. Importantly, these findings were also 
demonstrated for two other brands of mouse chow. Thus, it is plausible that dietary 
geranylgeraniol contributed to the modest effect of pitavastatin in the xenograft study. 
 
The discovery that lipids in mouse chow could inhibit the cytotoxic effects of 
pitavastatin raised the concern that lipids in common foodstuffs consumed by patients 
could suppress the activity of statins in ovarian cancer clinical trials.  Geranylgeranyl 
diphosphate, geranylgeraniol or geranylgeranyl esters have been extracted from 
several foodstuffs including Kinuhikari polished rice [456], sunflower oil [527], olive oil 
[527], and virgin olive oil [528]. In most cases, lipid extracts from sunflower oil, olive oil 
and rice modestly inhibited the effects of pitavastatin on cell growth and apoptosis. 
Notably, extracts from sunflower oil, which is commonly used in cooking, almost 
completely attenuated the pro-apoptotic effect of pitavastatin in cells. The lipids in 
these foodstuffs (e.g. geranylgeraniol) may contribute to the production of 
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geranylgeranyl diphosphate, resulting in an inhibition of the cytotoxic activity of statins. 
Collectively, these results have significant implications for future clinical trials 
evaluating statins as a therapy for cancer, as the consumption of foodstuffs which 
contain these lipids may prevent the anti-cancer activity of statins, potentially resulting 
in tumour progression.  
 
As these observations could potentially undermine clinical trials of statins, we 
therefore identified a food that could be consumed by patients during a clinical trial 
which may lack geranylgeraniol. Lipids extracted from the food replacement drinks, 
Ensure Plus and Fresubin, did not prevent the anti-growth and pro-apoptotic effects of 
pitavastatin in ovarian cancer cells. Taken together, these results suggest that 
xenograft studies and clinical trials evaluating statins as a cancer treatment should 
ensure that dietary fat intake is minimised and this can be achieved through the 
administration of a controlled diet using food replacement drinks.  
 
Further studies aimed to determine the mechanism of statin-induced cytotoxicity in 
ovarian cancer cells. Previous data suggested that both simvastatin and pitavastatin 
inhibited cell growth and caused cell death in cells, although the mechanism is 
complex (chapter 4). Statins have been shown to inhibit the proliferation of many 
cancer cell lines by G0/G1 cell cycle arrest [217-233]. Despite a significant decrease in 
the fraction of ovarian cancer cells in G2/M phase(s) of the cell cycle following 
pitavastatin exposure, there was no corresponding increase in cells in G1 phase. The 
significant increase in subG1, potentially corresponding to an induction of apoptosis in 
pitavastatin-treated cells, may have masked G1 phase cell cycle arrest. In contrast to 
this increase in subG1, there was no significant increase in Ovcar-8 cell death 
following exposure to simvastatin for 48 hours (chapter 4). This discrepancy may 
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reflect differences in the sensitivity of Ovcar-8 and Ovcar-3 cells to statin after 48 
hours. This is supported by greater caspase 3/7 activity in Ovcar-3 cells compared to 
Ovcar-8 cells after 48 hours of pitavastatin treatment. Furthermore, cell cycle analysis 
involves the permeabilization of cell membranes, which enables propidium iodide to 
label DNA, and this is likely to enable the earlier identification of apoptotic cells which 
have a reduced DNA content due to degradation by endonucleases. Trypan blue can 
only penetrate cells that have lost plasma membrane integrity, a feature occurring in 
the very late stages of apoptosis (secondary necrosis). Taken together, after 48 hours 
of statin treatment, DNA fragmentation may be occurring in a significant proportion of 
cells, whilst the plasma membrane remains intact.  
 
Simvastatin was previously reported to induce apoptosis in ovarian cancer cells 
through the activation of JNK, which resulted in an induction of Bim expression, and 
subsequent stimulation of the intrinsic apoptotic pathway [338]. Caspase-9 is cleaved 
and activated following cytochrome c release from the mitochondria, and therefore, 
can be used as a marker of intrinsic apoptosis pathway stimulation. Pitavastatin 
caused a significant increase in the activation of caspase-9, caspase-3, caspase-7 
and PARP cleavage in ovarian cancer cell lines, confirming that pitavastatin induced 
apoptosis though the intrinsic pathway. Previous research also demonstrated that 
pitavastatin increased levels of the pro-apoptotic protein, Bad, and decreased 
expression of Bcl-2 mRNA in liver cancer xenograft studies, further supporting 
activation of the intrinsic apoptosis pathway [512]. Despite this, pitavastatin also 
increased the level of caspase-8, which is stimulated by the death-inducing signalling 
complex in the extrinsic apoptosis pathway. This raised the possibility that pitavastatin 
also induced the activation of the extrinsic pathway, potentially though the 
upregulation of death receptor ligands, as previously observed for simvastatin in 
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prostate cancer cells [364]. FLIP inhibits the cytoplasmic adaptor protein and caspase-
8 complex, which prevents caspase-8 activation, and therefore, negatively regulates 
the extrinsic apoptosis pathway. Furthermore, FLIP has also been shown to be 
implicated in resistance to chemotherapy in ovarian cancer [521, 522]. Despite this, 
FLIP knockdown did not significantly sensitise ovarian cancer cells to the anti-growth 
effects of pitavastatin. There are several potential explanations for this. An inadequate 
knockdown of FLIP may have contributed to the absence of a significant effect on the 
sensitivity of Ovcar-3 cells to pitavastatin. Conversely, statins have been shown to 
decrease the expression of FLIP in cancer cells, and this may also explain why any 
further knockdown of FLIP did not alter sensitivity to pitavastatin [240]. Caspase-8 can 
also be activated by the execution caspases (caspase-3 and caspase-7) in the 
intrinsic apoptosis pathway, and therefore, pitavastatin may not directly activate the 
extrinsic apoptosis pathway, rather caspase-8 activation serves as an amplifier of 
execution caspases in the intrinsic apoptosis pathway [535]. Furthermore, statins 
cause an accumulation of both LC3-II and p62, and the association of these proteins 
has previously been demonstrated to recruit FADD-caspase-8 complexes to 
autophagosomal membranes, through interactions with Atg5, which facilitates the self-
activation of caspase-8 [536]. Taken together, pitavastatin induced apoptosis in 
ovarian cancer cells most likely through the intrinsic pathway, although direct 
activation of the extrinsic pathway cannot be excluded. 
 
To further investigate the mechanism by which pitavastatin induced cytotoxicity, the 
effects of pitavastatin on autophagy were also determined. Simvastatin was previously 
shown to simultaneously induce and inhibit the autophagy pathway at different points 
in vitro, and this may contribute to cell death (chapter 4). A recent study demonstrated 
that pitavastatin increased the level of the autophagy protein, LC3-II, in cancer cells 
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[517]. However, LC3-II can accumulate either when autophagy is stimulated due to an 
increase in LC3-II synthesis, or when autophagy is inhibited as the turnover of LC3-II 
is prevented. To address this, p62 was also measured as p62 accumulation is a 
marker of autophagy inhibition [486]. Pitavastatin caused an accumulation of both 
LC3-II and p62, consistent with an inhibition of autophagy. Furthermore, in addition to 
simvastatin (chapter 4), pitavastatin also decreased the level of Rab7, and this was 
moderately reversed by supplementation with geranylgeraniol, suggesting that 
pitavastatin may block the later stages of autophagy by inhibiting the 
geranylgeranylation of Rab7. To assess whether the inhibition of autophagy 
contributed to apoptosis, the expression of Atg5, an essential autophagy-related 
protein involved in autophagosome formation, was inhibited by RNA interference. 
Knockdown of Atg5 and subsequent inhibition of autophagy sensitised ovarian cancer 
cells to apoptosis induced by pitavastatin, suggesting that autophagy inhibition may 
contribute to the cytotoxic effects of pitavastatin. This is supported by previous results, 
where Atg5 knockdown modestly sensitised cells to the anti-growth effects of 
simvastatin (chapter 4). Blocking autophagy may prevent the turnover of mitochondria 
(mitophagy), leading to an increase in the production and release of ROS from the 
mitochondria [295, 523]. ROS have previously been shown to induce apoptosis in 
statin-treated colon cancer cells [352]. This raised the possibility that inhibition of 
mitophagy may contribute to pitavastatin-induced apoptosis through an elevation of 
ROS in ovarian cancer cells. Indeed, when mitochondria were stained with Mitotracker 
dye, pitavastatin caused a small but significant increase in mitochondrial staining in 
both Ovcar-3 and Ovcar-8 cells. This could represent either an increase in 
mitochondrial number or larger mitochondria with more surface area for Mitotracker 
binding, both of which may be consistent with an inhibition of mitophagy [537, 538]. To 
confirm an increase in mitochondria, the mitochondrial DNA (mtDNA) content was 
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determined by measuring mitochondrial NADH dehydrogenase 1 (ND1) DNA. There 
was an increase in the relative mtDNA content in Ovcar-8 cells exposed to 
pitavastatin, which corresponded to the increase in mitochondria previously observed, 
but there was no difference in mtDNA content in Ovcar-3 cells. The reason for this 
discrepancy is unclear, but it may reflect the presence of larger deformed 
mitochondria in Ovcar-3 cells exposed to pitavastatin, which may have an 
accumulation of damaged mtDNA. The cis-regulatory element in the non-coding (D-
loop) region of mtDNA is involved in the replication of mtDNA, and is more susceptible 
to oxidative damage compared to other regions of mtDNA [539]. A mutated sequence 
in the D-loop may affect binding to trans-acting factors, resulting in a decrease in 
mtDNA replication [540]. Pitavastatin caused a significant increase in ROS in Ovcar-3 
cells, and elevated ROS in these cells may contribute to mutations in the D-loop 
region, which may impede mtDNA replication. Exposure of Ovcar-8 cells to 
pitavastatin did not increase ROS, suggesting that these cells may have additional 
protective mechanisms against oxidative stress. A previous study also reported that 
DNA-damaging agents including cisplatin and doxorubicin did not induce an 
accumulation of ROS in Ovcar-8 cells [541]. In contrast to previous reports, the 
inhibition of ROS in ovarian cancer cells exposed to pitavastatin did not prevent 
apoptosis, suggesting that the presence or accumulation of ROS is unlikely to 
significantly contribute to statin-induced apoptosis in ovarian cancer cells. Notably, the 
oxidising agent TBHP caused a small increase in caspase 3/7 activity in Ovcar-8 cells, 
which was partially blocked by the superoxide scavenger NAc, suggesting that other 
cytotoxic agents may stimulate ROS-induced apoptosis in ovarian cancer cells. Taken 
together, these results suggest that pitavastatin may inhibit autophagy, by preventing 
the geranylgeranylation of Rab7, which could result in an accumulation of 
mitochondria with damaged mtDNA, and an increase in ROS. Despite this, it is likely 
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that there are other mechanisms, independent of ROS, involved in pitavastatin-
induced apoptosis, which may also be mediated through the inhibition of autophagy.  
 
Statins have been previously shown to inhibit cancer cell migration and invasion 
through the inhibition of geranylgeranyl diphosphate in the mevalonate pathway [238, 
257-260]. However, in ovarian cancer cells, pitavastatin did not inhibit migration after 
36 hours, suggesting that inhibition of cell migration may not contribute to the anti-
growth effects of pitavastatin. This may reflect the relatively short time that cells were 
exposed to pitavastatin in this assay (36 hours), as prolonged exposure to statins may 
be required to allow the turnover of prenylated proteins that are required for cell 
migration (chapter 4). Significant cell detachment was observed at higher drug 
concentrations or after longer exposure times, potentially masking any effects of 
pitavastatin on cell migration. 
 
Drug-related biomarkers are a measure of the response of the body to a drug, and 
can be used to predict drug efficacy earlier than conventional clinical endpoints. 
Clinical trials evaluating statins for the treatment of cancer have frequently used 
plasma cholesterol levels and urinary mevalonate excretion as markers of HMGCR 
inhibition. Urinary mevalonate excretion has been correlated with the rate of 
cholesterol synthesis, although urinary mevalonate levels can be affected by dietary 
sources of mevalonate [542, 543]. However, cholesterol levels have not been 
correlated with the anti-cancer activity of statins, and moreover, inhibition of 
cholesterol synthesis is not responsible for statin-induced cytotoxicity [518]. It is also 
unsurprising that well characterised drugs such as statins can inhibit plasma 
cholesterol levels. Therefore, there is a requirement to identify biomarkers which can 
be used to directly monitor the cytotoxic response of cancer cells to statin treatment. 
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Cytokeratin 18, a protein expressed predominantly in epithelial cells [544], is cleaved 
by caspases 3, 7 and 9 during apoptosis to produce ccCK18, which can be detected 
in the plasma of breast cancer patients receiving chemotherapeutic drugs [519]. 
Theoretical calculations have suggested that ccCK18 may be detected in patient 
serum following apoptosis of only 10-20 million cancer cells [545]. Therefore, ccCK18 
may be useful as a biomarker in patients with tumours that undergo apoptosis in 
response to exposure to pitavastatin. To test this, the release of ccCK18 into the cell 
culture medium of ovarian cancer cells exposed to pitavastatin was measured. The 
level of ccCK18 was significantly increased in medium of Ovcar-3 and Ovcar-8 cells 
exposed to pitavastatin or paclitaxel. However, there was no accumulation of ccCK18 
in medium taken from Igrov-1 or Skov-3 cells exposed to pitavastatin concentrations 
which had previously induced cell death. This could reflect differences in cell death 
after 96 hours, as cell death was considerably lower in Igrov-1 and Skov-3 cells (35-
60% cells dead) compared to Ovcar-3 and Ovcar-8 cells (80-90%). Despite this, the 
relative activities of caspases 3, 7 and 9 in Ovcar-8 and Igrov-1 cells exposed to 
pitavastatin for 48 hours were comparable, suggesting that there may be other 
reasons for the lack of ccCK18 release from Igrov-1 cells. A recent study found that 
both Ovcar-3 and Ovcar-8 are likely to represent high-grade serous ovarian carcinoma 
(HGSC), whereas the origin of Igrov-1 and Skov-3 is uncertain [438]. Furthermore, 
Igrov-1 and Skov-3 have been reported to express lower levels of cytokeratin 18 
compared to other ovarian cancer cell lines, suggesting that these cells may have a 
different origin [546]. Taken together, the small increases in ccCK18 from Igrov-1 and 
Skov-3 cells exposed to pitavastatin may have been below the detection threshold of 
the assay (25 pM).  
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The lack of detectable ccCK18 production in half of the ovarian cancer cell lines 
evaluated made it important to discover additional biomarkers released from ovarian 
cancer cells in response to statin exposure. To do this, cells in culture were exposed 
to pitavastatin or simvastatin, and the proteins released into the cell culture medium 
were identified. Seven protein bands were found in statin-treated ovarian cancer cells 
which were present at a higher amount compared to either cancer cells exposed to 
solvent or pravastatin, or normal cells exposed to solvent or statins. This suggested 
that these proteins were specifically released from cancer cells in response to 
pitavastatin or simvastatin. Further mass spectrometry analysis of the isolated 
proteins revealed that three protein bands corresponded to alpha-enolase, 
glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase, all of which are 
involved in glycolysis. Cancer cells frequently upregulate these glycolytic enzymes, 
resulting in an increase in aerobic glycolysis termed “the Warburg effect”, and this has 
been correlated with tumorigenesis and poor prognosis [547]. A further three bands 
were identified to be the cytoskeletal proteins, alpha-actinin 1, actin, ezrin, radixin and 
moesin (ERM). Alpha-actinin 1 and all three of the ERM proteins have been shown to 
be upregulated in cancer, and contribute to tumour progression and invasion [548, 
549]. Lastly, heat shock protein 90 (HSP90) was also identified in the cell culture 
medium of pitavastatin-treated cells. Heat shock protein 90 (HSP90) is involved in 
maintaining cellular protein homeostasis by regulating the folding, stability, activation, 
function, and proteolytic turnover of more than 100 proteins [550]. HSP90 is frequently 
upregulated in tumorigenesis, and contributes to the survival, growth, migration and 
invasion of cancer cells [550]. Notably, these data were confirmed by a recent 
proteomic analysis of proteins released from endothelial cells exposed to atorvastatin, 
which identified these proteins in the secretome and many others involved in 
glycolysis/gluconeogenesis, cytoskeleton organisation, antigen processing and 
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presentation, cell communication, focal adhesion and gap junctions [520]. HSP90, 
alpha-enolase and pyruvate kinase have previously been reported to be released into 
the extracellular environment by an unknown mechanism, as these proteins do not 
have an N-terminal peptide sequence for direction to the endoplasmic reticulum and 
secretion through the classical secretory pathway [520, 551, 552]. In the absence of a 
signal sequence, these may be abundant proteins that are released by unknown 
secretory independent pathways, cell autolysis or necrosis. Several studies have 
reported that statins may induce necrosis in some cancers, and this can result in the 
loss of cell membrane integrity, leading to the release of the cellular contents into the 
extracellular matrix [219, 333, 553-555]. Further validation of these potential 
biomarkers is required to establish which proteins are predominantly released from 
cancer cell lines compared to normal cells, and whether these proteins can be 
detected in the plasma following pitavastatin treatment in vivo. 
 
Taken together, these results suggest that pitavastatin is the most potent statin that 
possesses anti-growth and pro-apoptotic activities in a panel of ovarian cancer cell 
lines. Pitavastatin should be evaluated in clinical trials at high concentrations with an 
appropriate dosing schedule which will enable continual inhibition of HMGCR. 
Furthermore, clinical trials should ensure that dietary fat intake is minimised, in order 
to reduce the potential exposure of cancer cells to exogenous sources of isoprenoids, 
which may reverse the cytotoxic effects of statins. Clinical trials evaluating statins in 
cancer should also aim to validate potential drug biomarkers identified in vitro, in order 
to obtain novel biomarkers that can be used to predict response to statin treatment in 
patients. 
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CHAPTER 6 
 
PRECLINICAL EVALUATION OF 
PITAVASTATIN IN COMBINATION WITH 
OTHER ANTI-CANCER AGENTS 
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6.1   Introduction 
 
The design of rational drug combinations takes into account the biology of the tumour 
and the molecular pharmacology of the drugs involved. Strategies are frequently 
focussed on reversing drug resistance, and can include horizontally targeting parallel 
signalling pathways or vertically targeting one signalling pathway at several nodes, in 
order to block any compensatory signalling mechanisms which may confer 
chemoresistance. Nevertheless, any drug combination which combines flux into a cell 
death signal is a valid approach to combination therapy.  
 
Chapters 4 and 5 have evaluated the anti-cancer activity of simvastatin and 
pitavastatin in ovarian cancer cells, demonstrating that both high concentrations and 
continuous exposure to these statins was required to induce cell death. Pitavastatin 
has been evaluated in clinical trials at doses between 16 mg and 64 mg daily for the 
treatment of high cholesterol [162]. Dose-limiting toxicities observed after 2-4 weeks of 
treatment were reversed within 2 weeks of discontinuing therapy [162]. The 
concentrations of pitavastatin required to cause ovarian cancer cell death (0.2 – 7.6 
µM depending on cell line) are similar to the predicted plasma concentration in 
patients following administration of 64 mg pitavastatin (2.7 µM, assuming linear 
pharmacokinetics and using data from [530-532]). Whilst pitavastatin can be 
administered as a single agent at high doses for up to 2 weeks, it may be possible to 
further reduce the concentration required to cause cancer cell death by combination 
with other agents that also cause apoptosis, including ABT-737, obatoclax, pictilisib 
and metformin (figure 6.1). 
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Figure 6.1: Modulation of the PI3K/Akt/mTOR and intrinsic apoptotic pathways by various drugs. Statins inhibit 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCR), which prevents the geranylgeranylation of many proteins that regulate diverse 
intracellular processes, including the PI3K/Akt/mTOR pathway. Both pictilisib and metformin also inhibit components in the 
PI3K/Akt/mTOR pathway. BH3 mimetics (‘BH3M’) occupy Bcl-2 family inhibitors (‘I’), preventing them from sequestering apoptosis 
activators (‘A’), and sensitising cells to apoptosis. TCS2, tuberous sclerosis complex 2; AMPK, AMP-activated protein kinase; PI3K, 
phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; mTORC1, mammalian target of rapamycin complex 1. 
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6.1.1   BH3 mimetics: ABT-737 and obatoclax 
 
Pro-apoptotic signals increase the expression of pro-apoptotic molecules including 
apoptosis activators (e.g. Bim, Bid and Puma) and sensitisers (e.g. Bad, Bmf and 
Noxa), which contain a single BH3 domain. The activators can be sequestered by 
apoptosis inhibitors (e.g. Bcl-2, Bcl-XL and Mcl-1) through the hydrophobic BH3-
binding groove of the inhibitor binding to the BH3 domain of the activator, thereby 
preventing apoptosis. Sensitisers or BH3 mimetics (e.g. ABT-737 and obatoclax) can 
competitively inhibit anti-apoptotic molecules and prevent them from binding to the 
activators, thereby allowing pro-apoptotic signalling to continue (figure 6.1) [556]. 
Preliminary reports suggested that obatoclax in combination with cisplatin or TNF-
related apoptosis-inducing ligand (TRAIL) increased apoptosis in ovarian cancer cell 
lines [557]. Furthermore, ABT-737 and the orally bioavailable analogue ABT-263 
inhibit Bcl-XL, Bcl-2 and Bcl-w, and have been shown to enhance the cell death 
induced by carboplatin or paclitaxel in ovarian cancer cells [450, 558]. One 
mechanism of these synergistic interactions is thought to be through modulation of the 
Noxa/Mcl-1 axis. The anti-apoptotic proteins Bcl-XL and Mcl-1 co-operate to inhibit 
apoptosis in ovarian cancer cells [559]. Platinum-based compounds decrease Mcl-1 
expression and increase the expression of the pro-apoptotic proteins, Noxa and Bim, 
which increases the sensitivity of chemoresistant cells to ABT-737 [559]. A number of 
drugs which inhibit Mcl-1 including NVP-BEZ235 are currently being evaluated in 
combination with ABT-737 for the treatment of ovarian cancer [560]. Statins have also 
been shown to decrease Mcl-1 in leukemia cells [217], gastric cancer cells [561] and 
hepatocellular carcinoma [562], and induce the expression of the apoptotic activator 
Bim in ovarian cancer cell lines [338] and glioblastoma cells [349]. These observations 
suggest that statins may also demonstrate synergy with ABT-737. 
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6.1.2   Phosphatidylinositol 3-kinase inhibitors: pictilisib 
 
The phosphatidylinositol 3-kinase (PI3K) pathway plays an important role in cell 
survival, proliferation, migration and metabolism, and has recently been reported to be 
frequently activated in advanced epithelial ovarian cancers [56, 563]. Pictilisib is an 
orally active PI3K inhibitor which is more than 100 times more potent against class I 
PI3K compared to class II, III and IV family members (figure 6.1) [564]. Pictilisib has 
previously been shown to inhibit the growth of ovarian cancer cell lines [565], and 
Igrov-1 ovarian cancer xenografts by 80% [566]. Furthermore, pictilisib enhanced the 
anti-cancer effects of doxorubicin in ovarian cancer models, resulting in synergy that 
may be predicted by the dependence of cancer cells on the PI3K pathway for survival 
[565]. Statins have also been shown to interfere with PI3K signalling by inhibiting 
NFκB, resulting in an increase in the transcription of phosphatase and tensin homolog 
(PTEN) and a reduction in Akt phosphorylation [567]. Therefore, statins in combination 
with PI3K inhibitors could synergistically inhibit PI3K signalling, leading to an increase 
in cell death.  
 
6.1.3   Biguanides: metformin 
 
The biguanide metformin, currently indicated for diabetes and polycystic ovary 
disease, has also been shown to have antineoplastic activity both in vitro [568] and in 
vivo [569]. Retrospective studies have demonstrated that patients treated with 
metformin for diabetes may have a significantly reduced risk of developing 
gastrointestinal cancer [570]. In ovarian cancer, millimolar concentrations of metformin 
supressed cell growth in vitro [571, 572] and in vivo [573]. Furthermore, an increase in 
apoptosis was accompanied by an induction of Bax and Bad expression, and the 
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down regulation of Bcl-2 and Bcl-XL expression [574]. Metformin inhibits complex I in 
the mitochondrial respiratory chain, leading to the inhibition of mammalian target of 
rapamycin (mTOR) signalling through AMP-activated protein kinase (AMPK) 
dependent and independent pathways (figure 6.1) [575, 576]. This can result in a 
decrease in both protein synthesis and cell growth. The PI3K inhibitor LY294002 in 
combination with metformin synergistically inhibited ovarian cancer growth and 
induced apoptosis, through the simultaneous repression of the PI3K/Akt/mTOR 
pathway [577]. Statins have also been shown to induce the activation of AMPK, with 
subsequent inhibition of mTOR [317], and therefore, may demonstrate promising anti-
cancer activity in combination with metformin.  
 
 
6.2   Aims 
 
The work described in this chapter aimed to investigate the anti-cancer activity of 
pitavastatin in combination with ABT-737, obatoclax, pictilisib or metformin in a panel 
of ovarian cancer cell lines in order to identify successful combinations, which could 
potentially be further evaluated in ovarian cancer clinical trials. 
 
 
6.3   Results 
 
6.3.1   Single agent activity in ovarian cancer cell lines 
 
To investigate the activity of drug combinations with pitavastatin, the potencies of 
pitavastatin, ABT-737, obatoclax, pictilisib and metformin were first determined in a 
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panel of four ovarian cancer cell lines. Pitavastatin (IC50 = 0.26 – 5.8 µM), ABT-737 
(IC50 = 2.1 – 4.0 µM), obatoclax (IC50 = 0.15 – 0.36 µM) and pictilisib (IC50 = 0.072 – 
0.88 µM) inhibited the growth of ovarian cancer cell lines (table 6.1). Conversely, 
metformin did not measurably inhibit the growth of the same panel of cell lines (IC50 > 
100 µM) (table 6.2). 
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Table 6.1: The potency of pitavastatin, ABT-737, obatoclax and pictilisib as single agents in ovarian cancer cell lines were measured in 
cell growth assays for 72 hours, and surviving cells were estimated by staining with sulforhodamine B  (mean ± S.D., n = 3-9 ).  
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Table 6.2: The potency of pitavastatin and metformin as single agents in ovarian cancer cell lines were measured in cell growth assays 
(columns 1-2, mean ± S.D., n = 3-9). To measure the activity of pitavastatin in combination with metformin, cells were exposed to a range 
of concentrations of pitavastatin and a fixed concentration of metformin (15 µM). Combination indices (CI) (mean ± S.D., n = 3-9) are 
quoted at a fraction affected of 0.5 and differed significantly from unity where indicated (*, paired t-test, P<0.01).
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6.3.2   Combinations of pitavastatin and ABT-737, obatoclax, pictilisib or 
metformin are additive or antagonistic in ovarian cancer cells 
 
Concentrations of ABT-737 above 20 µM have previously been anticipated to inhibit 
cell growth independently of Bcl-XL [450]. Therefore, experiments were completed 
using a low fixed concentration of ABT-737 to inhibit cell growth by <10%, in 
combination with a range of concentrations of pitavastatin. ABT-737 was additive in 
combination with pitavastatin in Igrov-1 cells, and was additive (fraction affected, 0.75) 
or mildly antagonistic (fraction affected, 0.5) when combined with pitavastatin in 
Ovcar-3 and Ovcar-8 cells (figure 6.2). ABT-737 in combination with pitavastatin was 
significantly antagonistic in A2780 cells (fraction affected, 0.5; figure 6.2).  
 
Cells were exposed to a range of concentrations of either obatoclax or pictilisib and 
pitavastatin combined at a ratio of their single agent IC50 values. The combination of 
obatoclax and pitavastatin was additive in Ovcar-3 and A2780 cells (figure 6.2). 
However, in Ovcar-8 and Igrov-1 cells, there was significant antagonism (fraction 
affected, 0.5), which was slightly reduced at higher drug concentrations (fraction 
affected, 0.75; figure 6.2). Pictilisib and pitavastatin were additive in most cell lines 
tested, even at higher drug concentrations (fraction affected, 0.75), with significant 
antagonism observed only in A2780 and Igrov-1 cells (fraction affected, 0.5, figure 
6.2).  
 
Metformin exhibited limited activity in single agent studies (table 6.2), and therefore, a 
fixed concentration of 15 µM metformin was added to cells in combination studies. 
This concentration reflects the maximum concentration of metformin that is achieved 
in the plasma of patients following administration of the maximum daily dose (2550 
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mg) for the treatment of diabetes [447]. Metformin at 15 µM had no effect on ovarian 
cancer cell growth in these studies, and the combination of pitavastatin and metformin 
resulted in additivity or mild antagonism in four cell lines (table 6.2). 
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Figure 6.2: Pitavastatin in combination with ABT-737, obatoclax or pictilisib. To measure the activity of drug combinations in cell growth 
assays, cells were exposed to a range of concentrations of pitavastatin and either a fixed concentration of ABT-737 (A2780, 3 µM; Ovcar 
3 and Ovcar-8, 1 µM; Igrov-1, 0.6 µM) or a range of concentrations of either obatoclax or pictilisib, combined with pitavastatin at the ratio 
of their single agent IC50s. Combination indices (CI) (mean ± S.D., n = 3-9) are quoted at a fraction affected (FA) of 0.5 and 0.75, and 
differed significantly from unity where indicated (*, paired t-test, P<0.05). 
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6.3.3   Pitavastatin in combination with ABT-737 or pictilisib increases cell death 
in Igrov-1 or Ovcar-3 cells 
 
Igrov-1 and Ovcar-3 cells were exposed to pitavastatin in combination with ABT-737, 
obatoclax or pictilisib for 72 hours and visualised by light microscopy. An increase in 
cell death was observed in Ovcar-3 cells exposed to pitavastatin and pictilisib, and 
Igrov-1 cells exposed to pitavastatin and ABT-737 compared to the single agents 
alone (figure 6.3). Although this is not necessarily indicative of synergy, these 
observations prompted further investigation. 
 
To quantify the cell death observed by microscopy, the cells were collected by 
trypsinisation, stained with Trypan blue and counted. To determine whether a 
synergistic interaction occurred, the number of dead cells observed was compared to 
that expected from the Bliss independence criterion. The percentage of dead cells 
was significantly higher in Ovcar-3 cells exposed to pictilisib and pitavastatin, and in 
Igrov-1 cells treated with pitavastatin and ABT-737, than that expected (figure 6.4). In 
other combinations, the percentage of dead cells was not significantly different to that 
predicted by Bliss independence (figure 6.4). 
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Figure 6.3: Phase contrast microscopy images of ovarian cancer cells exposed to 
pitavastatin in combination with ABT-737, obatoclax or pictilisib. Cells were exposed 
to either solvent (DMSO), 6 µM (Igrov-1) and 12 µM (Ovcar-3) pitavastatin (3 x IC50), 
0.6 µM (Igrov-1) and 1 µM (Ovcar-3) ABT-737, 2 µM (Ovcar-3) and 3 µM (Igrov-1) 
obatoclax (10 x IC50), or 0.7 µM (Igrov-1) and 2 µM (Ovcar-3) pictilisib (10 x IC50). The 
cells were assessed by microscopy after 72 hours. The results are representative of 
three experiments. 
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Figure 6.4: The effects of pitavastatin in combination with ABT-737, obatoclax or pictilisib on cell death. The number of dead Ovcar-3 and 
Igrov-1 cells was determined by Trypan blue staining after exposure for 72 hours to either solvent (DMSO), 6 µM (Igrov-1) and 12 µM 
(Ovcar-3) pitavastatin (3 x IC50), 0.6 µM (Igrov-1) and 1 µM (Ovcar-3) ABT-737, 2 µM (Ovcar-3) and 3 µM (Igrov-1) obatoclax (10 x IC50), 
or 0.7 µM (Igrov-1) and 2 µM (Ovcar-3) pictilisib (10 x IC50). The number of dead cells (mean ± S.D., n = 3) was significantly different from 
Bliss independence calculated for each drug combination where indicated (*, paired t-test, P<0.05; #, paired t-test, P<0.0005). 
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6.3.4   Apoptosis contributes to the mechanism of cell death in combinations of 
pitavastatin and ABT-737 or pictilisib 
 
To determine whether the increase in cell death observed following exposure to 
pitavastatin in combination with ABT-737, pictilisib or obatoclax was due to apoptosis, 
caspases 3 and 7 were measured in Ovcar-3 and Igrov-1 cells. Reminiscent of the 
results observed in the Trypan blue assay, there was a modest, but significant, 
increase in caspase 3/7 activity in Ovcar-3 and Igrov-1 cells exposed to pitavastatin 
and pictilisib or ABT-737 respectively, compared to that predicted by Bliss 
independence (figure 6.5). This was also supported by a slight increase in poly (ADP) 
ribose polymerase (PARP) cleavage in Igrov-1 cells exposed to pitavastatin and ABT-
737 compared to pitavastatin alone (figure 6.6). These results are consistent with 
those obtained in the Trypan blue assays, however significant synergy was not 
observed in the cell growth assays. 
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Figure 6.5: The effects of pitavastatin in combination with ABT-737, obatoclax or pictilisib on apoptosis. Caspase 3/7 activity in Ovcar-3 
and Igrov-1 cells was measured following exposure to either solvent (DMSO), 6 µM (Igrov-1) and 12 µM (Ovcar-3) pitavastatin (3 x IC50), 
0.6 µM (Igrov-1) and 1 µM (Ovcar-3) ABT-737, 2 µM (Ovcar-3) and 3 µM (Igrov-1) obatoclax (10 x IC50), or 0.7 µM (Igrov-1) and 2 µM 
(Ovcar-3) pictilisib (10 x IC50) for 48 hours. Caspase 3/7 activity (mean ± S.D., n = 3) was significantly different from Bliss independence 
calculated for each drug combination where indicated (*, paired t-test, P<0.01; #, paired t-test, P<0.001). 
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The mechanism by which ABT-737 potentiated the apoptosis induced by pitavastatin 
was further evaluated by determining the levels of several Bcl-2 family members. 
Pitavastatin increased the level of the pro-apoptotic protein, Bim, and decreased the 
level of Bcl-XL (figure 6.6). In contrast, exposure to ABT-737 resulted in an increase in 
Mcl-1. Whilst there were no significant changes in Bcl-XL and Mcl-1 levels in cells 
exposed to pitavastatin and ABT-737 compared to pitavastatin alone, the level of Bim 
was modestly decreased in cells exposed to the drug combination (figure 6.6). 
 
 
Figure 6.6: The effects of pitavastatin in combination with ABT-737 on proteins 
involved in the apoptosis pathway. Igrov-1 cells were exposed to solvent or 6 μM 
pitavastatin (pit, 3 x IC50) or 0.6 μM ABT-737 as single agents, or in combination, for 
48 hours. The levels of PARP, Bim, Bcl-XL and Mcl-1 were measured by western 
blotting (n = 3). PARP cleavage was significantly increased in cells exposed to 
pitavastatin and ABT-737 compared to cells exposed to pitavastatin alone (*, paired t-
test, P<0.05). GAPDH was used as a loading control. 
220 
 
6.4   Discussion 
 
Statins have been previously evaluated in combination with various chemotherapeutic 
agents including cisplatin and doxorubicin, resulting in an additive or synergistic 
reduction in ovarian cancer cell proliferation [337, 484]. The exposure of cells to high 
concentrations of simvastatin prior to carboplatin resulted in profound antagonism 
(chapter 4), and this led to the investigation of compounds which inhibit the same 
pathways as statins, or sensitise ovarian cancer cells to apoptotic cell death. 
 
ABT-737 or pictilisib in combination with pitavastatin additively inhibited cell growth, 
and modestly, but significantly, increased apoptosis induced by pitavastatin in Ovcar-3 
and Igrov-1 cells. The PI3K pathway contributes to proliferative and anti-apoptotic 
effects on tumour cells, and is deregulated in 45% of high-grade serous ovarian 
cancers [56]. Ovcar-3, Ovcar-8, Igrov-1 and A2780 cells have PI3K/Akt pathway 
alterations consistent with activation of PI3K/Akt signalling, suggesting that these cell 
lines may be particularly sensitive to PI3K pathway inhibition [578, 579]. This was 
confirmed by the submicromolar IC50 values obtained for pictilisib in all cell lines. 
Statins have also been shown to inhibit PI3K signalling by inhibiting NF-κB, which 
results in an increase in the expression of PTEN and a reduction in Akt 
phosphorylation [567, 580]. Dual inhibition of PI3K/Akt/mTOR signalling with a 
combination of pictilisib and pitavastatin modestly increased apoptosis in Ovcar-3 
cells, whilst demonstrating antagonism in A2780 and Igrov-1 cells. In contrast to the 
other cell lines, A2780 and Igrov-1 have PTEN mutations with low or undetectable 
levels of PTEN protein [578], which may render these cells resistant to further 
inhibition of PI3K signalling through PTEN modulation by statins.  
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The activity of ABT-737 has previously been attributed to inhibition of the pro-
apoptotic mediators, Bcl-2, Bcl-XL or Bcl-w, of which Bcl-XL is overexpressed in 
ovarian cancer [450, 581]. Statins have been shown to induce apoptosis through a 
number of pathways, including suppression of Akt/Erk activation [350, 567], increased 
phosphorylation of the p38 MAPK pathway [350], and attenuation of Mcl-1, probably 
through the inhibition of NF-κB [582]. Igrov-1 cells were sensitive to the addition of 
ABT-737, and are therefore likely to have been “primed” for cell death as previously 
described [583]. In “primed” cells, ABT-737 prevents Bcl-XL from sequestering pre-
existing pro-apoptotic mediators, thereby enabling apoptosis to occur more readily. In 
contrast to previous reports, pitavastatin did not decrease Mcl-1 levels, but instead 
reduced the levels of Bcl-XL and increased Bim. This, together with ABT-737 
preventing the interaction of Bim with Bcl-2, Bcl-XL or Bcl-w, may have contributed to 
the small, but significant, increase in apoptotic cell death in the combination. Additivity 
and mild antagonism was observed in the other cell lines exposed to this drug 
combination, and these differences could be related to the expression of apoptosis 
inhibitors. Mcl-1 expression may indicate cellular resistance to ABT-737 due to the 
poor affinity of ABT-737 for Mcl-1 [584]. Previous research demonstrated that 
expression of Bcl-XL was markedly lower in A2780 cells, together with increased Mcl-1 
levels compared to other ovarian cancer cell lines [450], and this could account for the 
antagonism observed in this cell line.  
 
Obatoclax is a pan-Bcl-2 inhibitor which also inhibits Mcl-1, and therefore, may 
overcome the resistance mechanisms which limit ABT-737 activity. Despite this, 
obatoclax in combination with pitavastatin was additive at best in A2780 and Ovcar-3 
cells, with significant antagonism observed in Ovcar-8 and Igrov-1 cells. Interestingly, 
the latter cell lines express lower Mcl-1 protein levels compared to A2780 and Ovcar-3 
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cells [450], and this could explain the reduction in sensitivity to obatoclax in Ovcar-8 
and Igrov-1 cells in single agent studies, and the antagonism in combination studies. 
Obatoclax is also thought to have off-target effects in ovarian cancer cells, which may 
contribute to the antagonism observed in combination studies [585]. Taken together, 
these results suggest that the combination of obatoclax and pitavastatin may be of 
limited value in a heterogeneous tumour environment in a clinical setting. 
 
Pitavastatin in combination with a fixed dose of metformin was mostly additive in 
ovarian cancer cell lines. Metformin has previously been reported to induce autophagy 
[586], a process involved in the degradation of cellular organelles and proteins during 
nutrient starvation and metabolic stress. Statins have also been shown to induce 
autophagy, and in combination with metformin, may exceed the capacity of the cell, 
leading to the degradation of cytoplasmic contents and death. Despite this, autophagy 
is no longer widely believed to contribute to cell death, and therefore, autophagy is 
unlikely to be the only mechanism of cell death. The anti-cancer activity of metformin 
was limited as cells were exposed to low concentrations of 15 µM, and concentrations 
of around 5-10 mM have been previously required to inhibit the proliferation of ovarian 
cancer cell lines [576]. These millimolar concentrations of metformin are not clinically 
achievable using the maximum tolerated dose (MTD) of metformin (2550 mg) [447], 
although one study has suggested that metformin may accumulate in mitochondria, 
and therefore, may reach higher concentrations in cancer cells [587]. However, until 
metformin is proven to accumulate in cancer tissue, it seems unlikely that metformin 
will confer a clinical benefit at the MTD in ovarian cancer. 
 
To summarise, pictilisib or ABT-737 in combination with pitavastatin could be used in 
a subset of ovarian tumours in a clinical setting, and this may have several 
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implications. The concentration of pitavastatin required for ovarian cancer cell death 
could be reduced in drug combinations compared to the concentration required as a 
single agent. These lower concentrations are likely to be clinically achievable since 
the MTD of pitavastatin in humans (64 mg daily) gives a plasma concentration of 2.7 
µM (calculated based on linear pharmacokinetics and previously reported data from 
[530-532]), and this alone is representative of the IC50 of pitavastatin in several cell 
lines. Reducing the dose of pitavastatin would minimise the dose-limiting side effects 
including myalgia, myoglobinurea and elevated creatine phosphokinase levels, which 
may be experienced at high doses of statins [533]. Furthermore, consideration should 
be given to identifying which patient groups may be sensitive to these combination 
treatments. Mcl-1 has been shown to confer resistance to ABT-737, and therefore 
measurement of Mcl-1 could be used to exclude patients from ABT-737 and 
pitavastatin treatment [584]. One disadvantage of this is that short-term exposure to 
ABT-737 can increase Mcl-1, and therefore, measurement prior to drug exposure may 
not give an accurate indication of drug response. Therefore, patients may require brief 
drug exposure prior to the collection of tumour tissue to predict sensitivity of the 
cancer to the combination therapy [584]. Additionally, the sensitivity of 
activator/apoptosis inhibitor complexes to ABT-737 in cells and that predicted from in 
vitro binding studies is often conflicting [588, 589], and therefore, translation to the 
clinical setting may also be difficult. “BH3 profiling” is one method that can be 
employed to overcome this. This is a measurement of the sensitivity of cancer cells to 
ABT-737 by determining the effects of the drug or related peptide on mitochondria 
isolated from the cancer cells [590]. This allows the identification of apoptosis 
inhibitors required for cancer cell survival, which negates the requirement to have prior 
knowledge of the expression or interactions of Bcl-2 family members. Furthermore, 
this assay could be used clinically in the future [590]. For PI3K inhibitor and 
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pitavastatin combinations, measurement of PTEN expression may indicate which 
patients may respond to this combination. A genomic analysis of ovarian cancer cell 
lines found that good predictors for the presence or loss of PTEN protein were PTEN 
copy number neutral (diploid) or homozygous deletion, rather than a hemizygous loss 
of the PTEN gene [578]. Furthermore, in a clinical assessment of PTEN loss, 
immunohistochemistry (IHC) detected most of the endometrioid tumours with PTEN 
protein loss [591]. A PTEN IHC assay (PREZEON) detected PTEN protein loss 
resulting from PTEN mutations (verified by copy number analysis in a range of human 
tumour cell lines), and this assay has already been implemented in a clinical 
laboratory [592]. These promising drug combinations warrant further preclinical 
investigations, including ovarian cancer xenograft studies, before clinical trials can be 
justified. 
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CHAPTER 7 
 
CONCLUSION AND FURTHER STUDIES 
  
226 
 
Treatment for advanced ovarian cancer is currently comprised of surgery followed by 
adjuvant chemotherapy consisting of 3-weekly cycles of carboplatin and paclitaxel. 
Although the majority of patients respond to initial chemotherapy, drug resistance 
often emerges with few remaining treatment options, and only around 40% of patients 
survive 5 years after initial diagnosis with advanced ovarian cancer. Therefore, new 
treatments for ovarian cancer are urgently required.  
 
There is currently considerable enthusiasm for re-developing drugs to treat conditions 
for which they were not originally established. For example, rapamycin was initially 
approved as an immunosuppressant for the prevention of transplant rejection. 
However, analogues of rapamycin have since been developed for the treatment of 
renal carcinoma. The use of statins to treat ovarian cancer fits this evolving paradigm. 
Mevastatin was the first 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) 
inhibitor isolated from the culture broth of Penicillium citrinum by Akira Endo [593], and 
was subsequently shown to have anti-growth activity in Chinese hamster ovary cells 
and human malignant lymphoma cells [594]. Around a decade later, the cytotoxic 
activity of statins was confirmed in ovarian cancer cell lines [595]. This early study 
highlighted that the concentration of lovastatin required to inhibit the growth of ovarian 
cancer cell lines was achievable in the plasma of cancer patients exposed to high 
doses of lovastatin [595, 596]. The research presented here also found that the 
concentrations of both simvastatin and pitavastatin required for cytotoxicity in vitro 
were similar to the plasma concentrations achieved in patients following administration 
of the maximum tolerated dose. Furthermore, continual blockade of HMGCR for 
several days was required for cell death, suggesting that statins with short half-lives of 
2-3 hours (e.g. simvastatin or lovastatin) may require frequent administration. 
Pitavastatin has a longer half-life of around 11 hours and was demonstrated to be the 
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most potent statin in ovarian cancer cell lines, and therefore, offers the best prospect 
to evaluate the clinical efficacy of statins in ovarian cancer. In addition to the choice of 
statin and dosing frequency, further consideration should be given to the patient’s diet, 
as lipids present in many commonly consumed foodstuffs may reverse the cytotoxic 
effects of statins. Nomura and colleagues recently reported that a high-fat diet 
rescued the anti-cancer effects of monoacylglycerol lipase inhibition in a xenograft 
model, suggesting that exogenous lipids may contribute to cell survival pathways 
[526]. Further research could determine the effect of diets with varying fat content on 
the cytotoxic activity of statins in xenograft studies. Collectively, these data are in 
contrast to most ongoing clinical trials, which are evaluating statins at standard doses 
(40-80 mg once daily) used for the treatment of high cholesterol in patients 
presumably receiving a normal diet, and suggest that these clinical trials are unlikely 
to succeed. With the exception of hepatocellular cancer, clinical trials that have 
previously evaluated standard doses of statins in combination with chemotherapy for 
cancer treatment have not reported any survival benefit compared to standard 
chemotherapy regimens [409-411, 415].  
 
Research investigating which patients should receive statins for the treatment of 
cancer is currently underway. Previous studies have reported that increased HMGCR 
contributed to cancer cell growth and migration [137, 146]. However, HMGCR level 
did not significantly correlate with the sensitivity of ovarian or breast cancer cells to 
statins, suggesting that there are likely to be other molecular features which determine 
sensitivity to statins [597]. Goard and colleagues recently identified a 10-gene 
signature that could be used to predict fluvastatin sensitivity in a panel of breast 
cancer cell lines [597]. A similar approach could be employed in ovarian cancer cell 
lines to determine a statin-sensitivity signature, and this could be used to identify 
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patients with ovarian cancers that are more likely to respond to statin treatment in 
clinical trials. Importantly, statins retained potency in ovarian cancer cell lines 
relatively resistant to chemotherapy, suggesting that statins could be used in 
chemoresistant disease. One possibility is that patients with disease that has failed to 
respond to carboplatin or paclitaxel treatment could receive high doses of pitavastatin 
in a clinical trial setting. An initial phase I clinical trial to identify a therapeutic window 
could evaluate escalating doses of pitavastatin (8-32 mg), administered orally twice 
daily for 1-2 weeks. Each dose level should be tested in a new group of patients to 
minimise the risk of toxicity (e.g. myopathy). Adverse effects should be determined by 
clinical assessment, and laboratory analysis including a full blood count, liver 
enzymes, creatine phosphokinase and renal function. Furthermore, efficacy should be 
assessed by computed tomography (CT) scans and measurement of the serum 
biomarker CA125. The results of the phase I trial could be used to inform a phase II 
study, which should incorporate two arms, pitavastatin versus placebo drug, and 
assess overall survival as the primary endpoint.  
 
There is currently a requirement for the development of accurate, non-invasive 
biomarkers which can be used to predict response to statin therapy in cancer patients. 
A recent proteomic analysis of proteins released from endothelial cells exposed to 
atorvastatin identified approximately 83 differentially expressed proteins in the statin-
treated “cell secretome” [520]. This research confirmed that nine of these proteins 
were also predominately detected in the medium of ovarian cancer cells exposed to 
statins, although the mechanism by which they were released is unknown. The gel 
approach to identifying proteins can have several drawbacks as it can be difficult to 
analyse proteins with very low (<15 kDa) or high (>100 kDa) molecular weights, and 
there may be multiple proteins in one band [520]. Further studies could incorporate a 
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gel-free proteomic approach involving a liquid chromatography/mass spectrometry-
based method to identify proteins exclusively released by ovarian cancer cells but not 
normal cells in response to statin exposure. Cellular necrosis could contribute to the 
mechanism of protein release from cells exposed to statins, and therefore, this 
potential mechanism of cell death should also be investigated. 
 
 
Combination of Statins with Other Chemotherapeutic Agents for the Treatment 
of Ovarian Cancer 
 
Novel therapeutic agents are frequently evaluated in combination with existing 
chemotherapy in oncology. However, simvastatin did not demonstrate synergy with 
either carboplatin or paclitaxel in ovarian cancer cell lines [492]. Statins can also be 
used in combination with targeted therapeutic agents. Pitavastatin in combination with 
pictilisib or ABT-737 modestly increased cell death in several ovarian cancer cell lines, 
and therefore, these drug combinations may be superior over single agent therapy in 
a subset of ovarian tumours. The identification of appropriate biomarkers will help to 
determine which tumours may be sensitive to combination treatment. The remainder 
of this discussion will focus on the potential of statins in combination with current 
chemotherapeutic agents or targeted therapeutic agents.    
 
Statins and Platinum-Containing Compounds 
The platinum-containing compound, carboplatin, is included in the first line 
chemotherapeutic regimen for the treatment of ovarian cancer (chapter 1), and 
therefore, is a candidate for combination therapy. Previous research evaluating 
combinations of statins and cisplatin have reported that statins enhance the cytotoxic 
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effects of cisplatin by increasing apoptosis and S or G2/M phase cell cycle arrest in 
colon, ovarian and squamous cell cancers [337, 357, 466, 484]. Furthermore, in non-
small cell lung cancer cells, atorvastatin and carboplatin synergistically reduced cell 
viability and increased apoptosis [598]. This was confirmed in xenograft studies, 
where the combination reduced tumour size and increased survival time compared to 
the single agents alone [598]. Despite this, the simultaneous combination of 
simvastatin and carboplatin demonstrated additive or mild antagonistic interactions in 
seven ovarian cancer cell lines [492]. Furthermore, in dose scheduling experiments, 
significant antagonism was observed when ovarian cancer cells were exposed to high 
concentrations of simvastatin before carboplatin treatment (chapter 4). Therefore, it is 
unlikely that this combination will produce any clinical benefits compared to the single 
agents alone. Instead, these results suggest that high doses of statin should not be 
administered immediately prior to carboplatin treatment, as this may result in the 
antagonism of existing chemotherapy. Statins could be used after carboplatin 
treatment as “consolidation therapy” or in cancer which is resistant to carboplatin.  
 
Statins and Paclitaxel 
Paclitaxel can also be administrated in combination with carboplatin, as first line 
adjuvant chemotherapy in ovarian cancer (chapter 1). Statins in combination with 
paclitaxel have achieved variable results in cell-based studies. In leukemia cells, 
simvastatin or lovastatin in combination with paclitaxel resulted in a synergistic 
increase in cytotoxicity and G2/M phase cell cycle arrest [599, 600]. However, similar 
combinations were antagonistic in anaplastic thyroid cancer cells [601], and ovarian 
cancer cells [492]. Further research could evaluate the activity of statins combined 
with paclitaxel in dose scheduling experiments, as this has previously been shown to 
influence whether synergy is observed [450, 602]. However, statins induce G0/G1 
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phase cell cycle arrest and this could prevent G2/M arrest induced by paclitaxel, 
thereby contributing to antagonism. Indeed, carboplatin was demonstrated to 
antagonise the cytotoxic effects of paclitaxel in several dose schedules, by preventing 
breast cancer cells from progressing to M phase of the cell cycle [602]. Therefore, as 
statins induce G0/G1 phase cell cycle arrest, it may be preferable to administer 
paclitaxel prior to the statin. 
 
Statins and Doxorubicin 
Doxorubicin is used for the treatment of recurrent ovarian cancer; however chronic 
cardiotoxicity is a major factor limiting its prolonged use. Statins have been reported to 
potentiate the cytotoxic effects of doxorubicin in osteosarcoma cells [603], malignant 
melanoma cells [604, 605], ovarian cancer cells [485], and in p53-deficient cancer 
cells [606]. Furthermore, the synergistic interaction between lovastatin and 
doxorubicin has also been confirmed in animal studies, where the combination 
reduced tumour volume, increased apoptosis, and reduced the number of metastases 
compared to the single agents alone [604, 605, 607]. Statins have been proposed to 
reverse doxorubicin resistance in cancer cells by directly inhibiting the multidrug 
resistance protein, P-glycoprotein (P-gp) [485, 608]. P-gp resides in the cell 
membrane where it functions to remove toxins or drugs from the cell. In the presence 
of statins, cells accumulate doxorubicin in the nucleus resulting in a reduction in 
topoisomerase II activity, and an increase in double-strand DNA breaks [608, 609]. 
These results suggest that the combination of statins and doxorubicin should be 
further evaluated in dose scheduling experiments and ovarian cancer xenograft 
studies.  
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Statins and Bevacizumab 
Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis, 
and is upregulated in ovarian cancer [610]. Bevacizumab is a humanised monoclonal 
antibody which inhibits circulating VEGF. Similarly, at high concentrations, statins 
have also been shown to have anti-angiogenic activity, including the attenuation of 
VEGF. These converging effects on angiogenesis provide a rationale for the use of 
statins in combination with bevacizumab to inhibit angiogenesis in ovarian cancer. 
Statins were first combined with bevacizumab and radiotherapy in a case study of a 
young woman presenting with an embryonal rhabdomyosarcoma of the retromaxillary 
space, which was refractory to two chemotherapy regimens [611]. The tumour growth 
was well controlled by this treatment and this enabled surgical removal of the tumour 
[611]. More recently, statins in combination with bevacizumab significantly reduced 
the growth and metastasis of colon cancer xenografts compared to bevacizumab 
alone [248]. Interestingly, statins were administered at doses equivalent to those used 
in patients with hypercholesterolaemia. Furthermore, the combination of bevacizumab 
and simvastatin (0.2 µM) also reduced cell viability, migration and invasion of human 
umbilical vein endothelial cells in vitro by attenuating the release of angiogenic 
mediators including angiopoietin2, binding immunoglobulin protein and HSP90α from 
colon cancer cells [248]. Taken together, these results suggest that statins at clinically 
achievable concentrations in combination with bevacizumab may be beneficial for the 
treatment of ovarian cancer.  
 
Statins and Bisphosphonates 
Nitrogen-containing bisphosphonates, including pamidronate, alendronate, 
ibandronate, risedronate and zoledronic acid, inhibit farnesyl diphosphate synthase in 
the mevalonate pathway, which prevents the synthesis of farnesyl diphosphate and 
233 
 
geranylgeranyl diphosphate. Therefore, bisphosphonates, like statins, also interfere 
with the prenylation of signalling molecules involved in many cellular processes. 
Furthermore, inhibition of farnesyl diphosphate synthase results in the accumulation of 
isopentenyl diphosphate, which can be metabolised to the intracellular ATP analogue, 
ApppI, and this may directly induce apoptosis [612, 613]. Bisphosphonates have been 
shown to inhibit the growth and migration of ovarian cancer cells in vitro [614, 615] 
and in vivo [616]. Furthermore, zoledronic acid in combination with simvastatin or 
fluvastatin was synergistic in breast [617] and myeloma [618] cancer cells, and 
ovarian tumours [619]. Interestingly, ovarian tumour cells were less sensitive to 
zoledronic acid following pre-exposure to fluvastatin [619], suggesting that statins may 
be more effective when given after zoledronic acid. This supports the alternative 
ApppI mechanism, as the accumulation of isopentenyl diphosphate may be required 
for zoledronic acid-induced cell death. Subsequent addition of statins may further 
prevent the synthesis of isoprenoids, thereby contributing to an inhibition of the 
prenylation of essential GTPases. Clinical trials combining statins and zoledronic acid 
for the treatment of cancers including multiple myeloma are ongoing [425]. Taken 
together, these results give further support to combined strategies aimed at inhibiting 
the mevalonate pathway for the treatment of ovarian cancer. Future studies could aim 
to confirm the synergy between statins and zoledronic acid in xenograft models, prior 
to ovarian cancer clinical trials. 
 
Statins and Geranylgeranyltransferase Inhibitors  
The post-translational prenylation of proteins requires prenyltransferase enzymes, 
including farnesyltransferase (FT) and geranylgeranyltransferase (GGT), which 
catalyse the addition of the isoprenoid onto a C-terminal CaaX motif [181]. Prenylation 
facilitates the correct cellular localisation and interactions of proteins involved in many 
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processes including cell proliferation, angiogenesis, migration and invasion. 
Farnesyltransferase inhibitors (FTI) were developed to inhibit the prenylation, 
membrane localisation, and function of the Ras oncogene, which is frequently 
activated in cancer. However, FTIs lacked significant cytotoxicity in clinical trials, and 
this was later attributed to the discovery that GGTs alternatively prenylated Ras when 
FT was blocked [620]. Consequently, FTIs were used in combination with 
geranylgeranyltransferase inhibitors (GGTI), however this dual prenyltransferase 
inhibitor therapy resulted in unacceptable toxicity in preclinical models [621]. Another 
approach to prevent the geranylgeranylation of proteins involved in tumorigenesis 
involves simultaneously inhibiting the prenylation pathway at two points, one to reduce 
the production of geranylgeranyl diphosphate using statins, and the other to 
competitively inhibit the binding of geranylgeranyl diphosphate to the GGT using 
GGTIs. These two compounds may exhibit synergistic activity in combination because 
statins deplete the cellular pool of geranylgeranyl diphosphate, which may allow the 
isoprenoid-competitive GGTI to target the GGT more efficiently. The combination of 
GGTI-2Z and lovastatin resulted in synergistic anti-proliferative effects in malignant 
peripheral nerve sheath tumour cells [322]. Furthermore, there was no significant 
toxicity in normal immortalized Schwann cells [322]. Ageberg and colleagues reported 
that both GGTI-298 and the combined Rab geranylgeranyltransferase and 
farnesyltransferase inhibitor, BMS1, inhibited the growth of lymphoma cells [500]. 
Interestingly, the addition of geranylgeraniol did not reverse the cytotoxic activity of 
either GGTI-298 or BMS1, suggesting that these compounds may specifically inhibit 
Rab GGT [500]. Additional studies have also shown that inhibition of Rab GGT and 
subsequent prevention of Rab prenylation cannot be reversed by geranylgeraniol 
[622, 623]. This can be explained by the mechanism of action of the inhibitors, 
although it is also possible that both GGTI-298 and BMS1 may have anti-cancer 
235 
 
effects independent of prenylation [500]. These results raise the possibility that statins 
could be used in combination with Rab GGTIs for the treatment of ovarian cancer. 
This may have several implications. Statins have been demonstrated to reduce the 
levels of Rab GTPases involved in autophagy, which may contribute to an inhibition of 
the autophagy pathway and potentiation of cell death (chapters 4 and 5; [327]). Rab 
GGTIs have also been shown to reduce the prenylation of Rab GTPases including 
Rab6 [622, 623]. Therefore, Rab GGTIs in combination with statins may 
synergistically inhibit autophagy and this may sensitise cancer cells to apoptotic cell 
death. Furthermore, it would also be important to determine what effect the addition of 
geranylgeraniol had on the cytotoxic activity of this drug combination, since this lipid 
may be present in the diet of patients receiving treatment for ovarian cancer (chapter 
5). Isoprenoids including geranylgeraniol reversed the cytotoxic effects of statins in 
vitro, raising the possibility that isoprenoids ingested from the diet may also inhibit the 
anti-cancer activity of statins in clinical trials. The activity of Rab GGTIs is not 
prevented by geranylgeraniol and therefore, Rab GGTIs in combination with statins 
could maintain cytotoxic activity in the presence of exogenous isoprenoids from the 
diet. 
 
 
Conclusion 
Pitavastatin should be evaluated as a single agent in clinical trials of ovarian cancer, 
in patients with disease that is chemoresistant or after chemotherapy as “consolidation 
therapy”, using high doses with twice daily administration, as determined by a phase I 
study. Administration of pitavastatin at these doses is required for at least 4 days to 
allow inhibition of HMGCR and cell death, although this duration may be longer in 
vivo, and the maximum tolerated dose can be administered for up to two weeks 
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without significant toxicity. The validation of biomarkers of statin-induced cancer cell 
death will help to identify a biological response to statin treatment. Clinical trials 
should ensure that dietary fat intake is minimised, and this can be achieved by 
substituting a standard diet with food replacement drinks. These findings go a 
considerable way toward informing future clinical trials of statins in ovarian cancer. 
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Appendix 1: siRNA transfection 
 
SMARTpool (Dharmacon) or individual siRNA (Dharmacon) were reconstituted in 
siRNA buffer (Dharmacon) to 20 µM solutions. The siRNA used are detailed in the 
table below.  
 
Name Concentration Target Sequence 
Rab7 SMARTpool 20 nM N/A 
Atg5 SMARTpool 20 nM N/A 
Beclin 1 SMARTpool 20 nM N/A 
FLIP SMARTpool 0.3 nM N/A 
FLIP #4 25 nM AAUAACUUCAGGCUCCAUAUU 
FLIP #18 3 nM UAAAGAACAUCCACAGAAUUU 
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Appendix 2: Primer sequences and amplicon sizes 
 
The primers used for qPCR were reconstituted in DNase/RNase-free distilled water to 
a concentration of 100 µM. The final primer concentration in the reaction mix was 100 
nM. Primers were obtained from Sigma-Aldrich.  
 
Primer 
Name 
Forward (5’ → 3’) Reverse (5’ → 3’) 
Amplicon 
Size (bp) 
ND1 TAATGCTTACCGAACGAA TTATGGCGTCAGCGAAGG 104 
β-actin GCAAAGTTCCCAAGCACA AAGCAAGCAGCGGAGCAG 105 
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Appendix 3: Antibodies used for protein immunodetection 
 
The primary and secondary antibodies used for protein immunodetection were 
prepared in TBST (or PBS for immunofluorescence) containing 5% skimmed milk 
powder or 5% BSA at the following dilutions.  
 
Antibody  Dilution 
Product Code and 
Supplier 
anti-LC3 primary antibody  
1/2000 (western 
blotting) or 1/100 
(immunofluorescence) 
LC3-2G6, Nanotools 
anti-Rab7 primary antibody 
1/1000 (western 
blotting) or 1/100 
(immunofluorescence) 
9367, Cell Signaling 
Technology 
anti-SQSTM1/p62 primary 
antibody 
1/1000 AB56416, Abcam 
anti-GAPDH primary antibody 1/5000 MAB374, Millipore 
anti-PARP primary antibody 1/1000 
9542, Cell Signaling 
Technology 
anti-Bim primary antibody 1/1000 
2819, Cell Signaling 
Technology 
anti-Bcl-XL primary antibody 1/1000 
2762, Cell Signaling 
Technology 
anti-Mcl-1 (D35A5) primary 
antibody 
1/1000 
5453, Cell Signaling 
Technology 
anti-α-Actinin primary antibody 1/1000 
3134, Cell Signaling 
Technology 
anti-HSP90 primary antibody 1/1000 
4874, Cell Signaling 
Technology 
anti-Enolase-1 primary antibody 1/1000 
3810, Cell Signaling 
Technology 
anti-Pan-Actin primary antibody 1/1000 
4968, Cell Signaling 
Technology 
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anti-Ezrin primary antibody 1/1000 
3145, Cell Signaling 
Technology 
anti-Moesin (Q480) primary 
antibody 
1/1000 
3150, Cell Signaling 
Technology 
anti-Radixin (C4G7) primary 
antibody 
1/1000 
2636, Cell Signaling 
Technology 
anti-Atg5 primary antibody 1/1000 
2630, Cell Signaling 
Technology 
anti-Beclin 1 (D40C5) primary 
antibody 
1/1000 
3495, Cell Signaling 
Technology 
anti-FLIP (D16A8) primary 
antibody 
1/1000 
8510, Cell Signaling 
Technology 
anti-PMK1/2 (C103A3) primary 
antibody 
1/1000 
3190, Cell Signaling 
Technology 
anti-HMGCR [EPR1685(N)] 
primary antibody 
1/1000 AB174830, Abcam 
anti-mouse IgG secondary 
antibody linked to HRP 
1/2000 
7076, Cell Signaling 
Technology 
anti-rabbit IgG secondary 
antibody linked to HRP 
1/2000 
7074, Cell Signaling 
Technology 
anti-mouse Cy2 antibody 1/1000 AB6944, Abcam 
anti-rabbit Alexa Fluor 568 
antibody 
1/1000 
A10042, Life 
Technologies 
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Appendix 4: Peptide sequences identified from mass spectrometry analysis of 
proteins in cell culture medium from Ovcar-8 cells exposed to pitavastatin 
 
Protein Name Matched Peptides (Bold Red) 
Alpha-actinin 1 
 
Heat shock protein 90 
 
Ezrin 
 
Pyruvate kinase M1/M2 
 
Alpha-enolase 
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Actin 
 
Glyceraldehyde-3-phosphate 
dehydrogenase 
 
 
 
 
 
 
